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ABSTRACT 
 
 Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are 
clinically and neuropathologically highly related a-synucleinopathies that collectively 
constitute the second leading cause of neurodegenerative dementias. Genetic and 
neuropathological studies directly implicate a-synuclein (aS) abnormalities in PDD and 
DLB pathogenesis. However, it is currently unknown how aS abnormalities contribute to 
memory loss, particularly since forebrain and hippocampal neuron loss in PDD and DLB 
is less severe than in Alzheimer’s disease.  
 Previously, we found that familial Parkinson’s disease (PD)-linked human mutant 
A53T aS causes aberrant localization of the microtubule-associated protein tau to 
postsynaptic spines in neurons, leading to postsynaptic deficits. Thus, we directly tested 
if the synaptic and memory deficits in a mouse model of a-synucleinopathy (TgA53T) are 
mediated by tau. TgA53T mice exhibit progressive memory deficits associated with 
postsynaptic deficits in the absence of obvious neuropathological and neurodegenerative 
changes in the hippocampus. Significantly, removal of endogenous mouse tau expression 
in TgA53T mice (TgA53T/mTau-/-), achieved by mating TgA53T mice to mouse tau 
knockout mice, completely ameliorates cognitive dysfunction and concurrent synaptic 
deficits without affecting aS expression or accumulation of selected toxic aS oligomers. 
Among the known tau-dependent effects, memory deficits in TgA53T mice were 
associated with hippocampal circuit remodeling linked to chronic network hyperexcitability. 
This remodeling was absent in TgA53T/mTau-/- mice, indicating that postsynaptic deficits, 
aberrant network hyperactivity, and memory deficits are mechanistically linked. Our results 
directly implicate tau as a mediator of specific human mutant A53T aS-mediated 
abnormalities related to deficits in hippocampal neurotransmission and suggest a 
mechanism for memory impairment that occurs as a consequence of synaptic dysfunction 
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rather than synaptic or neuronal loss. We hypothesize that these initial synaptic deficits 
contribute to network hyperexcitability which, in turn, exacerbate cognitive dysfunction.  
 aS is also central to sporadic PD pathogenesis. Pathogenic species of aS, such as 
fibrils, have recently been implicated as a pathogenic component of synucleinopathies, 
capable of transmission between functionally and anatomically connected brain regions, 
including the hippocampus. However, how aS fibrils impact hippocampal function and 
contribute to memory deficits is not well understood. We hypothesized that aS fibril-
induced synaptic changes could be mediated by other through interactions with other 
proteins, including tau. Wild-type primary hippocampal neurons acutely exposed to fibrillar 
aS species display tau missorting to dendritic spines as well as electrophysiological 
deficits in both pre and postsynaptic neurotransmission. However, some of these findings 
may be a product of concentration-dependent aS fibril-induced spine collapse. 
Importantly, aS fibril-mediated tau missorting and synapse loss could be differentiated by 
examining key proteins and pathways in vitro, pointing to both structural and functional 
deficits at hippocampal synapses as contributors to cognitive impairment in PDD and DLB. 
Taken together, these initial studies using aS fibrils suggest that pathologic species of aS 
may act through distinct intracellular and extracellular mechanisms to contribute to 
neuronal dysfunction and neuronal toxicity.  
 Through these two approaches and methodologies, our results indicate that these 
synaptic changes, along with key pathological species of aS, present potential therapeutic 
targets for amelioration of memory deficits in a-synucleinopathies.   
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INTRODUCTION 
 
 
Non-communicable diseases are on the rise and neurological disorders are leading 
the charge 
 
 Over history, disease burden has shifted.  Within the last century, while the 
epidemiological burden of infectious diseases (e.g. smallpox and polio) as well as chronic 
and developmental diseases (e.g. nutritional deficiencies) has lessened, others have 
risen. Initiated in the 1990s by the World Bank, the Global Burden of Diseases (GBD), 
now organized by the World Health Organization, has brought global attention to hidden 
and neglected health challenges, as well as revealed alarming trends. One such trend 
points to a shift in the types of diseases affecting the world: as deaths from communicable 
diseases decreased in 2016, more than three-quarters of all deaths in 2016 were caused 
by non-communicable diseases (NCDs) (James et al., 2018). Currently, NCDs now 
account for more than one-half of the global burden of disease. Compounding this 
increasing burden of NCDs is the growing global population. By 2050, the global 
population aged 60 and 80 years or older is expected to double and triple, respectively 
(United Nations, 2017 World Population Aging Study). This increase in the aging 
population is accompanied by an increase in diseases that are more prominent in later 
stages of life. In particular, neurological disorders are NCDs and major contributors to the 
global disease burden as the second leading cause of death in 2015 and leading cause 
of disability worldwide (Feigin et al., 2019). The number of people living with Alzheimer’s 
disease (AD) and other dementias are among the most burdensome of neurodegenerative 
diseases worldwide and has increased over 100% since 1990. In 2016, dementia was the 
fifth leading cause of death globally (Nichols et al., 2019). In that same time frame, the 
number of people with Parkinson’s disease (PD), the second most common 
neurodegenerative disorder, has also more than doubled. PD is now the fastest growing 
of any neurological disease, seeing the greatest rise in prevalence, disability, and mortality 
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(Dorsey et al., 2018). A conservative projected doubling of patients over the next 30 years 
would yield more than 12 million PD patients by 2050.  
 Within the United States, the economic burden of PD exceeded $20 billion in 2010 
(Kowal et al., 2013), a value that will most certainly increase with an expanding PD 
population. Moreover, almost 60% of the $14 billion in direct medical costs due to PD is 
associated with nursing home services, highlighting the strain an aging and diseased 
population places not only on the patient, but also medical providers and caregivers. The 
economic cost of PD is substantial, and increases as the disease progresses. While a 
curative silver bullet for PD is desired and a valid motivator for current research, the need 
for preventative and disease-modifying therapies are critical in combatting the complex 
burden an aging population presents. Interestingly, one model estimated that a treatment 
that slows PD progression by 50% would yield a 35% reduction in costs, a dramatic 
reduction in cost of care that is coupled to a longer expected survival (Johnson et al., 
2013).  
 Unfortunately, no effective curative or disease-modifying treatments exist for these 
major neurodegenerative diseases and causes of dementia. There is an emerging need 
to bridge the gap between life expectancy and healthy life expectancy. Until therapeutic 
breakthroughs are made, neurological disorders, neurodegenerative disease and 
dementia in particular, will constitute and increasing challenge to health-care systems 
worldwide. To that end, there is an urgent need for research identifying new interventions 
for people with PD.  
 
Parkinson’s disease is a rising neurological disorder 
 The increasing contributions neurodegenerative diseases, including PD, impart on the 
global burden of disease supports placing them on the top of the global public health 
agenda. The dramatic rise in PD’s prevalence, disability, and deaths can partly be 
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explained by a growing global population as well as increased longevity. Age is the 
greatest risk factor for PD, affecting 1% of the population of 60 years of age, and 5% of 
the population over the age of 85 (Van Den Eeden, 2003). PD is rare before 50 years of 
age, but the incidence increases 5-10-fold from the sixth to ninth decade of life (Poewe et 
al., 2017). The progressive increase in the number of aged individuals is one driver of an 
increase in PD prevalence, but the incidence of PD has also increased since 1976, 
particularly in men 70 years or older (Savica et al., 2016). Unfortunately for us, age is an 
unmodifiable risk factor. Given the lack of preventative, disease-modifying, or curative 
treatments for PD, identification of modifiable risk factors is critical to understanding key 
drivers of these trends.  
 Environmental and social factors have consequently come into the limelight. Industrial 
and chemical and pollutants, such as pesticides, solvents, and metals appear to be 
associated with an increased risk for PD (Pezzoli and Cereda, 2013; Tanner et al., 2011; 
Weisskopf et al., 2010). Surprisingly, there is a lower risk of Parkinson’s disease among 
smokers, both current and former (Thacker et al., 2007). Dramatic changes in smoking 
behavior that include increased cessation and decreased use (Dorsey et al., 2018; Savica 
et al., 2016) may partly explain the rise of PD over the past several decades, but a 
mechanistic understanding of this relationship remains unknown.  
 In addition to population aging, another emerging trend in global demographics is 
urbanization. In 2018, 55% of the world lived in urban areas, but is expected to increase 
to 68% by 2050 (United Nations, 2018 Revision of World Urbanization Prospects). 
Paralleling the idea of environmental exposures as disease risk factors, ambient air 
pollution from traffic sources is associated with an increased risk for PD (Ritz Beate et al., 
2016). Interestingly, a higher incidence of neurodegenerative diseases and cognitive 
dysfunction has been observed in individuals living in close proximity to major roads (Chen 
et al., 2017; Wellenius et al., 2012; Wilker et al., 2015).Taken together, managing the 
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health of an aging, more urbanized global population presents quite a challenge. 
Complementing our need to better identify risk factors driving neurological disease and 
PD in particular, a better understanding of the key mechanisms driving PD pathogenesis 
are critical to improving disease management and quality of life for those affected by PD.  
 
Parkinson’s disease: a brief history  
 PD was first medically described as a collective, single neurological syndrome by 
British physician James Parkinson in 1817 in his “Essay on the Shaking Palsy” (Parkinson, 
2002). In his “Essay,” Parkinson systematically outlined a syndrome he had observed in 
six patients in London, discussing the progressive and disabling condition, parkinsonian 
posture, festinant (Parkinsonian) gait, and tremor. While these clinical symptoms had been 
observed before, going as far back at Galen during the Roman Empire, their 
understanding was limited and classification into a common disorder was incomplete. 
Dutch physician Fanciscus Sylvius first described resting tremor in 1680. And François 
Boissier de Sauvages, a French physician, wrote on the Parkinsonian gait in 1768. 
Moreover, prior to Parkinson’s essay, using tremors alone as diagnostic criteria meant 
significant overlap with other conditions such as seizures.  
 In 1872, Jean-Martin Charcot, a French neurologist and largely considered to be the 
founder of modern neurology, advanced Parkinson’s clinical observations. Charcot was 
instrumental in recognizing that patients, similar to the cohort described by Parkinson, all 
displayed tremor, rigidity, facial immobility, postural instability, and bradykinesia. With this 
new understanding of the cardinal motor features, Charcot was the first to suggest the 
term “Parkinson’s disease” to define this constellation of symptoms (Goetz, 1986). Prior 
to Charcot, the classification of neurological diseases was primitive, where disorders were 
grouped by primary symptoms, such as tremors or weakness. Having established the 
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symptoms, Charcot now had tools in place to classify PD as a neurological disorder and 
differentiate it from other tremor-producing disorders such as multiple sclerosis.  
 Fritz Heinrich Lewy, in 1912, was the first to describe characteristic proteinaceous 
intra-neuronal inclusions bodies in several brain regions of patients with PD, including the 
dorsal motor nucleus of the vagus nerve. Lewy’s work was shortly followed by that of 
Konstantin Tretiakoff in 1919. Tretiakoff’s anatomical and pathological studies identified a 
severe loss of pigmented neurons in the substantia nigra in PD patients. In surviving nigral 
cells, he also reported protein aggregates, subsequently terming them “Lewy bodies” 
(Goedert et al., 2013).  
 Insight into substantia nigra (SN) dysfunction and PD came from Swedish scientist 
Arvid Carlsson. His group first noticed drug-induced parkinsonism in rabbits treated with 
the dopamine antagonist, reserpine, and subsequently identified dopamine’s presence in 
the brain (Carlsson et al., 1958). Having demonstrated high dopamine concentrations in 
the striatum, Carlsson was the first to propose dopamine as a neurotransmitter, acted on 
circuits involved in motor control, and deficiency of this catecholamine might underlie the 
motor symptoms in PD (Carlsson, 2002; Lees et al., 2015). Austrian biochemist Oleh 
Hornykiewicz shortly after advanced Carlsson’s hypotheses by documenting dopamine 
deficiency in the striatum and SN in individuals with PD (Lees et al., 2015). Californian 
neurologist William Langston’s clinical and pathological study of sudden-onset 
parkinsonism in patients with prior history of intravenous drug use aged 26 to 42 years 
yielded two major benefits: 1) further implicating cell death in the SN and Lewy pathology 
as findings specific for parkinsonism, and 2) identifying 1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine (MPTP, “synthetic heroin”) as the compound injected into these 
patients suggested that PD could be caused by environmental factors (Langston et al., 
1983). The remarkable selectivity of MPTP for producing neurotoxicity in the SN has since 
proved invaluable in both in vitro and in vivo toxin models of PD. Collectively, these 
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findings provided the initial evidence connecting the substantia nigra, dopaminergic 
neurotransmission, and PD together that has since guided a century of research on PD 
pathogenesis and therapy.  
 In light of progressive advances into the neuroanatomical, pathological, and 
neurochemical basis for PD, the causes driving these changes in the disease remained 
unknown for almost two centuries following Parkinson’s “Essay.” The first piece of 
evidence linking PD to the presynaptic neuronal protein a-synuclein (aS) came from the 
first study demonstrating a genetic abnormality in the aS gene as casual for PD. This 
single nucleotide G209A mutation in the SNCA gene lead to the missense A53T amino 
acid substitution identified in an Italian kindred and several Greek families with an 
autosomal dominant pattern (Polymeropoulos et al., 1997). An interesting caveat to this 
finding came from the finding wild-type (WT) rodent SNCA homolog sequence that has 
threonine (T) at amino acid residue 53 (though this is just one of seven total amino acids 
that differ between rodent and human aS) (Hamilton, 2004). This familial mutation raised 
the questions if rodents, such as mice (Mus musculus) and rats (Rattus rattus) used in the 
laboratory setting, were more likely to develop parkinsonism. Identification of the A30P 
and E46K missense point mutations in SNCA for autosomal dominant PD in distinct 
families soon followed, further highlighting a genetic component in the development of PD  
(Krüger et al., 1998; Zarranz et al., 2004). More recent studies identifying the G51D and 
H50Q missense mutations have further pointed to mutant aS a strong genetic factor in 
familial PD (Appel-Cresswell et al., 2013; Proukakis et al., 2013). Interestingly, all these 
PD-linked point mutations are located within the amino terminal (N-terminal) domain, 
suggesting that interference in membrane interactions mediated by this region may be 
one pathogenic mechanism underlying PD pathophysiology. The connection between 
SNCA, aS, and PD was further strengthened through subsequent studies demonstrating 
  7 
that duplications or triplications in the WT human SNCA gene were sufficient to cause 
familial autosomal dominant PD (Chartier-Harlin et al., 2004; Singleton et al., 2003). These 
findings led to the hypothesis and subsequent observation that increased aS in the brain 
could be a potential contributor to PD pathogenesis (Miller et al., 2004). 
 Although familial forms only account for a small percentage of all PD cases, identifying 
a genetic link from SNCA to PD advanced the understanding of disease onset and 
pathogenesis. Through the use of newly-generated antibodies against aS, it was shown 
that Lewy bodies (LBs) and Lewy neurites (LNs) in the substantia nigra of idiopathic PD 
patients, along with several dementia with Lewy body (DLB) cases, immunostained for aS 
(Spillantini et al., 1997). The use of these aS antibodies not only helped to define the 
protein components of Lewy pathology, but simultaneously provided insight into the 
filamentous organization of aS in LBs and LNs (Spillantini et al., 1998a). With SNCA gene 
duplications, triplications, or mutations being causal for PD, and aS comprising the major 
protein component of PD (Lewy) pathology in both familial and sporadic PD cases, it is 
evident that the mechanisms underlying neurodegenerative changes in PD is likely to 
involve aS.  
 
a-Synuclein is a major component of Parkinson’s disease pathophysiology 
 aS is a 140 amino acid abundantly expressed protein throughout the nervous system 
that comprises upwards of 1% of total cytosolic protein. Although now synonymous with 
PD, the discovery of aS in normal neurophysiology began with its identification in both 
nuclei and presynaptic nerve terminals in the electric organ of the Pacific electric ray 
(Torpedo californica) by using antibodies against purified synaptic proteins (Maroteaux et 
al., 1988). aS, along with its 134 amino acid b-synuclein (bS) homolog, were subsequently 
identified in rat brains (Maroteaux and Scheller, 1991), and shortly after, human 
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hippocampi (Jakes et al., 1994). While amino acid residues 61-95 of aS, now termed the 
“non-Ab component of AD” (NAC) domain, were also discovered as components of 
amyloid-b (Ab) plaques (Ueda et al., 1993), this finding has failed to be confirmed (Bayer 
et al., 1999). However, these cross-species similarities provided for the establishment of 
the homologous synuclein protein family in humans that includes aS, bS, and g-synuclein 
(gS), all three of which are predominantly neuronal proteins that preferentially localize to 
presynaptic terminals under physiologic conditions (Stefanis, 2012). 
 aS is encoded for by the SNCA gene, located on the long arm of chromosome 4: 
4q22.1. aS primarily exists in the brain as a monomer (Burré et al., 2013), but its assembly 
into higher order structures, such as oligomers or tetramers under both physiological and 
pathologic conditions, while controversial, has been demonstrated (Bartels et al., 2011; 
Burré et al., 2014; Nuber et al., 2018). Still, although defined as a “natively unfolded” or 
“intrinsically disordered” protein, aS does adopt an a-helical secondary structure upon 
binding to negatively charged lipids, such as phospholipid head groups present on cellular 
membranes. The protein can be divided into three regions: a highly conserved N-terminal 
repeat region, hydrophobic middle, and negatively-charged carboxy-terminal (C-terminal) 
region. The N-terminus contains (residues 7-87) seven repeats of an 11 amino acid 
residue sequence, each having a conserved six acid sequence core of KTKEGV. Although 
isolated alongside presynaptic vesicles, aS is located adjacent to, but not inside these 
structures (Maroteaux et al., 1988). aS prefers membranes with high curvature. This 
biological penchant for presynaptic terminals and synaptic vesicles is likely mediated 
through its N-terminus amino acid repeat sequences adopting an a-helical structure upon 
contact with such membranes (Chandra et al., 2003; Fortin et al., 2004; Jensen et al., 
1998). aS is unique as the only synuclein to harbor the hydrophobic NAC domain, 
potentially contributing to its unique aggregation-prone status when compared to bS or gS 
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(Conway et al., 2000a; Weinreb et al., 1996). The acidic C-terminus is polar, mostly 
unstructured, and contains several phosphorylation sites including serine at residue 129 
(pSer129) (Bendor et al., 2013; Samuel et al., 2016). Phosphorylation of aS, and in 
particular Ser129 serves to regulate its structure, membrane binding, protein interactions, 
multimer organization, and neurotoxicity (Canerina-Amaro et al., 2019; Chen and Feany, 
2005; Samuel et al., 2016).  
 In addition to phosphorylation, aS is subject to other forms of post-translational 
modifications. N-terminal acetylation of aS is observed in both healthy and individuals with 
PD, and data supports a role for acetylation increasing membrane affinity and aggregation 
resistance (Dikiy and Eliezer, 2014; Kang et al., 2012; Trexler and Rhoades, 2012). 
However, other modifications exist, such as ubiquitination (Nonaka et al., 2005), 
sumoylation (Krumova et al., 2011), and nitration (Giasson et al., 2000). Interestingly, 
monoubiquitinated forms of aS are aggregate-prone and more likely to be components of 
LBs as compared to being targeted for proteasome-mediated degradation (Rott et al., 
2008). Proteolysis of aS, and in particular C-terminal truncation, has been demonstrated 
to be pathogenic (Li et al., 2005; Murray et al., 2003).   
 
The function of a-Synuclein 
 The investigation of aS function predates its implication in disease. The presynaptic 
localization of aS was first supported by studies showing isolation of the protein alongside 
purified cholinergic vesicles, suggesting to a presynaptic role for the protein (Maroteaux 
and Scheller, 1991). In brain regions of the zebra finch uniquely involved in bird song 
acquisition, sustained reductions in aS expression were observed, suggesting a role for 
the protein in synaptic plasticity (George et al., 1995). Despite this, several lines of 
evidence point to aS not being critical for synaptic or nervous system function. First, aS 
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expression is restricted to vertebrates, and homologs in other laboratory model organisms 
such as yeast, worms, or flies have not been identified (George, 2002). Second, aS 
appears to arrive at developing synapses only after integral synaptic and membrane 
proteins have entered the region (Withers et al., 1997). And lastly, mice lacking aS 
expression (SNCA-/-) are viable, fertile, display intact gross nervous system and neuronal 
architecture including dopaminergic neurons, fibers, and synapses, with only subtle 
alterations in striatal DAergic neurotransmission being noted (Abeliovich et al., 2000). As 
such, it is likely that aS contributes to more complex neuronal activities beyond synaptic 
development or basic neurotransmitter release.  
 At the synapse, aS exists between soluble or membrane-bound states. Although 
soluble, cytosolic aS behaves as a natively unfolded protein (intrinsically disordered 
protein) (Binolfi et al., 2012; Fauvet et al., 2012; Weinreb et al., 1996). However, there is 
evidence to suggest aS may exist as a stable tetramer in physiological conditions that 
protects against aggregation and breaks down in pathological states like PD (Bartels et 
al., 2011; Nuber et al., 2018; Wang et al., 2011). aS binding to lipid-rich surfaces, such as 
cell membranes and synaptic vesicles, can induce aS stabilization and aggregation into 
multimeric species (Burré et al., 2014). This process may be due to the N-terminal portion 
of aS adopting an a-helical structure in the presence of lipids, which further mediates its 
binding to membranes (Bussell and Eliezer, 2003; Middleton and Rhoades, 2010). In 
contrast, under pathological states, aS adopts a b-sheet-rich conformation that promotes 
aggregation, fibrillization, and deposition into pathological Lewy structures (Conway et al., 
1998, 2000b) 
 It is hypothesized that aS localizes to presynaptic terminals due to its preference for 
highly curved membranes (Maroteaux et al., 1988; Nuscher et al., 2004). As synaptic 
vesicle membranes represent some of the smallest curved membranes within a neuron, 
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this, in combination with aS’s affinity for vesicular SNARE proteins, synapsins, and Rab3A 
likely aid in its targeting to the presynaptic site (Chen et al., 2013; Kahle et al., 2000; 
Zaltieri et al., 2015). Consistent with this, aS disperses from presynaptic boutons following 
stimulation, suggesting that the protein may dissociate from the vesicle membrane when 
it fuses with the presynaptic terminal plasma membrane and flattens out (Fortin et al., 
2005). Another driving force behind the presynaptic localization of aS may be its 
colocalization with lipid rafts, regions of plasma membrane enriched in cholesterol and 
saturated acyl chains, often found at the presynaptic bouton (Fortin et al., 2004). 
 The presynaptic location of aS and its preference for synaptic proteins and vesicles 
has guided efforts to understand aS function in the context of presynaptic 
neurotransmission. Initial work in the presynaptic context proposed a role for aS in 
promoting vesicle release, suggesting that SNCA-/- mice have an impaired capacity to 
activate reserve pools of vesicles following prolonged stimulation (Cabin et al., 2002). 
However, this contrasts more contemporary studies demonstrating a mild reduction in DA 
conten in striatal neurons, consistent with increased DA release in SNCA-/- mice 
(Abeliovich et al., 2000). DA release in neurons from mice lacking aS also shows more 
rapid facilitation and attenuated depression following repeated stimulation (Yavich et al., 
2004), suggesting a role for aS in regulating vesicle mobilization as a means to modulate 
neurotransmission.  
  As increased aS expression is associated with, and causal for, PD (Miller et al., 2004; 
Singleton et al., 2003), it has also been valuable to study the consequences of aS 
overexpression on synaptic physiology. Overexpression of human wild-type aS (haSWT) 
in the PC12 chromaffin cell line has been found to inhibit dense core vesicle exocytosis 
as measured by a reduction in total events without affecting key synaptic aspects like 
quantal size (Larsen et al., 2006). Another study showed similar findings in primary 
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midbrain neurons, primary hippocampal neuron, and ex vivo slices in recording from CA1 
pyramidal neurons, where aS overexpression reduced synaptic vesicle exocytosis without 
affecting quantal size or production of overt neurotoxicity (Nemani et al., 2010). 
Interestingly, while haSWT overexpression in PC12 cell studies also revealed an 
accumulation of granules adjacent to the plasma membrane (Larsen et al., 2006), and 
haSWT overexpression in hippocampal neurons displayed reduced synaptic vesicle 
recycling dynamics, with vesicles accumulating in regions away from the synapse active 
zone (Nemani et al., 2010). A disease-relevant caveat to aS-mediated inhibition of 
exocytosis is the A30P missense mutation associated with familial PD (Kruger et al., 
2001). Human A30P aS has (haSA30P) been shown to impair aS interactions with 
membranes (Jo et al., 2002). However, while overexpression of haSA30P in neurons does 
not produce inhibition of exocytosis as compared to its WT counterpart (Nemani et al., 
2010), PC12 cells overexpressing either haSWT or haSA30P had similar effects on decrease 
exocytotic function (Larsen et al., 2006). Taken together, these studies demonstrate that 
aS functions in the modulation of neurotransmission in several neuronal types, including 
dopaminergic and glutamatergic neurons.  
 The regulatory aspect of aS may also be due to its ability to form multimers following 
membrane interaction (Burré et al., 2014), whereby aS reportedly clusters synaptic 
vesicles in neurons away from the active site to further regulate vesicle mobilization and 
exocytosis (Wang et al., 2014). This is in line with observations in neurons lacking aS that 
highlight a specific deficiency in vesicles not docked at presynaptic sites (Cabin et al., 
2002). aS may also exert its modulatory effect on signaling through another vesicle-centric 
aspect, such as recycling and endocytosis of vesicles following periods of high frequency 
stimulation and neurotransmission (Vargas et al., 2014). These studies collectively 
suggest that aS suppresses synaptic transmission through vesicle exocytosis and 
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recycling as opposed to affecting the actual packaging of initial vesicles at presynaptic 
boutons. Moreover, it is likely that aS is not vital for synaptic formation or basal 
neurotransmission but may play a more intricate role in modulation of synaptic plasticity 
and maintenance of synapses.  
 From a biochemical perspective, aS overexpression reduces both synapsin and 
complexin levels, key presynaptic proteins involve in vesicle release (Nemani et al., 2010). 
However, homozygous knockout mice of aS (SNCA-/-) and bS (SNCB-/-) display restored 
complexin levels (Chandra et al., 2004), suggesting that pathologic levels of aS that 
reduce synaptic transmission do so potentially through by direct mechanisms such as 
blocking vesicle fusion or recycling, but also indirect mechanisms, such as reducing the 
levels of protein machinery required for presynaptic vesicle release.  
 In addition to its role in modulation the modulation of neurotransmission, aS may also 
function to maintain presynaptic terminals. Knockout of cysteine string protein a (CSPa), 
a presynaptic chaperone, in mice, leads to rapid and progressive synaptic degeneration 
and death. However, overexpression of haSWT compensates for this loss and delays the 
degenerative and lethal phenotype observed in CSPa knockout mice (Chandra et al., 
2005), suggesting that aS may have additional roles as a chaperone for presynaptic 
machinery and vesicles. Evidence supporting this hypothesis comes from another study 
that demonstrated that aS can directly interact with synaptobrevin 2, a member of the 
vesicle-SNARE (soluble NSF attachment protein receptor) complex, and potentially 
contribute to SNARE complex formation that mediates vesicle binding to presynaptic 
nerve terminals (Burré et al., 2010). This supportive role of aS in neuronal function is 
furthered by studies demonstrating that mice lacking all three synucleins (aS, bS, and gS) 
have reduced SNARE complex formation, reduced excitatory presynaptic terminal size, 
neuronal dysfunction, and shortened lifespan (Anwar et al., 2011; Greten-Harrison et al., 
  14 
2010; Vargas et al., 2017). SNCA-/- mice have also been reported to have impaired 
performance on behavioral assays of spatial learning and memory (Kokhan et al., 2012), 
suggesting that the role of aS in presynaptic neurotransmission has greater implications 
on synaptic plasticity and behavior.  
 In line with its presynaptic enrichment, aS is almost exclusively localized to neuronal 
tissues (Iwai, 2000). However, one exception to this is aS expression in cells of 
hematopoietic lineages, including red blood cells as well as platelets (Barbour et al., 2008; 
Li et al., 2002). Interestingly, the role of aS in the vasculature seems to parallel its role in 
synaptic function in the nervous system. For example, aS has been demonstrated to play 
a role in inhibition of granule release from platelets, serving to regulate and modulate 
clotting, and overexpression of familial PD-linked A53T or A30P aS mutants further 
reduced exocytosis of granule contents from platelets. (Park et al., 2002). PD patients, 
both familial and idiopathic cases, are at an increased risk for stroke, potentially shedding 
light onto a new mechanisms underlying PD/DLB pathogenesis, motor and non-motor 
symptoms, and contributors to morbidity and mortality following diagnosis of a-
synucleinopathy (Garcia-Gracia et al., 2013; Jellinger, 2003).  
 
Parkinson’s disease as a movement disorder and a-synucleinopathy 
 Movement disorders represent a broad family of neurological diseases that often have 
similar clinical presentations but with strikingly different origins. As such, a clinical 
challenge in the diagnosis of movement disorders is understanding drivers of the 
presenting symptoms and differentiating among diseases with common presentations. 
Clinically, these disorders are classified as hyperkinetic, hypokinetic, or dystonic. 
Hypokinetic disorders include PD, multiple system atrophy (MSA), progressive 
supranuclear palsy (PSP), and corticobasal degeneration (CBD), all of which can give rise 
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to a constellation of physical exam findings (resting tremor, bradykinesia, rigidity, postural 
instability) collectively termed “parkinsonism” (Stoessl and Mckeown, 2016). MSA, PSP, 
and CBD are also part of group of neurodegenerative diseases called Parkinson-plus 
syndromes, all of which possess key features to help differentiate them from each other 
and from PD. For example, while individuals with MSA-induced parkinsonism can display 
a reduction in motor symptoms in response to L-DOPA treatment, this response wanes 
with disease progression. PSP patients display a supranuclear gaze palsy and disease-
specific midbrain findings upon MRI, both of which serve as exclusionary criteria for a 
diagnosis of PD as the cause of parkinsonism (Postuma et al., 2015). Further 
differentiation can be made pathologically as CBD and PSP are tauopathies, displaying 
characteristic aggregates of the protein tau in glial cells, astrocytes. In addition to being 
movement disorders sharing parkinsonism as common clinical findings, PD and MSA, 
along with DLB, also share pathological findings that place them into the 
synucleinopathies, a group of neurodegenerative disease characterized by the formation 
of intracellular a-synuclein-containing inclusions in the brain. These include Lewy bodies 
(LBs) and Lewy neurites (LNs) found in the neurons of PD and DLB, and glial cytoplasmic 
inclusions (GCIs) within oligodendrocytes of MSA patients (Yang and Yu, 2017).  
 Despite sharing many clinical and pathological features, cognitive deficits in particular, 
dementia in PD (PDD) and DLB are classified as separate entities in the latest version of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Interestingly, their 
differential diagnosis is made based upon an arbitrary distinction concerning the temporal 
onset of motor and cognitive deficits. DLB is diagnosed when the onset of dementia 
precedes onset of parkinsonian signs for at least one year (McKeith et al., 2017). 
Conversely, the diagnosis of PDD is made when cognitive impairment develops in the 
setting of long-standing PD (Emre et al., 2007). However, the rationale for considering 
PDD and DLB as separate but related neurodegenerative diseases may be becoming 
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increasingly antiquated, and whether these two are the same disease or not has been the 
subject of recent debate (Friedman, 2018; Jellinger, 2018; Jellinger and Korczyn, 2018; 
McKeith et al., 2017). Beyond the defined 1-year rule, PDD and DLB share many non-
motor symptoms, including autonomic dysfunction and psychiatric changes, further 
complicating clinical presentation as the singular means for differential diagnosis. As 
synucleinopathies, PDD and DLB share neuropathological features that include striatal LB 
pathology, but also cortical LB pathology (Braak Stage 5-6, Braak et al., 2003) as well as 
hippocampal aS pathology. It is possible that the extent of AD pathology measured either 
postmortem or antemortem via PET, including extracellular Ab plaques and intraneuronal 
fibrillary tau tangles (NFTs), may represent a key pathological difference as DLB brains 
display higher cortical Ab and tau loads (Jellinger and Korczyn, 2018). Despite this 
considerable pathological and clinical overlap between PDD and DLB, biomarker and 
neuroimaging studies have proven beneficial in providing potential mechanisms for 
discrimination. Elevated tau and reduced Ab levels in the cerebrospinal fluid (CSF), a 
profile associated with AD, is higher in DLB as compared to PDD (van Steenoven et al., 
2016; Vranová et al., 2014). However, unlike AD, medial temporal lobe and hippocampal 
volume is commonly preserved in PDD and DLB (McKeith et al., 2017). When combined 
as neurological disorders with shared clinical and pathological findings, PDD and DLB 
collectively represent the second-leading cause of dementia, behind AD (Aarsland, 2016). 
As such, considering them, with some caution, as a common neurodegenerative disorder 
is beneficial in improving our understanding of the pathogenesis and pathophysiology in 
a-synuclein-mediated cognitive decline.  
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Motor symptoms in Parkinson’s disease and dementia with Lewy bodies 
 200 years have passed since James Parkinson’s original account, but the majority of 
the clinical features of the eponymous disorder he described have persisted (Parkinson, 
2002). Today the clinical diagnosis of PD still centers on a defined motor syndrome, 
“parkinsonism”, defined as bradykinesia, in combination with either a resting tremor, 
rigidity, or both (Postuma et al., 2015; Tolosa et al., 2006). Bradykinesia is defined as 
slowness of movement and decreased amplitude or speed as movements are continued. 
A resting tremor refers to a 4- to 6-hertz (Hz) tremor in a limb at rest, which is suppressed 
with movement, and often described as “pill-rolling.” Rigidity is observed to be a resistance 
to slow, passive movement of major joints when limbs are being manipulated on physical 
examination. Colloquially this can be referred to “cogwheel rigidity.” In addition to an initial 
diagnosis of parkinsonism, there are additional supportive and exclusion criteria to 
determine whether a patient meets the criteria for PD as the cause of parkinsonism 
(Postuma et al., 2015). These core clinical findings, in combination with the 
neurodegenerative, pathologic, and dopaminergic changes, have traditionally defined PD 
as a motor disorder. This has, consequently, focused more basic science approaches 
through a motor-centric lens, pushing towards understanding disease pathophysiology in 
the context of the basal ganglia. However, as PD prevalence increases and lifespan 
increases as well, non-motor symptoms in PD are gaining increasing clinical and scientific 
relevance. 
  
Non-motor symptoms in Parkinson’s disease and dementia with Lewy bodies 
 While a major theme of his “Essay” was shaking palsy as a motor disorder, Parkinson 
also recognized and documented non-motor symptoms that remain relevant to this day. 
In particular, he noted sleep disturbances, constipation, dysphagia, and incontinence 
(Parkinson, 2002). Today, non-motor symptoms (NMS) are considered a critical aspect of 
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PD and may even present prior to the onset of motor symptoms, representing a prodromal 
stage of the disease (Postuma et al., 2012, 2015). Further support for non-motoric 
prodromal PD comes from postmortem studies of sporadic PD patients demonstrating that 
the pathologic process may begin in regions outside of the substantia nigra pars compacta 
(SNPc) such as the anterior olfactory nucleus and dorsal motor nucleus of the vagus nerve 
(Braak et al., 2003). In line with these pathological findings, hyposmia, impaired olfaction, 
is sensitive for PD (> 80%) but not specific (Postuma et al., 2012).  
 Braak staging demonstrating Lewy body pathology beginning in the medulla and pons 
is possibly associated with rapid eye movement (REM) sleep behavior disorder (RBD), a 
pathological condition where REM sleep is not accompanied by the typical atonia (lack of 
skeletal muscle activity) (Postuma et al., 2012). The clinical implications of sleep changes 
in the context of prodromal PD is highly significant as longitudinal studies demonstrate 
that RBD patients develop PD at rates that climb up to 90.9% at 25 years following 
diagnosis of RBD (St Louis and Boeve, 2017). Despite this high phenoconversion rate, it 
is important to note that RBD has been shown to occur in only 30 to 50% of PD patients 
(Schenck et al., 2013), suggesting that pathological processes mediating RBD may be 
contributing to, rather than essential for, PD pathogenesis.  
 Autonomic dysfunction is another NMS in PD and potentially also in the prodromal 
stage. Orthostatic hypotension and urinary incontinence represent two key products of 
autonomic dysfunction in PD, and these symptoms are found in both early and prodromal 
stages of the disease (Obeso et al., 2017; Postuma et al., 2012, 2013). A more prominent 
manifestation of autonomic dysfunction is gastrointestinal dysfunction, which occurs along 
the length of the gastrointestinal tract in PD, including excess salivation, dysphagia, and 
gastroparesis. Constipation and gastroparesis are common in individuals with PD 
(Postuma et al., 2013; Schapira et al., 2017) and are believed to be secondary to impaired 
activity of the enteric nervous system. Like RBD, support for gastrointestinal dysfunction 
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being a component of prodromal PD first comes from epidemiological studies 
documenting constipation representing an increased risk for PD (Savica et al., 2009), and 
is furthered by pathological studies demonstrating PD pathology in cells of the 
gastrointestinal tract and enteric nervous system (Braak et al., 2006; Chandra et al., 2017; 
Lebouvier et al., 2009). Moreover, the vagus nerve is important for autonomic control of 
the bowel, the dorsal motor nucleus of the vagus is one of the earliest sites of PD 
pathology (Braak et al., 2003), potentially explaining why gastrointestinal disturbances are 
a common non-motor feature of PD, but also may occur prior to alterations in motor 
function. 
 
Cognitive decline: a prominent non-motor symptom in Parkinson’s disease and 
other synucleinopathies 
 
 In James Parkinson’s 1817 definition of the shaking palsy, cognitive impairment does 
not appear to be a prominent disease feature. This is highlighted in two of his six cases: 
“the senses and intellects being uninjured” in one, and another “the powers of his mind, 
unimpaired.” Two centuries of clinical observations have advanced Parkinson’s initial 
findings to now include cognitive decline and dementia as one of the most frequent non-
motor problems in advanced stages of PD that greatly impairs quality of life (Winter et al., 
2011). Together, PDD and DLB represent a multifactorial burden and challenge, 
increasing caregiver burden, health-related costs, risk for admission to a nursing home or 
assisted living facility, duration of hospital stays, and even mortality (Fletcher et al., 2011; 
Vossius et al., 2011).  
 Mild cognitive impairment (MCI) is often considered a precursor to dementia, where 
cognitive deficits are present and detectable via assessment, but, unlike dementia, are not 
severe enough to significantly impair daily life and one’s ability to live independently. MCI 
is evident in approximately 10-20% of individuals at the same time they are diagnosed 
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with PD (Svenningsson et al., 2012), however not all individuals with MCI progress to 
dementia. PD patients have a three-to-six times higher risk of developing dementia than 
age-matched healthy individuals (Svenningsson et al., 2012). Cross-sectional studies 
have demonstrated that upwards of 30% of all patients with PD have dementia (Aarsland 
et al., 2008). The incidence of dementia in PD is 100 per 100,000 patient-years, with 80% 
of individuals with long-standing PD likely to develop dementia at some point during the 
course of the disease (Aarsland et al., 2017). Given that the mean age of PD diagnosis is 
near 60 years of age, and life expectancy for adequately-managed, non-demented PD 
individuals is similar to that of unaffected individuals (Winter et al., 2011), cognitive 
impairment and dementia in the a-synucleinopathies is a pressing clinical challenge.  
 
Current treatments and the need for studying non-motor symptoms in Parkinson’s 
disease and dementia with Lewy bodies 
 
 Loss of dopaminergic (DAergic) neurons in the SNPc leading to depletion of striatal 
dopamine (DA) loss underlies the cardinal motor features in PD. Since its identification in 
the 1960s, DA replacement in the form of levodopa (L-DOPA, the blood-brain-barrier-
permeable precursor to DA) continues as the current gold standard in treatment of PD 
symptoms, attempting to mitigate decreased dopaminergic output from the SNPc. Current 
L-DOPA preparations include aromatic amino acid decarboxylase (AADC) inhibitors such 
as carbidopa in order to prevent metabolism of L-DOPA to DA in the periphery and 
enhance half-life and bioavailability in the brain. To complement AADC inhibitors, 
catechol-O-methyltransferase (COMT) inhibitors are also employed to further enhance DA 
half-life and brain bioavailability. In addition to reuptake from the synaptic cleft, DA is 
cleared through oxidation via monoamine oxidase B (MAO). As such, pharmacologic MAO 
inhibitors, such as selegiline are used to increase synaptic concentrations of DA. Beyond 
DA replacement and pharmacologic tools to support this process, DA agonists are also 
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palliative approaches to motor dysfunction in PD, acting on DA receptors of striatal 
medium spiny neurons. While DA agonists are marginally less effective as compared to 
L-DOPA, they are less prone to inducing striatal DA receptor stimulation as compared to 
L-DOPA, and thus less likely to induce unwanted motor side effects (dyskinesia). It is, 
however, important to note the DA replacement therapies are even incomplete in their 
capacity to treat motor dysfunction in PD, as many forms of tremor, freezing of gait, and 
postural instability are often resistant to L-DOPA therapy.  
 Deep brain stimulation (DBS) of the subthalamic nucleus or globus pallidus internus 
emerged in the 1990s for management of motor dysfunction in PD for patients whose 
symptoms were not adequately controlled pharmacologically (Okun, 2012). Importantly, 
DBS has proven to improve quality of life in PD patients by serving to reduce drug dosage 
needs and dyskinesia and improve activities of daily living. However, several non-motor 
symptoms found in PD are exclusion criteria for DBS, such as dementia, psychosis, and 
depression, and thus non-motor symptoms are not currently able to be managed via DBS. 
 Gene therapy also presents an area of clinical opportunity for therapeutic advance in 
PD. The two major strategies for gene therapy in PD is delivery of viral vectors to mediate 
expression of growth factors or neurotransmitter-synthesizing enzymes. Delivery of 
trophic factors such as glial cell line-derived neurotrophic factor (GDNF) and neurturin has 
proven beneficial in animal models of PD and certain clinical trials (Kordower and 
Bjorklund, 2013). Viral vector delivery of enzymes involved in DA synthesis such as TH or 
AADC have been injected into the striatum, with the goal of modifying striatal neurons to 
produce and release DA locally, compensating for SPNc neurodegeneration (Mittermeyer 
et al., 2012; Palfi et al., 2014). Fetal cell transplantation of DAergic neurons have also 
been shown to restore DA neurotransmission and connectivity in PD patients, but sadly 
no evidence of clinical benefit was reported (Freed et al., 2001). Active and passive 
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immunization focusing on aS have more recently come into the realm of clinical trials 
(Mandler et al., 2014).  
 While an improved knowledge of disease pathophysiology has led to considerable 
advances in PD therapies, there remains a focus on treating PD as a movement 
neurological disorder centered around the basal ganglia. The therapeutic limitation of 
DAergic therapies in PD comes from the Levodopa in Early Parkinson Disease (LEAP) 
trial, where L-DOPA had no disease-modifying effect (Verschuur et al., 2019). Moreover, 
all current DA-centric therapies fail to (Seppi et al., 2011) address NMS in PD, particularly 
cognitive decline. Treatments addressing dementia and cognitive dysfunction in PD and 
DLB are extremely limited primarily borrowed from AD via repurposing of 
anticholinesterase or and N-methyl-D-aspartate (NMDA) receptor inhibitors (Connolly and 
Fox, 2014; Seppi et al., 2011). While this approach has indeed provided some clinical 
benefit for dementia in the a-synucleinopathies, it is clear that meaningful therapeutic 
advances truly rely on a better understanding of the pathological mechanisms and 
processes underlying cognitive dysfunction in PDD and DLB.  
  
Models for studying a-synucleinopathies 
 Clinical, pathological, and genetic studies have greatly informed our capacity to model 
a-synucleinopathies, PD in particular, both in vitro and in vivo. However, it is important to 
understand that disease models are likely to not be complete replications of the human 
disease and identifying the right model for the question being asked and understanding 
both the benefits and limitations of that model, are essential to drawing meaningful 
conclusions from experiments. Indeed, while an ideal model for PD would capture all 
aspects of the disease, none of the current models completely recapitulate the cardinal 
clinical and neuropathological findings observed in PD. This is not to say that any of these 
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current models are considered to be failures but are, instead, effective and versatile 
experimental tools used in pursuit of answering a scientific and clinical hypothesis. Despite 
these challenges in modeling PD and the a-synucleinopathies and not without caveats, 
these disease models have yielded significant insight into disease pathogenesis and 
served as platforms to test potential therapeutics and will continue to be major contributors 
in the quest towards better understanding disease mechanisms and developing treatment 
interventions.  
 Some of the initial animal models used to investigate PD were born out of a connection 
between toxins and parkinsonism. The identification of MPTP-induced parkinsonism, 
specific DAergic neuron loss, and Lewy pathology in patients (Langston et al., 1983) 
established MPTP as an tool to study the mechanisms underlying DAergic neuron death 
in disease. First generation MPTP animal models consisted of intravenous MPTP 
injections into primates. These monkeys developed almost all of the motor symptoms 
observed in PD patients, were responsive to levodopa, and also had DAergic neuron loss 
(Burns et al., 1984). Mice injected with MPTP also demonstrated destruction of the nigro-
striatal pathway, loss of DAergic neurons in the SNPc, and locomotor abnormalities 
(Jackson-Lewis et al., 1995; Muthane et al., 1994; Taylor et al., 2010). However, Lewy 
pathology (LBs and LNs) are noticeably absent in the MPTP toxin model (Halliday et al., 
2009). Despite this shortcoming, MPTP-induced neurodegenerative changes are specific 
and reproducible, a major strength when considering the landscape of genetic models of 
PD and the a-synucleinopathies. Additional toxin models were informed by 
epidemiological studies connecting the pesticides rotenone and paraquat with early-onset 
parkinsonism (Tanner et al., 2011). Chronic exposure to rotenone in rats has proven to 
induce degeneration of DAergic nigro-striatal neurons and postural and motor 
abnormalities resembling the parkinsonian phenotype (Betarbet et al., 2000). Rotenone-
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injected rats also display a-synuclein- and ubiquitin-positive cytoplasmic inclusions in 
nigral neurons reminiscent of Lewy bodies (Betarbet et al., 2000; Sherer et al., 2003). The 
rotenone model is exciting for its ability to reproduce these key neuropathological and 
locomotor findings, but faces challenges with variability between animals and high 
mortality (Betarbet et al., 2000). Systemic application of the herbicide paraquat has been 
shown to impair locomotor activity due to DAergic neuron and striatal tyrosine hydroxylase 
(TH) loss (Brooks et al., 1999). 6-OHDA functions similarly to MPTP as a neurotoxin 
selective for dopaminergic neurons. However, in contrast to MPTP and other neurotoxins, 
6-OHDA is  blood-brain-barrier impermeable and thus requires direct injection into the 
striatum to exert its pro-parkinson effects that include DAergic neuron loss in the SNPc 
(Sauer and Oertel, 1994). Collectively, these models, directly informed by clinical and 
epidemiological observations, represent a platform to provide insight into the mechanisms 
driving selective neuron loss in PD, traditionally through a focus on differential bioenergetic 
demands and mitochondrial dysfunction (Halliday et al., 2009; Meredith and Rademacher, 
2011; Surmeier et al., 2010). While potentially limited in disease scope, the toxin animal 
models are the only systems currently employed that provide for the development SNPc 
DAergic neuron loss. 
 The identification of genetic mutations in the late 1990s as a cause for inherited forms 
of PD provided for the generation of transgenic models. There are two known autosomal-
dominant inherited causes of PD: mutations in the SNCA gene encoding aS and mutations 
in the LRRK2 gene encoding the leucine rich repeat kinase 2 (LRRK2) protein. SNCA 
gene duplications, triplications, or point mutations (A30P, E46K, H50Q, G51D, and A53T) 
cause familial PD, and many of these genetic abnormalities have been used to direct 
transgenic animal model generation. However, while SNCA was the first gene linked to 
familial autosomal-dominant PD (Polymeropoulos et al., 1997), its product, aS, is the main 
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component of LBs and LNs, found in both familial and idiopathic cases of PD (Spillantini 
et al., 1997). As such, while using aS-based transgenic mouse models for PD may be 
based on rare mutations, they have the potential to illuminate mechanisms of aS-mediated 
neuronal dysfunction and neurodegeneration in all cases of PD and DLB.  
 Some of the first genetic-derived in vivo models of PD were generated in the fruit fly 
(Drosophila melanogaster). Although Drosophila do not have an SNCA homolog, they 
present a unique and versatile model for studying PD pathogenesis given their rapid 
generation cycle (10-14 days from embryo to adult), short lifespan (50-60 days), relatively 
high homology to human genes (75%), and expression of dopaminergic neurons (Mizuno 
et al., 2010). Overexpression of haSWT, haSA30P, or haSA53T in Drosophila causes TH loss, 
neuronal cytoplasmic filamentous inclusions composed of aS, retinal neurodegeneration, 
and motor deficits (Feany and Bender, 2000). Interestingly, the parallel time course of 
dopaminergic neuron loss, aS inclusion formation, and behavioral deficits suggests that 
these three abnormalities and hallmarks of PD, are linked. Drosophila has proven to be a 
fruitful model for insight into the role of aS in PD, connecting aS with TH neuron loss, and 
phosphorylation of aS at serine 129 increasing toxicity and inclusion formation (Auluck et 
al., 2010; Chen and Feany, 2005). Another non-rodent animal model of PD that has helped 
to advance our understanding of PD has been the nematode (Caenorhabditis elegans). 
Early C. elegans model systems used relied on neuronal-specific promoters to direct either 
human WT or mutant aS overexpression and have been valuable for demonstrating aS-
mediated dopaminergic neuron loss as a key driver of locomotor dysfunction (Lakso et al., 
2003).  
 Advancing in terms of complexity, mouse models of disease have become increasingly 
common given the extremely high homology (~98%) to the human genome (Guénet, 
2005). To date, many aS transgenic (Tg) mouse models (overexpressing human WT or 
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mutant aS) via different promoters have been developed and remain a staple of PD 
research. While these mice may display decreased levels of TH or DA in the striatum, 
behavioral abnormalities, and cytoplasmic aS aggregates, degeneration of nigro-striatal 
DAergic neurons has not been observed. The first Tg mouse model of PD expressed 
haSWT under the PDGF-b promoter (PDGF-haSWT), targeting transgene expression to 
neurons (Masliah et al., 2000). While these mice display ubiquitin and aS-positive intra-
neuronal inclusions, TH fiber and DA reduction in the striatum, and impaired motor 
performance, neurodegeneration is markedly absent. Tg mice expressing haSWT under 
the mouse Thy-1 promoter (Thy-1- haSWT) demonstrated a higher and more broad 
expression of human aS throughout the nervous system, including basal ganglia and SN 
when compared to PDGF-b transgenic mice (Rockenstein et al., 2002). Thy-1- haSWT Tg 
mice also displayed intracellular aS inclusions in the SN, and low expression of aS in glia, 
consistent with aS being expressed almost exclusively in neurons, in contrast to what was 
observed in the PDGF-haSWT Tg model. In addition to promoter differences, it is also 
important to take the genetic background of the mouse strain used into consideration. The 
Tg mice previously discussed were both on the C57BL6/J x DBA mouse strain 
background. In contrast, an additional set of Thy-1-haSWT and Thy-1-haSA30P Tg mice 
under on the C57BL6/J mouse background alone display lower SNPc aS pathology but 
higher pathology and neurodegeneration in motor neurons (van der Putten et al., 2000). 
Generation of Thy-1-haSA30P Tg mice on the C57BL/6 background display several cardinal 
PD features including fibrillar LB-like inclusions, reduction in DA levels, and late-onset 
paralysis (Kahle et al., 2000; Neumann et al., 2002). However, neurodegeneration in these 
Thy-1-haSA30P Tg mice is found outside of the basal ganglia, localized to sensory and 
motor neurons in the brainstem and spinal cord (Neumann et al., 2002), While this 
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collection of murine Thy-1 Tg mice lack overt loss of nigro-striatal DAergic neurons, many 
show loss of DA reduction (van der Putten et al., 2000; Rockenstein et al., 2002). 
 Like Thy-1, the mouse prion promoter (mPrP) has also been a useful tool in driving 
pan-neuronal transgene expression. Homozygous Tg mice expressing human missense 
mutant A53T aS under the mPrP promoter (mPrP-haSA53T, line M83) display progressive 
motor impairment and diffuse LB-like aS pathology throughout the mouse brain (Giasson 
et al., 2002). Another mPrP-haSA53T Tg mouse replicates the pan-neuronal expression of 
human aS and deficits in motor coordination and performance, but no aggregation 
(Gispert et al., 2003). It is, however, important to note that these mice were on a different, 
FVB/NJ, mouse background. A caveat to the FVB/NJ model is retinal degeneration leading 
to blindness (Wong et al., 2012).  
 An exciting advance in the era of aS Tg mouse models in PD research came from the 
generation and comparison of mPrP-haSWT (TgWT, line I2-2), mPrP-haSA30P (TgA30P, 
line O2), and mPrP-haSA53T(TgA53T, line G2-3) in the C57BL6/J background (Lee et al., 
2002). The generation of these Tg mice all on similar backgrounds provided for a direct 
comparison of aS variants and expression. In addition to the G2-3 line, a lower expressing 
haSA53T line was generated, line H5. Both G2-3 and H5 mice develop progressive 
neurological abnormalities and premature death, but higher transgene expression was 
associated with earlier disease onset and death (Lee et al., 2002), in line with the 
observation that aS expression is a key determinant of PD progression (Singleton et al., 
2003). O2 mice, while expressing similar levels of transgene when compared to G2-3, do 
not develop overt neuropathology or neurological abnormalities. G2-3 mice also display 
ubiquitin- and aS-positive intracellular inclusions in deep cerebellar nuclei, reticulo-pontine 
nuclei, spinal cord, motor neurons, and neocortex, but not the SNPc. In line with lack of 
SNPc pathology, there is neither loss of DAergic neurons or DA in the striatum. Similar to 
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the O2 strain, I2-2 mice do not develop neurological dysfunction, suggesting that the 
missense A53T mutation in human aS is associated with increased neurotoxicity in mice.  
 Human aS (WT, A30P, or A53T) transgene expression has also been focused to the 
striatum via use of the TH promoter. Similar to Tg mice with pan-neuronal Thy-1 or mPrP 
promoters, TH Tg mice do not entirely capture the human version of PD and 
accompanying a-synucleinopathies. Initial studies from these mice demonstrate that 
despite high aS transgene expression, there is a lack of neuropathological or behavioral 
changes as indicated by an absence of Lewy-like inclusions, reduced striatal DA, or loss 
of nigral neurons (Matsuoka et al., 2001). While other iterations of the TH Tg mice 
displayed some modest neurological changes, including dystrophic neurites, reduced DA, 
and impaired motor coordination, intraneuronal Lewy-like aggregates of aS were 
noticeably absent (Richfield et al., 2002). 
 Improved genetic tools have provided for newer models of PD and the a-
synucleinopathies. An example of this is the tetracycline (tet)-regulated transgenic switch 
that employs two separate components acting in trans: a tissue-specific promoter 
(activator or driver component transcribing the tet-regulated transcription activator, tTA) 
plus responder component (transgene of interest under the tTA promoter) (Gossen and 
Bujard, 1992). tTA affinity for the target promoter can be altered, activated or inactivated, 
via tetracycline antibiotics such as doxycycline, providing for temporal control of transgene 
expression in addition to regional control. Tg mice overexpressing haSWT or haSA53T in the 
tet-OFF CaMKII conditional promoter system have targeted transgene expression to 
forebrain and midbrain neurons (Nuber et al., 2008). Neurodegeneration in these strains 
is observed in the SNpc, hippocampus, and non-DAergic neuron loss, modest loss of TH-
positive cells, but no aS Lewy-like pathology. These mice also display impaired motor 
learning and function as assayed via rotarod, but normal DA levels in the striatum. Another 
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tet-OFF system Tg-haSA53T mice under the Pitx3 promoter targets transgene expression 
to midbrain DA neurons (Lin et al., 2012). Pitx3-dicrected expression of haSA53T results in 
pronounced midbrain neurodegeneration, reduction in DAergic neurotransmission, and 
motor dysfunction. With these deficits and regionally-focused expression, use of the tTA 
system, in contrast to pan-neuronal promoters of the Thy-1 and mPrP mice, provides a 
powerful tool to parse out the brain region specificity and contributions to the 
neuropathological, biochemical, functional, and behavioral abnormalities occurring in 
these mice and potentially in PD brains as well.  
 While at first blush the lack of a complete recapitulation of all aspects of PD in these 
Tg mice may be interpreted to be a shortcoming in disease modeling, they provide an 
incredibly valuable window into the disease. These animals represent essential tools in 
advancing our understanding of key pathological processes and mechanisms driving the 
molecular, cellular, and behavioral changes underlying neurodegenerative disorders, and 
the a-synucleinopathies in particular.  
 
Cognitive decline in mouse models of Parkinson’s disease and dementia with Lewy 
bodies 
 
 NMS in PD, including psychiatric and sleep disorders, and cognitive, gastrointestinal, 
and autonomic dysfunction, are garnering increasing attention as they continue to remain 
unresolved by DA-centric therapies such as L-DOPA and DBS (Chaudhuri and Schapira, 
2009). As these treatments have been able to largely and successfully provide 
symptomatic relief from these cardinal motor symptoms, NMS often have a greater 
negative impact on quality of life when compared to motor dysfunction (Martinez-Martin et 
al., 2011). Motivated by the adverse influence of NMS in the quality of life in PD patients, 
it has been of interest to assess wither animal models of PD can be used to investigate 
the mechanisms driving NMS in PD and the a-synucleinopathies.  
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 Toxin models of parkinsonism are popular models for their capacity to produce 
DAergic neuron degeneration in the nigro-striatal pathway and motor dysfunction 
(Meredith and Rademacher, 2011). Bilateral injection of 6-OHDA into the SNPc of rats led 
to striatal loss of DA neurons, reduction in TH immunoreactivity, and the development of 
spatial memory deficits (Tadaiesky et al., 2008). In addition to producing cognitive 
dysfunction, this toxin model and approach produces partial replication of psychiatric 
NMS, including a depressive-like phenotype, that is likely due to reductions in DA, 
serotonin (5-HT) and noradrenaline (NA), demonstrating that 6-OHDA can induce 
changes in other neurotransmitter systems beyond DA (Santiago et al., 2010). However, 
whether these changes are a direct consequence of 6-OHDA neurotoxicity or due to 
neurodegenerative changes in DAergic circuitry remain to be elucidated. Systemic MPTP 
injection presents an established model for nigro-striatal DAergic neurodegeneration and 
parkinsonism in mice. MPTP-treated mice have been shown to develop deficits in cued 
fear conditioning that is accompanied by decreased DA and 5-HT levels in the striatum, 
amygdala, and cortex (Vučković et al., 2008). While these 6-OHDA and MPTP models do 
replicate several non-motor aspects of PD, particularly cognitive impairment, the rapid 
onset of neurodegeneration does not accurately reflect the more global and progressive 
nature of the disease. 
 Patients with familial PD due to SNCA duplications, triplications, or missense 
mutations including A30P, E46K, and A53T often have prominent NMS, including 
cognitive impairment and dementia (Bougea et al., 2017; Ikeuchi et al., 2008; Kruger et 
al., 2001; Puschmann et al., 2009; Singleton et al., 2003; Spira et al., 2001; Zarranz et al., 
2004). A53T aS carriers have also presented with cognitive decline resembling FTD prior 
to overt parkinsonism onset (Bougea et al., 2017). In addition to causal mutations in 
SNCA, different SNCA haplotypes associated with an increased risk for PD are also 
associated with impaired cognitive performance and learning (Kéri et al., 2008). Taken 
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together, these observations provide compelling evidence for aS-mediated cognitive 
decline in PD and DLB, a hypothesis that can be directly tested in aS genetic models of 
PD.  
 PDGF- haSWT Tg mice display a progressive loss of DAergic neuron terminals in the 
striatum and is accompanied by locomotor abnormalities (Masliah et al., 2000). Cognitive 
function, as assayed via the Morris water maze, is impaired by six months of age and 
given that these mice display extensive cortical, hippocampal, and limbic aS pathology, 
the PDGF-haSWT mouse is preferentially characterized as a DLB model rather than PD 
(Rockenstein et al., 2002). Thy-1-haSWT Tg mice display impaired performance in the Y-
maze spontaneous alternation and novel object recognition tasks beginning as early as 
four months of age, prior to neurodegenerative changes in the striatum and SNPc 
(Chesselet et al., 2012; Magen et al., 2012). More recently, 5-month-old Thy-1-haSWT mice 
have been shown to display cognitive deficits in the short-term spatial learning and 
memory setup of the Y maze (Ferreira et al., 2017). It is interesting to note that while these 
mice all express haSWT, their genetic backgrounds, promoter, transgene expression level, 
and aS-induced neuropathology and neurodegenerative phenotypes differ slightly. 
However, as they all have been reported to display deficits in cognitive performance, albeit 
in different experimental paradigms and at different age points, one can hypothesize that 
neuronal and synaptic mechanisms underlying memory impairment in these mice is 
independent of overt PD-associated neuropathology.  
 Many strains of Tg mice expressing human mutant aS have been shown to display 
increased neuropathology and neurotoxicity as compared to their haSWT counterparts, and 
thus it could be reasonably hypothesized that these strains demonstrate more robust 
NMS. Thy-1-haSA30P Tg mice display progressive, age-dependent cognitive deficits on the 
Morris water maze and via cued fear conditioning by 12 months of age, that appear to 
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coincide with development of fibrillar intraneuronal cytoplasmic aS inclusions in both the 
hippocampus and amygdala (Freichel et al., 2007). haSA30P-mediated deficits in contextual 
fear conditioning have been observed in much older mice, averaging 18-months-old, and 
were accompanied by increased pSer129-aS staining (Schell et al., 2012). 12-month-old 
mPrP-haSA53T (M83) mice display age-dependent spatial memory deficits when tested in 
the Y-maze, but not at younger age points (Paumier et al., 2013). Both mPrP-haSWT (I2-
2) and mPrP-haSA53T (G2-3) display cognitive deficits in spatial learning and memory as 
assessed via Barnes maze (Larson et al., 2012; Teravskis et al., 2018), yet I2-2 mice do 
not display neuropathology or neurotoxicity as compared to the G2-3 (Lee et al., 2002), 
contributing another layer to the argument that cognitive dysfunction in these mice and in 
PD may not be mediated by Lewy-like aggregates or DAergic neurodegeneration. Instead, 
soluble oligomeric species of aS have been demonstrated to impair synaptic structure, 
synaptic plasticity, and learning and memory in mice (Castillo-Carranza et al., 2018; 
Ferreira et al., 2017; Larson et al., 2012, 2017; Martin et al., 2012; Sengupta et al., 2015) 
 In contrast to the Tg mice above all using promoters that drive pan-neuronal 
expression, use of the CaMKII promoter restricts expression to forebrain structures. This 
represents an ideal system for assessing the consequences of regional haS expression, 
such as learning and memory deficits in the hippocampus due to specific haS expression 
in cortical and hippocampal neurons. Tg CaMKII-tTA mice expressing haSWT (CaMKII-
tTA- haSWT) display impaired memory function on the Morris water maze at 12 months of 
age and hippocampal aS pathology at 20 months (Nuber et al., 2008). CaMKII-tTA-
haSA53T mice also display age-dependent cognitive deficits as measured via contextual 
fear conditioning that is partly rescued by haSA53T suppression (Lim et al., 2011). Given 
that forebrain-directed haS expression is sufficient to induce progressive cognitive deficits, 
it is possible to conclude that DAergic neurodegeneration is not a major driver of aS-
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mediated memory dysfunction but rather due to aS-induced abnormalities in cortical and 
hippocampal neurons and their synapses. This is supported by studies demonstrating that 
overexpression of haSWT contributes to memory deficits in transgenic mouse models that 
lacking midbrain neurodegeneration (Larson et al., 2012, 2017; Magen et al., 2012).  
 Cell and region-specific overexpression of haS in midbrain DAergic neurons is 
achieved through use of the TH promoter or the Pitx3-tTA system. While DA and motor 
abnormalities have been observed in TH-haSWT Tg mice, cognitive deficits, to date, have 
not been reported (Richfield et al., 2002). In a similar vein, Pitx3-tTA-haSA53T animals 
display gait and motor deficits as early as two months of age that is accompanied by 
neuronal and DA loss neuron and striatal DA loss by six months (Lin et al., 2012). 
However, it is not known if these mice display any cognitive impairments, potentially 
suggesting that alterations in other circuits and neurotransmitter systems may be the 
predominant factors in driving cognitive decline in PD and DLB. 
 The causal relationship between the A53T missense mutation in the human SNCA 
gene and PD lends itself to the question if mice, which naturally have threonine (T) at 
residue 53 in the aS protein, are predestined to develop a rodent form of parkinsonism. In 
mice overexpressing mouse wild-type aS (maSWT) under the control of the Thy-1 promoter 
(Thy-1-maSWT) (Rieker et al., 2011), transgene expression was observed throughout the 
nervous system, similar to Thy-1-haSWT animals (Chesselet et al., 2012). Moreover, aS 
pathology, as demonstrated by ubiquitin and pSer129 staining was observed in both brain 
stem and spinal cord regions of mice, similar to G2-3 and M83 animals (Giasson et al., 
2002; Lee et al., 2002). Interestingly, pSer129 also accumulated in hippocampal neurons 
of Thy-1-maSWT mice. However, in contrast to the range of symptoms and phenotype 
displayed by mice expressing haSA53T, overexpression maSWT does not induce early-
onset behavioral changes by comparison, such as cognitive decline, but does drive similar 
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end-stage pathophysiological deficits such as mild synaptic and locomotor dysfunction 
(Rieker et al., 2011). Taken together, this study suggests that cognitive deficits in mouse 
models of PD is more likely a product of specific haS expression associated with PD as 
opposed to general overexpression of the protein.  
 Transgenic mouse models provide a vital role in the investigation of a-synucleinopathy 
pathophysiology but rely on a non-physiologic promoter of only complementary DNA 
(cDNA) that, together, may preclude the capacity to control any transcriptional or post-
transcriptional modifications involved in disease. As such, the generation of PD mouse 
models using bacterial artificial chromosomes (BAC) using the full gene sequence and 
endogenous promoter provide a more native spatial and temporal expression pattern and 
ideally create more physiologic-relevant system. While some of these models display 
modest DAergic neuropathological and neurodegenerative phenotypes observed in PD 
and other Tg models, NMS, including cognitive impairment, is largely absent (Janezic et 
al., 2013; Kuo et al., 2010). The modest phenotype observed in BAC lines is likely due to 
their low expression levels of haS. 
 
The TgA53T (G2-3) mouse model of a-synucleinopathy 
 G2-3 mice (Lee et al., 2002) represent one of many Tg mouse models expressing 
haSA53T, but has become a staple strain in the investigation of PD pathophysiology. 
Broadly speaking, it appears that haSA53Tappears more effective, or toxic, in mice as 
compared to overexpression of haSWT or haSA30P. Pan-neuronal transgene expression, 
driven by the mPrP promoter, produces aS at levels about six-times higher than 
endogenous maS. However, unlike other TgA53T aS mice such as M83 (Giasson et al., 
2002), homozygous G2-3 mice are not viable, and thus all G2-3 mice studied are 
hemizygous for their transgene. 
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 The initial reporting and characterization of G2-3 mice demonstrated that these mice 
develop progressive motor impairments around 10 months of age leading to premature 
death by 12 months of age (Lee et al., 2002). Early signs of motor impairments include 
wobbling and hindlimb retraction when picked up by the tail. This is followed by decreased 
locomotion, and mice ultimately become no longer able to walk upright and move, followed 
by hindlimb paralysis and cachexia en route to disease “end-stage” (“sick”). However, this 
time frame has since been shifting as this motor phenotype is about 90% penetrant, with 
“escaping” mice surviving to around 18 months (Jackson Laboratory, stock #006823, 
January 2019).  
 Use of the mPrP promoter drives haSA53T expression throughout the nervous system, 
including the SNPc. While in situ hybridization also confirmed mRNA in glia, levels were 
significantly reduced as compared to neurons (Lee et al., 2002). Consistent with aS being 
a presynaptic protein, haSA53T was detected in a punctate pattern in neurons and the 
neuropil, suggesting that trafficking and localization of the protein in mouse neurons 
remains physiological despite marked overexpression. Tg expression is also found in the 
SNPc, but neuropathology and neurodegeneration are noticeably absent from this region. 
Older and end-stage mice demonstrate accumulation of aS in other neuronal populations, 
however, including the midbrain, cerebellum, brainstem, and spinal cord motor neurons. 
In addition to being positive for aS, these aggregates are also immunoreactive for ubiquitin 
and neurofilament, and thioflavin-S-positive, indicative of a fibrillar structure similar to 
Lewy bodies (Lee et al., 2002). Reactive astrocytosis, and gliosis in general, is another 
feature in these mice, and is observed in regions with aS pathology such as the midbrain, 
brainstem, and spinal cord, but absent in regions without pathology such as the 
hippocampus and striatum.  
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 In addition to late-stage motor impairments and premature lethality, G2-3 mice display 
progressive locomotor hyperactivity between six and nine months (Daher et al., 2012; 
Smith et al., 2010; Unger et al., 2006). Unger and colleagues went on to demonstrate that 
this hyperactivity phenotype was shown to be a product of increase DA D1 receptor 
expression in the striatum and reduced DA transporter (DAT) at the synapse, which was 
accompanied by a reduced rate of DA uptake from the synaptic cleft. Consistent with the 
absence of significant neuron loss in the striatum, levels of DA and its metabolites DOPAC 
and HVA remain unchanged as compared to non-transgenic (nTg) littermate controls (Lee 
et al., 2002). This latter point has been recently under review as one study has 
demonstrated haSA53T-mediated impairment of autophagy as measured by reduced LC3-
II signal in the striatum and SNPc, which is accompanied by TH reduction in the striatum 
(Pupyshev et al., 2018). However, Pupyshev et al. (2018) also found a reduction in striatal 
DAT expression, similar to Unger et al. (2006). Although locomotor hyperactivity may not 
be a direct clinical observation in PD patients or those with parkinsonism, the G2-3 model 
and these studies clearly demonstrate that haSA53T expression is capable of disrupting DA 
metabolism and neurotransmission, and DAergic neurons as a whole, in line with what is 
observed in PD. Accompanying progressive these DAergic locomotor abnormalities, 
cognitive dysfunction at older ages like 11-12 months (Teravskis et al., 2018) 
 G2-3 mice have provided valuable insight into the mechanisms of aS-induced 
neuronal dysfunction. haSA53T demonstrates increased protein half-life, or decreased 
degradation rate, as compared to haSWT haSA30P variants (Li et al., 2004). It is therefore 
possible that this differential metabolism of haSA53T and age-dependent pathogenicity in 
when expressed in mice (Lee et al., 2002), and that toxicity is not just a product of 
increased translation of the protein, but stabilization of this translated product contributes 
to increased protein levels. G2-3 mice have been utilized to strengthen the mechanisms 
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connecting aging to neurodegenerative processes and have also been able to expand 
upon in vitro observations of haSA53T. In addition to aS aggregates, both G2-3 and M83 
mice display aS species at lower molecular weights than full-length around 14 kDa 
(Giasson et al., 2002; Lee et al., 2002). Moreover, these lower molecular weight species 
have been reported to be truncated on their C-terminus, a post-translational modification 
that enhances fibril assembly in vitro (Murray et al., 2003; Serpell et al., 2000). These C-
terminal truncated aS species are aggregation-promoting, pointing to another mechanism 
for aS-mediated abnormalities in neuronal dysfunction and PD pathogenesis (Li et al., 
2005).  
 Further insights into the mechanisms underlying aS-mediated neurodegeneration 
have been directly informed by studies in G2-3 animals. In line with proteostatic 
abnormalities being a core tenant of haSA53T-pathogenicity, G2-3 neurons accumulate 
toxic aS oligomers and are prominent in end-stage animals (Colla et al., 2012a). In 
particular, these oligomers preferentially localize to the endoplasmic reticulum (ER) and 
contribute to pathological ER stress, further impairing the cellular protein-folding 
machinery and rendering neurons more susceptible to accumulation of additional 
misfolded proteins. Along these lines, the unfolded protein response, while activated in 
response to aS aggregates, is dysfunctional in G2-3 mice and may also contribute to 
increased haSA53T accumulation and aggregation as animals age (Colla et al., 2012b). 
While ER chaperones are activated in G2-3 animals in a likely attempt to mitigate aS 
misfolding and aggregation, this ultimately leads to aS accumulation in the ER, 
ubiquitination, caspase activation, and ER stress-induced neurotoxicity, highlighting a 
pathway by which haSA53T contributes to neuronal dysfunction in vivo. Another component 
to protein folding are heat shock proteins (HSP), molecular chaperones that serve to 
ensure correct folding of proteins. Interestingly, G2-3 mice display increased levels of 
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HSP25 in reactive astrocytes found in regions of aS pathology such as the brainstem and 
spinal cord (Wang et al., 2008). By comparison, HSP25 levels were less prominent in 
neurons in these affected regions, suggesting that glial upregulation of HSP25 may 
represent a protective mechanism against neuronal dysfunction and degeneration in PD.  
 Additional pathological post-translational modifications of aS and the mechanisms 
driving them have also been investigated in vivo through the use of G2-3 animals. 
Activation of the tyrosine kinase c-Abl has been observed in the striatum and SNPc in 
human PD brains, and more recently G2-3 mice, where c-Abl hyperactivation leads to 
increased phosphorylation of haSA53T on tyrosine 39, with neurotoxic consequences 
including increased aS aggregation, brainstem neuropathology, and mortality 
(Brahmachari et al., 2016). In addition to pathological gain-of-function modifications of 
haSA53T that contribute to its aggregation, haSA53T contributes to disease pathogenesis by 
altering physiological protein interaction and function. For example, G2-3 mice display 
reduced LC3-II expression, indicative of impaired autophagic function (Pupyshev et al., 
2018). Earlier studies also shed light onto defective autophagy in this model. Synphilin-1 
has been shown to promote aS clearance via autophagy but appears to be defective and 
co-aggregate with aS in Lewy bodies in PD brains (Wakabayashi et al., 2000). G2-3 mice 
crossed with synphilin-1 overexpressing Tg mice display attenuated locomotor 
hyperactivity and delayed mortality, suggesting that haSA53T partly exerts its 
neurodegenerative effects via impairment of synphilin-1 function (Smith et al., 2010). In 
addition to behavioral rescue, these bigenic mice display increased markers of autophagy 
(beclin-1 and LC3-II) and decreased pro-apoptotic markers (caspase-3 activation), further 
suggesting that the A53T mutation leads to the disruption of protein-protein interactions 
essential to normal proteostatic processes like autophagy (Smith et al., 2010).  
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 Complementing these previous studies investigating the ER, autophagy, and 
proteasome, the potential role for mitochondrial dysfunction in PD pathogenesis has also 
been investigated through the use of G2-3 animals. Mitochondrial dysfunction has 
previously been linked to PD through several key observations: 1) MPTP inhibits complex 
1 of the electron transport chain on mitochondria; 2) mutations in proteins involved in 
mitochondrial dynamics, PINK and parkin, are linked to familial autosomal recessive forms 
of PD. G2-3 mice have been employed to define a mechanistic connection between 
mutant aS, mitochondrial dysfunction, and neurotoxicity in PD, with a recent study taking 
a comparative approach between Tg haSA53T Drosophila and G2-3 mice models of a-
synucleinopathy. haSA53T is shown to destabilize spectrin in vivo, a key protein involved in 
plasma membrane and cytoskeleton maintenance, impairing actin dynamics that 
ultimately disrupt proteins involved in key mitochondrial processes, specifically Drp1 and 
mitochondrial fission  (Ordonez et al., 2018).  
 The Tg mouse has also provided a system to test the relationship between key 
proteins involved in both familial and sporadic forms of PD.  LRRK2 mutations (missense 
G2019S) also cause familial autosomal dominant PD with neurochemical and 
neuropathological findings that are essentially identical to that of familial of PD due to aS 
mutations or idiopathic PD, especially aS-positive LBs and LNs. As such, crossing G2-3 
mice with G2019S-LRRK2 or LRRK2-knockout provided for the direct investigation of the 
role LRRK2 plays in aS-mediated neuro changes in mice. Surprisingly, neither 
overexpression of PD-associated mutant LRRK2 nor knocking out of endogenous mouse 
LRRK2 in G2-3 mice exacerbates or rescues the haSA53T-mediated disease phenotype, 
respectively (Daher et al., 2012), suggesting that the neurodegenerative phenotype 
observed in G2-3 is largely LRRK2-independent. It is therefore possible that LRRK2 may 
be upstream of aS in this specific disease cascade, and that haSA53T overexpression 
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masks the effects mutant G2019S-LRRK2 overexpression within the same neuron and 
animal. However, mice co-expressing of G2019S-LRRK2 and haSA53T under the forebrain-
specific CaMKII promoter display enhanced neuropathology, but even in this mice it 
appears that the neuronal and pathological changes observed are largely dependent on 
aS (Lin et al., 2009).  
 Mutations in PINK or parkin are responsible for familial autosomal recessive (juvenile) 
forms of PD. While PD patients with these mutations display the majority of PD-defining 
features, cases of PD due to parkin mutations characteristically lack Lewy pathology 
(Dawson and Dawson, 2010). LBs are immunoreactive for both aS and ubiquitin, and aS 
has been shown to be ubiquitinated by parkin, an E3 ubiquitin ligase, leading to the 
hypothesis that functional parkin promotes LB formation (Shimura et al., 2001). Parkin has 
also been shown to localize to LBs in PD (Schlossmacher et al., 2002). The autosomal 
recessive inheritance pattern of PINK and parkin mutations in PD is suggestive for a loss 
of function and thus parkin-deficient mice have been used as animal models of PD 
(Goldberg et al., 2003) and G2-3 mice have been utilized to examine the contributions of 
parkin to aS-mediated neurodegeneration. Homozygous knockout of parkin in G2-3 mice 
did not reveal any appreciable biochemical, pathological, or behavioral differences as 
compared to G2-3 controls, suggesting that haSA53T-mediated neurodegenerative features 
in mice do not require parkin (von Coelln et al., 2006). As such, it is reasonable to conclude 
that, while mutant aS-induced PD and parkin-induced PD produce common final outputs 
of parkinsonism and SNPc neurodegeneration, they achieve this via differing 
mechanisms.   
 One caveat to the transgenesis approach used in generating many of the mouse 
models for PD including the G2-3 and M83 strains is the random insertion in the transgene 
within the mouse genome following pronuclear injection into single cell muse embryos. 
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This randomness may partly account for differential expression levels of identical 
promoter-transgene combinations like that of the G2-3, H5, and N2.5 lines all expressing 
haSA53T under mPrP (Lee et al., 2002). One extreme example relevant to Tg models of 
neurodegenerative diseases is the rTg4510 mouse model of fronto-temporal dementia 
(FTD) and AD, that expresses human missense mutant P301L tau (SantaCruz et al., 
2005). However, insertion of the P301L tau transgene produces a 244 kb deletion that 
disrupts the Fgf14 gene and production of fibroblast growth factor 14 (FGF14), a protein 
involved in modulation of neurotransmission and also implicated in neurological disorders 
including ataxias and schizophrenia, and as a result the findings in the Tg4510 mouse 
cannot be exclusively linked to mutant tau as previously though (Goodwin et al., 2019). 
The haSA53T transgene insertion site in G2-3 mice has been located to chromosome 10. 
However, this insertion leads to a 48 kb deletion that disrupts 2310039L15Rik, a gene that 
encodes for a long intervening non-coding RNA (lincRNA) (Goodwin et al., 2019). While 
the function of this specific lincRNA is currently unknown, ncRNA are generally classified 
as functional RNA molecules that do not code for translation into a protein (“non-coding”), 
and do not overlap with protein-coding genes, but serve as regulators of gene transcription 
and post-transcriptional regulation (Ulitsky and Bartel, 2013). The consequence of this 
deletion in G2-3 mice, however, awaits further study.  
  
Parkinson’s disease pathogenesis, aS propagation, and new avenues for disease 
modeling  
 
 Lewy pathology is distributed throughout the PD brain but preferentially localizes to 
the SNPc, amygdala, frontal cortex, parietal cortex, and temporal cortex (Halliday et al., 
2011). It is therefore likely that the degenerative process advances throughout the nervous 
system along specific anatomic pathways (Braak et al., 2003). This Braak staging scheme 
for PD pathology posits that inclusions are likely found in the olfactory bulb and dorsal 
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motor nucleus of the vagus nerve, and then follow an ascending pattern through brainstem 
to reach midbrain and finally the cortex, gradually increasing in more brain regions as the 
disease progresses (Braak et al., 2003). Instead of each individual neuron within these 
regions developing aS pathology near-simultaneously, these pathological observations 
have supported the concept for pathologic aS aggregates being a transmissible species 
between neurons that follow defined, connected neuroanatomical pathways (Angot et al., 
2010). Several observations support the idea of aS propagation and PD pathology 
spreading in a prion-like mechanisms. Fetal DA cell grafts transplanted into the striatum 
of PD patients have been shown to develop PD pathology (Kordower et al., 2008; Li et al., 
2008). The pathological hallmark of another a-synucleinopathy, MSA, are GCIs, yet 
oligodendrocytes do not produce aS under normal or pathological states (Miller et al., 
2005), adding to the concept of aS propagation between neurons and now also other 
nervous system cells such as glia.  
 Motivated by pathological studies demonstrating that aS aggregates in LBs and LNs 
adopts a b-amyloid-rich fibrillar confirmation (Spillantini et al., 1998b), the in vitro 
production of aS pre-formed fibrils (PFFs) using human WT aS has emerged as a tool for 
studying a-synucleinopathy processes both in vitro and in vivo (Volpicelli-Daley et al., 
2014). Initial studies demonstrated that PFFs could induced pathology in transgenic mice 
overexpressing haS (Desplats et al., 2009; Luk et al., 2009). Follow-up studies 
demonstrated that aS PFFs are capable of entering neurons via endocytosis and serving 
as a template for the induction pathology in cells expressing endogenous levels of aS by 
recruiting endogenous aS into newly-forming aggregates (Volpicelli-Daley et al., 2011, 
2014). Importantly, these PFF-induced aggregates formed both in vitro and in vivo shared 
many features of aS aggregates in PD brains, including detergent insolubility, 
phosphorylation, ubiquitination, and filamentous in structure. Direct injection of aS PFFs 
  43 
into the striatum of nTg mice has also been shown to induce aS aggregate formation, DA 
cell loss, and parkinsonism (Luk et al., 2012a). While these previous in vivo studies utilized 
direct, intracerebral, injection into target brain regions of interest, aS PFFs have also been 
demonstrated to induce nervous system pathology following peripheral injection (Sacino 
et al., 2014), demonstrating both the pathogenicity of fibrillar aS species, but also the 
versatility of the tool itself. Although there is an initial application of high amounts of 
exogenous aS in the PFF model that are above physiologic levels, the advantages are 
that this system does not require genetic modification of the cell or rodent, chronic 
overexpression of aS that may alter other cell biological processes and therefore confound 
observations and conclusions. Moreover, this model is species-specific as  aS PFFs, but 
not monomers, are uniquely capable of inducing these pathological responses (Volpicelli-
Daley et al., 2011, 2014). The aS PFF model affords both regional and temporal control 
as both injection and site are the main factors to consider, a contrast to transgenic models 
that constitutively express their transgene of interest.  
 Work investigating the mechanisms of aS PFF-mediated neurodegenerative 
processes has elaborated upon these initial observations, but one of the biggest concepts 
established thus far is the requirement for endogenous aS to mediate aggregate 
formation, toxicity, and transmission between neurons (Luk et al., 2012b; Mao et al., 2016; 
Volpicelli-Daley et al., 2011; Wu et al., 2019), demonstrating that PFFs likely exert their 
toxic and downstream effects through recruitment of endogenous aS. Uptake of aS PFFs 
occurs through endocytosis and requires transmembrane proteins such as LAG3 (Mao et 
al., 2016; Volpicelli-Daley et al., 2011). aS PFFs also exert synaptotoxic effects, including 
reduction of synaptic protein expression and network synchronization in an aS-dependent 
manner (Volpicelli-Daley et al., 2011), suggesting that aS PFFs exert these effects 
following internalization. At the level of the individual synapse, chronic aS PFF exposure 
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to primary neuronal cultures also alters spine dynamics, leads to loss of synapses, 
reductions in vesicle release, and excitotoxic effects such as calcium entry and oxidative 
stress (Dryanovski et al., 2013; Froula et al., 2018; Wu et al., 2019). Taken together, the 
versatility of the aS PFF represents and exciting tool for studying an array of pathological 
processes in PD and the contributions of pathogenic aS species to them.   
 
Mechanisms driving cognitive decline in Parkinson’s disease and dementia with 
Lewy bodies 
 
 The increasing disease burden exerted by PD and the a-synucleinopathies highlights 
the need to better understand disease mechanisms to better inform new treatments. In 
particular, cognitive dysfunction is a highly prominent and debilitating component of these 
diseases whose origins are not well established. Given that mutations in the SNCA gene 
are causal for PD, and aS-rich Lewy pathology is found in both sporadic and familial forms 
of the disease, as well as DLB, examining memory deficits through the lens of aS has led 
to promising insights.  
 Progression of PD and the onset of both motor and non-motor symptoms is thought to 
parallel the spread of Lewy pathology (LBs and LNs) from brainstem to midbrain to cortical 
regions (Braak et al., 2003). Neuropathologically, the distribution of LBs in the cortex and 
limbic system are hypothesized to contribute to cognitive deficits. Initial observations found 
that presence of cortical LBs is both highly sensitive and specific (>90%) for PDD, more 
than Ab plaques or NFTs (Hurtig et al., 2000). Not surprisingly, the burden of cortical LB 
pathology positively correlates with severity of cognitive impairment and dementia, but it 
also inversely correlates with the duration between parkinsonism onset and dementia 
onset (Ballard et al., 2006). Given the arbitrary time distinction (1-year rule) between PDD 
and DLB, this finding may support placing dementia in PD and DLB as the same disease 
but on a continuum, potentially helping to simplify clinical management (Jellinger, 2018). 
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However, not all cases of PDD display cortical Lewy pathology, and not all patients with 
cortical LBs display dementia (Colosimo et al., 2003; Halliday et al., 2014). One possible 
explanation for this could be that LBs, especially in the context of cognitive dysfunction, 
may reflect the presence of pathogenic aS species and neuronal dysfunction in the cortex 
rather than a direct mediator of synaptic and cognitive deficits.  
 Upwards of 40% of PD patients at time of death have AD co-pathology, including Ab 
plaques and tau NFTs, which may contribute to PDD and DLB (Irwin et al., 2013). Of 
interest, AD co-pathology is more prominent in PDD and DLB patients as compared to PD 
patients without dementia (Selikhova et al., 2009). Increased levels of AD co-pathology in 
PDD and DLB strongly correlate with increased rate of dementia onset and decreased 
survival (Compta et al., 2011; Irwin and Hurtig, 2018; Ruffmann et al., 2016), but this 
relationship has also been established in the context of cortical LB burden (Compta et al., 
2011; Toledo et al., 2016), arguing for heterogeneity within this component of disease 
pathogenesis. In support, another study found that 28/51 of PDD cases had co-AD 
pathology (Sabbagh et al., 2009), yet the degree of cognitive impairment was clinically 
indistinguishable between the groups, suggesting that pathologic aS and cortical LB 
pathology may be a more critical determinant in driving deficits in PDD and DLB.  
 Instead of being an independent process in PDD and DLB, the high burden of AD co-
pathology in the a-synucleinopathies may represent a synergistic process that underlies 
or even precipitates neuronal and cognitive dysfunction. Bigenic mice overexpressing both 
pathogenic human amyloid precursor protein (APP) and haS developed memory and 
motor deficits prior to mice expressing only aS, had prominent presynaptic and cholinergic 
neurodegeneration, and also more intraneuronal aS inclusions as compared to single Tg 
animals (Masliah et al., 2001). Studies from another bigenic mouse model further this 
interaction: mice co-expressing haSWT and FTD-linked human mutant P301L tau 
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(SantaCruz et al., 2005) have increased presence of filamentous aS and tau inclusions in 
the same or separate neurons (Giasson et al., 2003). 3xTg-AD mice expressing human 
mutant APP, P301L tau, and PS1 crossed with M83 mice expressing haSA53T created a 
new mouse model that consequently exhibited accelerated cognitive decline and 
enhanced Ab, tau, and aS pathologies as compared to the individual 3xTg-AD or M83 
models (Clinton et al., 2010). More recent studies have continued to support this 
pathological interaction between aS and tau, with aS oligomers being capable of inducing 
tau oligomer production both in vitro and in vivo (Gerson et al., 2018; Greten-Harrison et 
al., 2010), and that antibody-mediated targeting of these tau oligomers prevented motor 
and cognitive deficits in M83 mice (Gerson et al., 2018). Another piece of evidence 
highlighting this relationship, the concept of driving neuronal dysfunction in the absence 
of overt neuropathology, is that the APOE4 genotype is associated with increased risk for 
dementia in the a-synucleinopathies, independent of Ab plaque burden (Tsuang et al., 
2013). Collectively, these findings, supported by clinical and neuropathological 
observations, directly implicate aS as a pivotal protein in mediating cognitive deficits in 
PDD and DLB, and that these pathogenic effects may be supported by interactions with 
other central neurodegenerative proteins like Ab, and especially, tau. 
 From a structural standpoint, overt neurodegeneration is not a prominent feature in 
the a-synucleinopathies. Hippocampal sclerosis, particularly in CA1, is not a pervasive 
feature in PDD and DLB (Hely et al., 2008). Additionally, while reductions in hippocampal 
volume and gray matter are present in some cases, the severity of such reductions are 
less severe when compared to AD (Sanchez-Castaneda et al., 2009). More recently, 
hippocampal volume has become a tool for distinguishing causes of dementia, where 
preserved hippocampal volume in the context of memory deficits is a diagnostic feature of 
DLB and rules out AD (Kantarci et al., 2016). Indeed, hippocampal dysfunction, rather 
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than overt aS pathology or hippocampal loss, is a driver of cognitive deficits in PDD and 
DLB (Adamowicz et al., 2017; Hall et al., 2014). Although overt neuronal loss may not be 
observed in cortices or hippocampi of PDD/DLB patients, there are data suggesting 
synapse loss (Masliah et al., 1993; Schulz-Schaeffer, 2010). Along these lines, one line 
of TgWT mice  displays aS aggregates at presynaptic terminals as well as a reduction in 
presynaptic terminals (Lim et al., 2011).  
 The hippocampus receives inputs from a variety of cortical and subcortical regions, 
and thus perturbation of these neurons and neurotransmitter systems may contribute to 
cognitive dysfunction. Degeneration of cholinergic neurons has been noted in PDD 
patients (Ballard et al., 2006, 2002; Zweig et al., 1993) and contribute to cognitive deficits, 
likely in similar fashion to that of AD. In this respect, loss of noradrenergic terminals has 
also been observed in haSA53T mice (Sotiriou et al., 2010). Within the cortex of PDD 
patients, decreases in cortical DA are observed without a loss of DAergic neurons 
(Takahashi et al., 2008). Synaptic plasticity (both long-term potentiation and depression) 
within the hippocampus has also been shown to be modulated by DAergic 
neurotransmission from the ventral tegmental area (VTA) and mesolimbic system through 
D1 and D5 receptors (Lemon and Manahan-Vaughan, 2006; Lisman and Grace, 2005; 
Wiescholleck and Manahan-Vaughan, 2014). It is therefore also conceivable that reduced 
DA levels and altered DA neuron function can lead to impaired hippocampal function. As 
such, while frank neurodegeneration within the hippocampus is not likely a primary driver 
of memory deficits in PDD and DLB, it is clear that altered neurotransmission within the 
hippocampus, likely a product of dysfunction and degeneration in other regions, 
contributes to this non-motor symptom.  
 Synaptic dysfunction is also likely contributor to cognitive decline in PDD and DLB. 
haSWT overexpression in mice promotes clathrin-mediated endocytosis of NMDARs from 
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postsynaptic sites, leading to reduced surface NMDAR expression and altered 
GluN2A/GluN2B NMDAR subunit ratios, ultimately producing impairment in LTP and 
memory (Chen et al., 2015; Cheng et al., 2011; Costa et al., 2012). Deficits in AMPA 
receptor (AMPAR) function, another integral postsynaptic glutamatergic receptor, have 
also been implicated in aS-dependent deficits in mice overexpressing haSA53T (Teravskis 
et al., 2018). This study furthered the connection between neuropathologic observations 
in PDD and DLB and synaptic dysfunction, as haSA53T-mediated AMPAR deficits were 
associated with tau missorting to dendritic spines and in the absence of spine loss. Studies 
employing exogenous aS species have also advanced the role of pathogenic aS at the 
synapse. aS oligomers (aSOs) have been demonstrated to alter membrane permeability 
at the synapse through their capacity to induce pore formation (Pacheco et al., 2015; 
Tsigelny et al., 2012). Presynaptically, these aSOs can also impair vesicle recycling and 
reduce expression of key presynaptic proteins involved in this process such as SNAREs 
(Cheng et al., 2011; Scott et al., 2010; Volpicelli-Daley et al., 2011). At the postsynaptic 
surface, neurons exposed to aSOs display altered spine morphogenesis and stability, and 
altered NMDAR and AMPAR function that may lead to excitotoxic downstream events 
(Diogenes et al., 2012; Mattison et al., 2014). More recent studies have worked to 
establish a mechanism for aSO-mediated synaptotoxicity, which focus on pathogenic 
signal transduction via binding of aSOs to cellular prion protein (PrPC) on postsynaptic 
surfaces, leading to a downstream cascade of signaling that involves adenosine receptors 
(A2A) and metabotropic glutamate receptors (mGluR5) that ultimately produce increased 
NMDAR activation (via GluN2B phosphorylation) and excitotoxicity (Ferreira et al., 2015, 
2017). Pharmacological inhibition of this pathway in TgWT mice restored synaptic and 
memory function, providing in vivo relevance to this pathway described via in vitro and ex 
vivo studies (Ferreira et al., 2017).  
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 Studies in aS PFF-induced synaptic dysfunction support the major theme of aSO, that 
higher order, soluble, aggregates of aS are key drivers of pathological processes in PDD 
and DLB, in particular synaptic abnormalities underlying memory deficits. Exposure to aS 
PFFs leads to reductions in presynaptic proteins such as VAMP2 and SNAP25 in primary 
neuron cultures (Volpicelli-Daley et al., 2011), which may underly deficits in neuronal 
synchronization and neurotransmission as measured via mini excitatory postsynaptic 
current (mEPSC) frequency (Froula et al., 2018; Volpicelli-Daley et al., 2011; Wu et al., 
2019). Similar to aSOs, aS PFF treatment in vitro also lead to spine abnormalities, 
including decreased density and amount of mature spines (Froula et al., 2018). However, 
an important distinction between aSO- and PFF-mediated impairments in synaptic 
plasticity likely result from their putative mechanisms. The current pathways defined in 
aSO-driven deficits suggest that aSO exert their toxic effects through both pre and 
postsynaptic mechanisms, but that postsynaptic abnormalities occur through receptor-
mediated signal transduction. In contrast, aS PFF-mediated deficits appear to occur via 
cell-intrinsic mechanisms requiring recruiting and templating of endogenous aS to mediate 
their pathogenic effects. As such, it is evident that more studies are warranted to better 
delineate the intrinsic and extrinsic mechanisms driving these pathological processes. 
While is also clear that use of pathogenic aS species to model and investigate the 
mechanisms underlying PDD and DLB at the synaptic and neuronal levels is likely to 
provide significant insight into disease pathogenesis, it is also important to consider how 
these outputs are achieved in order to draw meaningful conclusions.   
 Extending beyond the individual synapse, dysfunction at the circuit or network level is 
also hypothesized to contribute to cognitive deficits in neurodegenerative diseases, most 
notably AD, but also PD (Palop and Mucke, 2016; Palop et al., 2006). Interestingly, haSWT 
overexpression in mice leads to a left shift in spectral power resembling slowing of 
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electroencephalogram (EEG) activity characteristic in DLB patients, as well as 
immunohistochemical alterations within the hippocampus indicative of aberrant network 
excitability (Morris et al., 2015). Long-term exposure primary neurons to aS PFFs in vitro 
lead to altered neuronal synchronization (coordinated spontaneous activity between 
neighboring neurons) as measured via calcium imaging (Volpicelli-Daley et al., 2011). 
Interestingly, this altered synchrony was partly explained via reduction in excitatory tone, 
and altered excitatory tone is a potential mediated of network-level dysfunction and 
aberrant activity in vivo (Palop and Mucke, 2010), potentially linking aS-mediated synaptic 
changes, network abnormalities, and cognitive dysfunction through final common 
mechanisms in different experimental models.  
 
Hypotheses 
 The overarching objective of this thesis was to examine the mechanisms driving 
synaptic and memory deficits in a-synucleinopathies through several approaches. 
Considering the role of aS in presynaptic biology, abnormal aS, either mutated or 
aggregated, could be responsible for deficits in neurotransmission that underly PDD and 
DLB pathophysiology.  
 Additionally, given the contributions of other neurodegenerative disease-relevant 
proteins to neuropathology and cognitive decline in PDD and DLB, it is hypothesized that 
aS-mediated memory deficits may be produced via interactions with other proteins such 
as tau. However, prior to this work, it remained unknown of aS mediates cognitive decline 
in vivo and tau contributes to aS-mediated behavioral deficits. Through use of a transgenic 
mouse model of a-synucleinopathy (TgA53T), the mechanisms of haSA53T-mediated 
cognitive decline were first examined, with the hypothesis that tau-mediated postsynaptic 
deficits were critical for this process. In addition to characterizing the progressive nature 
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of aS-mediated synaptic and behavioral deficits in TgA53T mice, TgA53T mice lacking 
endogenous mouse tau expression were generated to directly test the role of tau in this 
process. To determine the cellular and molecular mechanisms underlying aS-mediated 
memory deficits in TgA53T mice, biochemical, immunohistochemical, and 
electrophysiological approaches were employed to examine changes in protein 
expression and function. While the TgA53T model represents a valuable model for 
investigating how aS abnormalities lead to pathological processes in a-synucleinopathies, 
the majority of PD cases are sporadic, without known genetic mutations in SNCA. As such, 
the second major hypothesis was if pathogenic species of aggregated haSWT, the aS PFF, 
were capable of driving cellular, molecular, and physiological abnormalities in a similar 
pathway to that of TgA53T, asking the question if pathogenic aS, either haSWT or aS PFFs, 
produced synaptic impairments through common mechanisms that could collective 
represent a final common pathway for deficits in synaptic deficits that ultimately underly 
memory deficits.  
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Chapter 2: Tau is required for progressive synaptic and memory deficits in a 
transgenic mouse model of a-synucleinopathy 
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Introduction 
 Parkinson’s disease dementia (PDD) and Dementia with Lewy Bodies (DLB) are 
closely related diseases in the a-synucleinopathy family that comprise the second most 
common neurodegenerative dementia (Jellinger and Korczyn, 2018). These and other a-
synucleinopathies are characterized by the presence of cytoplasmic inclusions termed 
Lewy bodies (LB) and Lewy neurites (LN), composed primarily of fibrillar a-synuclein (aS) 
(Spillantini et al., 1998b). In addition to motor dysfunction arising from the loss of 
dopaminergic neurons in the substantia nigra pars compacta (Obeso et al., 2010), the 
broad distribution of LB/LN across multiple neuronal populations has led to an 
understanding in PD that the disease extends beyond the basal ganglia (Aarsland et al., 
2008, 2017). Dementia in the a-synucleinopathies is hypothesized to be a product of aS 
abnormalities at cortical and hippocampal synapses. This pathogenic role for aS is 
supported by genetic and pathological observations: mutations in the SNCA gene 
encoding aS are causative for early-onset, familial autosomal dominant forms of PD 
(Houlden and Singleton, 2012; Poewe et al., 2017; Polymeropoulos et al., 1997), and LBs 
and LNs are found in both familial and sporadic cases of PD (Spillantini et al., 1997). While 
degeneration of cortical and hippocampal neurons is not a significant feature of PDD and 
DLB (Hall et al., 2014), cortical and hippocampal aS pathology show significant correlation 
with dementia (Adamowicz et al., 2017; Colom-Cadena et al., 2017; Hall et al., 2014; 
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Harding and Halliday, 2001; Jellinger and Korczyn, 2018; Spillantini et al., 1998b). 
Because aS is a cytosolic protein enriched at presynaptic terminals with established roles 
as an inhibitor of neurotransmitter release (Abeliovich et al., 2000; Nemani et al., 2010) 
and a presynaptic chaperone (Burré et al., 2010, 2013, 2014; Chandra et al., 2005), it is 
hypothesized that disease-associated aS may cause memory deficits through 
mechanisms involving presynaptic dysfunction. We recently showed that mutant A53T 
human aS (haSA53T) expression causes deficits in learning, memory, and synaptic 
plasticity in mice (Teravskis et al., 2018). Significantly, while we show that presynaptic 
deficits, characterized by decreased probability of neurotransmitter release, are present 
in both wild-type and mutant human aS expressing neurons, only haSA53T expression 
caused defects in postsynaptic function and synaptic plasticity. Mechanistically, this 
unique haSA53T-induced postsynaptic dysfunction is mediated through a process involving 
tau: GSK3b-dependent tau phosphorylation, subsequent tau missorting to dendritic 
spines, and calcineurin-dependent AMPA receptor (AMPAR) internalization. These 
deficits in neurotransmission appear in the absence of overt neuropathology, suggesting 
that neuronal dysfunction is not a consequence of neurotoxicity and neurodegeneration.  
In this study, we sought to extend our prior findings by mechanistically connecting our 
in vitro studies with the memory deficits in vivo. To accomplish this, we directly tested 
whether tau expression was required for aS-induced cellular, physiological, and 
behavioral deficits in the TgA53T mouse model of a-synucleinopathy. We show that 
TgA53T mice exhibit progressive memory deficits associated with the presence of 
postsynaptic, but not presynaptic, deficits. More important, we demonstrate that loss of 
tau completely reversed the onset of memory deficits in multiple experimental paradigms 
and that tau is required for aS-mediated neurophysiological deficits, including 
postsynaptic dysfunction, impairments in glutamatergic neurotransmission, and short- and 
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long-term plasticity. Significantly, these parameters are independent of any aS pathology 
or neurodegenerative changes. Finally, the onset of neurophysiological and memory 
deficits coincides with the onset of seizure-like network hyperactivity. We propose that 
early tau-dependent postsynaptic deficits caused by mutant aS is mechanistically linked 
to the onset of network abnormalities and memory deficits. Our results provide novel 
insights on how pathological aS precipitates impairments in neurotransmission and 
memory loss and may inform the development of new therapeutic approaches for PDD 
and DLB.  
 
Materials and methods 
 All animal studies were performed in accordance with the NIH guidelines for the use 
of animals in research and approved by the Institutional Animal Care and Use Committee 
at the University of Minnesota. Experimental group sizes (n) are reported in each figure.  
 
Transgenic A53T a-Synuclein mutant and tau-knockout mice 
 We bred four key genotypes for this study. TgA53T animals contain a transgene 
expressing the human mutant A53T a-synuclein (aS, haSA53T: line G2-3). All mice were 
maintained in the C57BL/6J background strain (stock 0006644, Jackson Labs; Bar Harbor, 
ME). TgA30P animals express human mutant A30P aS (haSA30P: line O2,TgA30P) at 
similar levels to TgA53T, and TgWT animals express human wild-type aS (haSWT: line I2-
2, TgWT), but at levels lower to TgA53T and TgA30P. Transgene expression for all 
animals is controlled by the mouse prion promoter (MoPrP) (Lee et al., 2002). TgA53T, 
TgA53T/mTau-/-, TgA30P, and TgWT were all heterozygous for their respective haS 
transgene. Non-transgenic (nTg) controls came from within these litters. To generate 
transgenic animals expressing haSA53T (TgA53T) and lacking endogenous mouse tau 
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(mTau-/-), TgA53T males were bred to Mapttm1(EGFP)Klt/J females (stock 004779, Jackson 
Labs) (Tucker et al., 2001) in successive generations to generate offspring that lacked 
endogenous mouse tau expression and with, or without, haSA53T transgene expression. 
Transgenic progenies were identified by PCR analysis of tail DNA as previously described 
(Lee et al., 2002). Because all mice were maintained on the C57BL/6J background, we 
were able to generate TgA53T and nTg cohorts separate from the TgA53T/mTau-/- and 
mTau-/- cohorts. This approach was used because the use of heterozygous mice for 
breeding leads to a very low yield of animals with the experimentally-desired genotype 
(25%), increased heterogeneity between littermates, and more importantly, a larger 
spread in birthdates and consequently ages of mice, introducing potential methodological 
variations. Additionally, this low yield of experimentally-desired mice would translate into 
a large population of unused, “wasted”, animals, something we consciously worked 
towards avoiding. Generating TgA53T/mTau+/+ (TgA53T) and TgA53T/mTau-/- cohorts via 
independent homozygous matings produced progeny within a tighter age range and 
allowed us to use 100% of the offspring for experiments. A breeding schematic and 
diagram elaborating the rationale can be found in Figure 2.1.  
 The TgA53T (G2-3) mouse model exhibits an adult-onset hyperactive locomotor 
phenotype (Unger et al., 2006) prior to the onset of motor dysfunction. This motor 
dysfunction phenotype rapidly progresses from slight ataxic signs (gait and balance 
abnormalities) to complete paralysis within 2-3 weeks (Lee et al., 2002). This pattern of 
motor deficit is also observed in another transgenic mouse model expressing haSA53T 
under control of the mPrP promoter (M83) as rotarod performance declines only following 
sudden and dramatic disease onset (Giasson et al., 2002). Since the initial 
characterization of TgA53T mice, the average age of disease onset has drifted from 
approximately 10 to 13 months of age (Lab of Michael K. Lee, unpublished data). 
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Neuropathologically, the onset of motor symptoms in mPrP-haSA53T transgenic mice (G2-
3 and M83) is associated with the presence of aS pathology in subcortical areas (midbrain, 
brain stem, and spinal cord) but not in forebrain regions including the hippocampus and 
amygdala (Giasson et al., 2002; Lee et al., 2002). Any animals showing overt motor 
symptoms were excluded from further analysis. 
 Male mice were exclusively used for all behavior studies. For the electrophysiological, 
biochemical, and immunohistochemical analyses, both males and females were used. In 
these studies, efforts were made to use equal numbers of mice from each sex within each 
genotype cohort. 
 All mice in the colony were kept under specific pathogen-free (SPF) conditions in a 14 
hours (hr) light/10 hrs dark cycle, and had free access to food and water. All housing and 
experimental protocols involving mice were conducted with strict adherence to the 
National Institutes of Health (NIH) Animal Care and Guidelines and were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) at the University 
of Minnesota.  
 
Dissociated neuronal culture electrophysiology 
 Dissociated neuronal cultures were established from harvested from mouse 
hippocampi postnatal day 0 or 1 (P0-P1) as previously described (Teravskis et al., 2018) 
with modifications. Briefly, mouse hippocampi were dissected out and stored individually 
by pup in Hibernate A media (Brain Bits; Springfield, IL) at 4°C. While stored, each pup 
from the cultured litter was genotyped. Cerebellar tissue was used for genomic DNA 
isolation via QuickExtract DNA (Epicentre-Lucigen; Madison, WI) and genotyping of pups 
was performed immediately after hippocampal isolation. Following genotype identification, 
hippocampi of identical genotypes were pooled, dissociated, and plated on onto 35 mm 
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µ-dishes containing a poly-D-lysine and laminin-coated polymer coverslip (Ibidi; Fitchburg, 
WI). 24 hrs after initial plating, media was removed and NbActiv4 growth media was added 
(Brain Bits). NbActiv4 media was refreshed every 3-4 days by removing 1 mL media in the 
dishes and adding 1 mL fresh media. For all procedures and media exchanges, solutions 
were equilibrated in a tissue culture incubator (37°C, 5% CO2) for at least 2 hrs prior to 
use. The age of in vitro dissociated cultured hippocampal neurons began with the day of 
initial plating, and each day that followed was counted as one day in vitro (DIV). All 
experiments were performed on neurons from at least 3 independent cultures with a 
minimum of 5 animals per culture. Miniature excitatory postsynaptic currents (mEPSC) 
were recorded from cultured dissociated mouse hippocampal neurons at 21–25 DIV with 
a glass pipette (resistance of ~5 MΩ) as previously described (Teravskis et al., 2018). 
Recordings ranged from 3-15 minutes (min) and stable traces longer than 1 min in duration 
were analyzed. All mEPSCs >2 pA were manually counted with MiniAnalysis (Synaptosoft 
Inc; Fort Lee, NJ). Each mEPSC event was visually inspected and only events with a 
distinctly fast-rising phase and a slow-decaying phase were accepted. Relative cumulative 
frequencies were derived from individual events and the averaged parameters from each 
neuron were treated as single samples in any further statistical analyses.  
 
Acute hippocampal slice electrophysiology  
 Acute coronal hippocampal slices (approximately 350 µm thick) were obtained from 
two age windows of mice (2-3 months and 5-6 months) from nTg, TgA53T, TgA53T/mTau-
/-, and mTau-/- animals utilizing well-established methods (Teravskis et al., 2018).  
 Briefly, slices were incubated in ACSF (containing in mM: NaCl 124, KCl 5, NaH2PO4 
1.25, MgSO4 2, NaHCO3 26, CaCl2 2, glucose 10; gassed with 95% O2, 5% CO2, and 
maintained between pH 7.3 and 7.4) at room temperature for at least 1 hr before use. For 
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studies, slices were transferred to an immersion recording chamber, superfused at 2 
mL/min with oxygenated ACSF and visualized under an Olympus BX50WI microscope 
(Olympus Optical; Japan). In order to study excitatory postsynaptic currents (EPSCs), 
picrotoxin (50 µM) and CGP54626 (1 µM) were added to the solution to block GABA-A 
and GABA-B receptors, respectively. Whole-cell electrophysiological recordings were 
obtained from hippocampal CA1 pyramidal neurons using patch electrodes (3-10 MW) 
filled with an internal solution containing in mM: cesium gluconate 117, HEPES 20, EGTA 
0.4, NaCl 2.8, TEA-Cl 5, ATP 2, GTP 0.3, and kept at pH 7.3. Recordings were obtained 
with PC-ONE amplifiers (Dagan Instruments; Minneapolis, MN). Membrane potentials 
were held at -70 mV. Signals were filtered at 1 kHz, acquired at a 10 kHz sampling rate, 
and fed to a Digidata 1440A digitizer (Molecular Devices; San Jose, CA). pCLAMP 10.4 
(Axon Instruments, Molecular Devices; San Jose, CA) was used for stimulus generation, 
data display, data acquisition, and data storage. To record evoked EPSCs, theta 
capillaries filled with ACSF were used for bipolar stimulation and placed in the stratum 
radiatum to stimulate Schaffer collaterals. Input-output curves of EPSCs were made by 
increasing stimulus intensities from 0 to 100 µA. Paired pulse facilitation was done by 
applying paired pulses (2 millisecond (msec) duration) with 25, 50, 75, 100, 200, 300, and 
500 msec inter-pulse intervals. The paired pulse ratio was calculated by dividing the 
amplitude of the second EPSC by the first (PPR = EPSC-2 / EPSC-1). Synaptic fatigue 
was assessed by applying 15 consecutive stimuli in 25 msec intervals. AMPA currents 
were obtained at a holding potential of -70 mV. NMDA currents were obtained at a holding 
potential of + 30 mV. To ascertain the AMPA to NMDA receptor current ratio the NMDA 
component was measured 50 msec after the stimulus, when the AMPA component had 
decayed. Recordings of miniature EPSCs (mEPSCs; Vh = -70 mV) were made in the 
presence of tetrodotoxin (TTX; 1 µM) in addition to the respective solution. For long-term 
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potentiation (LTP), CA1 pyramidal neurons first underwent a baseline recording of 10 mins 
followed by tetanic stimulation in the Schaffer collaterals (4 trains at 100 Hz for 1 second 
(sec); 30 sec intervals). After LTP induction, neurons were recorded for 50 mins. The 
presence of LTP was determined by comparing the average EPSC amplitudes from last 
5 mins of pre-stimulus baseline recording to the average EPSC amplitudes from the last 
5 mins post-stimulus recordings. All experiments were performed at room temperature.  
 
Behavioral testing 
 Behavioral testing was performed with the support and guidance of the Mouse 
Behavior Core at the University of Minnesota. ANY-maze software (Stoelting Co.; Wood 
Dale, IL) was used in conjunction with paired video cameras to track and record animal 
movements during all behavioral testing, and all subsequent analysis. Behavior 
experiments, unless dictated by testing protocols, were not performed on consecutive 
days, giving animals at least two days to rest between experiments. Mice were also 
habituated to handling prior to testing. Animals from all genotypes were tested together. 
Each behavioral age point came from a separate cohort. Additionally, all groups tested, 
including those at different age points, went through the battery of tests in the same order.  
Open field 
 Locomotor activity was assessed using open field testing. Animals were placed 
individually into a square 40 cm x 40 cm arena with white, opaque walls and flooring, lit to 
200 lux. Movement was video-recorded for 60 mins and began immediately after placing 
the animal in the open field testing chamber. After the test, animals were returned to their 
home cage.  
Barnes maze 
 Spatial learning and memory were assessed via Barnes maze (San Diego 
Instruments; San Diego, CA), following established protocols (Barnes, 1979; Sunyer et 
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al., 2007). The maze itself consists of a white plastic circular top with 20, evenly-sized and 
evenly-spaced holes around the perimeter. Spatial cues were placed on all four walls of 
the behavioral testing room, lit to 300 lux during testing. Mice were acclimatized to the 
testing room for 30 mins at the beginning of each training session. Training days consisted 
of 4 trials per day for 4 days.  Training trials ended with the subject climbed into the escape 
box within the goal quadrant located under 1 of the holes or when the maximum trial 
duration of 180 sec was reached. Upon entering the escape box during training, room 
lights turned off and animals remained in the escape box for 60 sec before returning to 
their home cage in the testing room to await the next trial. While the platform was rotated 
between each trial on each day (to obscure the impact any animal scents or non-spatial 
cues on the maze), the location of the escape box and goal quadrant relative to the room 
remained constant during all training trials and days. Subjects were run in small groups of 
6 mice or less so that no more than 20 mins passed between trials for a given animal 
during training. On the day following the last training trial, memory was assessed in single 
90 sec probe trial tests where the target escape box in the goal quadrant was replaced 
with a false box cover identical to the other 19 holes, and the exploration pattern of each 
subject was examined. 
Y maze 
 Short term spatial learning and memory was assessed via Y maze. Animals underwent 
30 mins acclimation periods in the testing room prior to testing. Cues were visible on walls 
of the testing room as well as within the maze, at the end of each arm (extra-maze and 
intra-maze, respectively). The Y maze was constructed out of opaque white plastic and 
located at the center of the testing room lit to 150 lux. During the first of two phases, only 
two of the three arms were available for exploring during the 10 mins learning trial: the 
start arm and the familiar arm. For all trials, animals were placed at the end of the start 
arm, furthest point from center. During the 60 mins inter-trial interval between learning and 
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recognition, animals returned to their home cage but remained in testing room. The 5 mins 
recognition trial was then performed, with all 3 arms were available for exploration: start, 
familiar, and novel. The Y maze was also cleaned between each trial/animal to avoid 
confounds due to scent.  
Context Fear Conditioning 
 Context fear conditioning was conducted using the Near Infrared (NIR) Video Fear 
Conditioning package for mice (Med Associates, Inc; Fairfax, VT). A context conditioning 
environment (specific olfactory, tactile, and visual elements) is paired with foot shocks on 
the first day: a 10 mins context conditioning trial was first performed in the NIR fear 
conditioning chamber: electrified metal bars on the floor, providing 0.7 V foot shocks for 2 
sec 5 times per trial at variable intervals averaging 90 sec between shocks, squared off 
corners and metal walls, and a 33% Simple Green solution for scent. 24 hrs following 
conditioning animals were underwent the context memory trial where freezing was 
assessed for 3 min with identical chamber conditions to the conditioning trial except no 
foot shocks (Similar). If the animal successfully learns the context-shock association, re-
exposure to the context environment 24 hrs post-conditioning, the “similar” setting, will 
elicit fear in the animal placed in that environment.  2 hrs after the similar trial, mice were 
placed in the chamber for the novel context trial (Novel), white, solid plastic flooring and 
curved walls with a stripe design inside, and a 0.5% vanilla solution for scent, to show the 
context specificity of the fear memory. 
 
Western blot analyses 
Chemiluminescence Western Blotting  
 At predefined age points, mice were harvested and brain regions (cortices and 
hippocampi, in particular) were dissected out and stored at -80°C. To extract proteins, 
cortical and hippocampal samples from -80°C were first thawed at -20°C overnight before 
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being weighed and homogenized via Dounce homogenization in 10 volumes of TNE 
solution in mM: Tris-HCl 50, NaCl 150, and EDTA 5. Following homogenization, an equal 
volume of Complete TNE was added: TNE plus 0.5% NP40, 0.5% DOC, 1% SDS, and 
HALT protease and phosphatase inhibitors (Thermo Fisher Scientific; Waltham, MA). 
Samples were then spun down at 16,000 g for 90 mins at 4°C. Supernatant was collected 
and subjected to immunodepletion via serial incubations with Protein A and G Mag 
Sepharose beads (GE Life Science; Pittsburgh, PA) rocking at 4°C for 60 mins. Protein 
concentration was assessed via BCA assay (Pierce, Thermo; Rockford, IL). Samples were 
prepared to equal concentration in reducing, SDS-sample, Laemmli buffer (Boston 
BioProducts; Ashland, MA). For western blot analysis, protein lysates were run on 
CriterionTM TGXTM gels (BioRad; Hercules, CA) and transferred onto nitrocellulose 
membranes. Membranes were then blocked using 5% non-fat dry milk in tris-buffered 
saline (TBS) with 0.1% Tween 20 (TBSTw) for 1 hr at room temperature (RT). Primary 
antibodies were diluted in OneBlock solution (Genesee Scientific; San Diego, CA) and 
incubated on membranes overnight at 4°C. Horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Invitrogen; Carlsbad, CA) were diluted in 5% non-fat dry milk in 
TBSTw and incubated on membranes 1 hr at RT. Membranes were then developed using 
chemiluminescent substrates (BioRad and Thermo) and the ImageQuant LAS 4000 
detection system (GE Life Sciences). Densitometry on western blot images were 
subsequently analyzed using ImageQuant TL 8.1 software (GE Life Sciences).  
 
Fluorescence Western Blotting 
 SDS-PAGE was performed on precast 10.5–14% CriterionTM Tris-Tricine gels, 10.5–
14% or 4–10.5% Tris-HCl gels (Bio-Rad). Protein levels were normalized by using 10-100 
μg of protein per sample (depending on the targeted protein). The samples were 
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resuspended with 4x Tricine loading buffer and boiled for 5 mins before loading. Proteins 
were transferred onto 0.2-µm nitrocellulose membrane (Bio-Rad) following 
electrophoresis. Membranes were blocked in 5% BSA (Sigma; St. Louis, MO) in TBSTw 
for 1–2 hrs at room temperature and probed with the appropriate antisera/antibodies 
diluted in 5% BSA in TBSTw. Primary antibodies were probed with secondary antibodies 
conjugated with infrared dyes (LI-COR Biosciences; Lincoln, NE). Densitometry analyses 
were performed using the Odyssey software (LI-COR Biosciences). Normalization was 
performed against GAPDH.  Quantification by software analysis was performed as 
described previously (Amar et al., 2017; Khan et al., 2018; Larson et al., 2012, 2017; 
Sherman et al., 2016). 
 
Dot blot analyses 
 Protein isolates were obtained from samples at the same time they were being 
prepared for western blotting. Samples diluted to identical concentrations (1 µg/µL) and 2 
µg of sample was adsorbed onto a nitrocellulose membrane and air dried for 30 mins. 
Following activation in 10% methanol (in TBS), membranes were blocked in TBS 
containing 5% bovine serum albumin (BSA) for 30 mins at room temperature (RT).  
Samples were then incubated in primary antibody overnight at 4°C in 5% BSA in TBS. 
Following primary antibody incubation and TBS washes, secondary incubation was 
performed for 1 hr at RT in the dark in 5% BSA in TBS with IRDye secondary antibodies 
(anti-mouse IgG-IR800 at 1:100,000 and anti-rabbit IgG-IR680 at 1:150,000) (LI-COR 
Biosciences). Membranes were then washed, imaged and analyzed using the LI-COR 
Odyssey imaging system. 
 
Insoluble and Soluble Protein Extraction 
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 An equal volume of 2% TritonTM X-100 (Sigma-Aldrich; St. Louis, MO) in TNE was 
added to the Dounce homogenized lysate in TNE, mixed, and then sonicated for 30 sec 
at 4°C. Samples were then spun down at 20,000 g for 60 mins at 4°C. The supernatant 
from this spin was saved as the soluble fraction. The pellet was saved as the insoluble 
fraction, washed in 1% TritonTM X-100 in TNE and spun down again. Complete TNE was 
added to both soluble and insoluble fractions. Fractions were then sonicated, boiled for 10 
mins at 95°C, spun down at 16,000 g for 15 mins at 4°C, and then the supernatant from 
each fraction was saved. Protein concentration was assessed via BCA assay (Pierce, 
Thermo; Rockford, IL). Samples were then prepared for western blotting identically to the 
“Chemiluminescent Western Blotting” protocol.  After transfer, membranes were stained 
with 0.1% Ponceau S solution (Sigma-Aldrich) to confirm equal protein loading and 
transfer. Samples then underwent primary and secondary antibody incubation and 
chemiluminescent detection following “Chemiluminescent Western Blotting” methods.   
 
Immunohistochemical analyses 
 At predefined age points, mice were anesthetized with isoflurane and euthanized via 
transcardial perfusion with saline. Animals were first perfused with ice cold K-free PBS, 
containing in mM: NaCl 13, Na2HPO4•2H2O 0.7, and NaH2PO4•2H2O 0.3, and adjusted to 
pH 7.2. Following saline perfusion, animals were then perfuse-fixed with 4% 
paraformaldehyde (PFA). Brains were then isolated and stored in 4% PFA at 4°C for an 
additional 48 hrs before being transferred to a 30% sucrose solution in PBS prior to slicing. 
After a minimum of 72 hrs in sucrose solution, brains were sliced coronally at a thickness 
of 30 µM via HM 450 sliding microtome (Thermo Fisher Scientific) and stored in a 
cryoprotectant solution (30% sucrose, 30% ethylene glycol in PBS) prior to 
immunostaining. Immunofluorescent staining was preformed utilizing the Pelco BioWave 
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Plus (Ted Pella; Redding, CA) and mounted on slides for imaging. Prior to staining 
sections were rinsed in TBS, permeabilized with 0.1% Triton X-100 in TBS and blocked in 
50% Background Sniper solution in TBS (Biocare Medical; Pacheco, CA). Primary and 
secondary antibodies were diluted to target concentrations in 5% Background Sniper 
(Biocare Medical) in TBSTw and allowed to incubate on sections in the Pelco BioWave for 
1.5 hrs each. Alexa Fluor (Abcam; Cambridge, MA) or Alexa Fluor Plus (Thermo Fisher 
Scientific) secondary antibodies were used as dictated by primary antibody host. If 
required, sections were then 4′,6-diamidino-2-phenylindole (DAPI)-counterstained 
(Thermo Fisher Scientific). All sections were treated with TrueVIEWTM (Vector 
Laboratories; Burlingame, CA) for autofluorescence quenching and mounted on slides for 
future imaging. Confocal microscopy images were acquired with the Nikon C2 Confocal 
Microscope System (Nikon; Melville, NY). Imaging processing and analysis were 
performed using NIS-Elements software (Nikon). Staining, imaging, and analysis were 
performed in collaboration with the University of Minnesota’s University Imaging Centers 
on the Twin Cities campus. Analysis and quantification of biomarkers of neuronal network 
hyperexcitability (c-Fos, neuropeptide Y (NPY), and calbindin) were performed as 
described previous (Palop et al., 2011).  
 
Preparation and peripheral injection of human wild-type a-synuclein pre-formed 
fibrils (haSWT PFFs) 
 Recombinant full length human wild-type aS pre-formed fibrils (PFFs) were generated 
following the protocol established by Volpicelli-Daley et al., 2014. aS PFFs were 
generated by first incubating purified recombinant monomeric aS at 5 mg/mL in 
phosphate-buffered saline (PBS) at 37°C with continuous shaking for 7 days via 
ThermoMixer (Eppendorf; Hamburg, Germany). During this shaking process, the 
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presence of amyloid aS fibrils production was assessed and confirmed using Thioflavin T 
fluorometry. Following shaking and saturation of Thioflavin T fluorescence levels, aS PFFs 
were subsequently aliquoted and stored at -80°C. The generation of aS PFFs and their 
seeding capacity were confirmed through sedimentation assay, subjecting an aliquot of 
PFFs to ultracentrifugation, and assessing the amount of aS in pellet and supernatant via 
SDS-PAGE (BioRad) and Coomassie Brilliant Blue (Thermo Fisher Scientific) staining. 
For peripheral injections into mice, 5 mg/mL aS PFF aliquots in PBS were taken from -
80°C, thawed at room temperature, and diluted to a working concentration of 0.25 mg/mL 
(250 μg/mL) in PBS. aS PFFs at this concentration were then sonicated utilizing a Fisher 
Scientific Branson micro probe tip sonicator (Fischer Scientific; Hampton, NH) with 60 
pulses at 20% power for a total of 120 sec, 1 sec “on”, 1 sec “off”. Following sonication, 
PFFs were ready for injections via Hamilton microliter syringe (Hamilton Company; Reno, 
NV). For injections, mice were lightly anesthetized using isoflurane and 5 µg of aS PFFs 
(50 µL of 250 ug/mL aS PFFs) were injected into the biceps femoris muscle bilaterally at 
rate of approximately 10 µL per sec, for a total of 10 µg aS PFFs per animal. To control 
for any between-batch differences of PFFs, all mice used for this study were injected on 
the same day with a common, single batch of prepared aS PFFs. Controls within each 
group were injected with 50 μL of PBS bilaterally. 
 
Antibodies 
 A detailed list of all antibodies used for experiments and studies here can be found in 
Table 2.1. 
 
Experimental design and statistical analyses 
  68 
 All statistical analyses were performed in Prism 8.1.0 (GraphPad Software; San Diego, 
CA). Data visualization and presentation were performed via Prism (GraphPad) and JMP 
14 (SAS; Cary, NC). For parametric data: one-, two-, and three-way ANOVAs were utilized 
for one, two, and three variable analysis on multiple groups, respectively; t tests were also 
performed when analyzing only two groups. For nonparametric data: Kruskal-Wallis one-
way ANOVA for three or more groups; Mann-Whitney test for two groups. Posthoc 
analyses were performed on all data that were significantly different. Welch’s correction, 
Sidak’s posthoc, and Tukey’s posthoc analyses were used due to considerations for 
within-group variances and sample size. The Geisser-Greenhouse correction was used 
for two- and three-way repeated measures ANOVAs due to considerations for sphericity. 
For all, statistical significance was set for a = 0.05. Data representations are described in 
figure legends 
 
Abbreviation Line Expression Reference 
TgA30P O2 Human missense mutant A30P aS 
Lee et al., 
2002, PNAS TgA53T G2-3 
Human missense mutant A53T aS 
 
Available via Jackson Labs: Tg(Prnp-
SNCA*A53T)23Mkle, strain 006823 
TgWT I2-2 Human wild-type aS 
 
Table 2.1 – List of transgenic mouse lines used in experiments.  
 
 
Loading Controls Company Reference Use 
Actin Sigma-Aldrich A2066 WB 
GAPDH (GA1R) Invitrogen MA5-1738 WB 
GAPDH (D16H11) Cell Signaling 5174 WB 
a-Synuclein Species Company Reference Use 
a-Synuclein (total) BD Transduction 610787 WB 
4D6 (total) BioLegend 834304 DB 
Phospho-serine 129 aS (pS129 
aS) Abcam Ab51253 WB 
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F8H7 (conformation-specific 
oligomers) Dr. Rakez Kayed (gift) Sengupta et al., 2015 DB 
FILA-1 (fibrillar aS) Dr. Poul Jensen (gift) Paleologu et al., 2009 DB 
LB509 (human) BioLegend 807707 DB 
MJFR-14-6-4-2 (MJFR14, 
conformation-specific) Abcam Ab209538 DB 
HuSyn1 (human) Dr. Michael K. Lee Lee et al., 2002 WB 
Syn33 (conformation-specific 
oligomers) Dr. Rakez Kayed (gift) Sengupta et al., 2015 DB 
Tau Species Company Reference Use 
Tau5 (total) Millipore MAB361 WB 
AT8 (phospho-Ser-202 and -Thr-
205) Invitrogen MN2010 WB 
A11 (tau and aS oligomeric 
species) Dr. Rakez Kayed (gift) Khan et al., 2018 DB 
CP13 (phospho-Ser-202) Dr. Peter Davies (gift) Khan et al., 2018 WB 
OC (tau and aS amyloid fibrils) Dr. Rakez Kayed (gift) Khan et al., 2018 DB 
PHF1 (phospho-Ser-396 and -
Ser-404) Dr. Peter Davies (gift) Khan et al., 2018 WB 
T22 (tau oligomers) Dr. Rakez Kayed (gift) Lasagna-Reeves et al., 2012 DB 
Neuron and Synapse Markers Company Reference Use 
b-Synuclein Thermo Fisher PA5-25738 WB 
MAP2 Novus Biologicals NB300-213 IF 
NeuN Abcam Ab177487 IF 
PSD95 Abcam Ab2723 IF 
PSD95 Cell Signaling 3450 IF, WB 
Synapsin 1/2 Synaptic Systems 106-002 WB 
Synaptophysin Abcam Ab32127 IF, WB 
Glutamate Receptors Company Reference Use 
GluA1 (D4N9V) Cell Signaling 13185 WB 
GluA2/3 Millipore 07-598 WB 
GluN1 BD Pharmingen 556308 WB 
GluN2A Cell Signaling 4205 WB 
PrP-Fyn-GluN2B Company Reference Use 
Fyn (FYN-01) Abcam Ab1187 WB 
pTyr417-Src Cell Signaling 2101 WB 
GluN2B (D15B3) Cell Signaling 4212 WB 
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pTyr1472-GluN2B Cell Signaling 4208 WB 
PrP (6D11) BioLegend 808004 WB 
PrP (8B4) Santa Cruz sc-47729 WB 
Network Markers Company Reference Use 
Calbindin (D1I4Q) Cell Signaling 13176 IF 
c-Fos Synaptic Systems 226-003 IF 
Neuropeptide Y (D75YA) Cell Signaling 11976 IF 
 
Table 2.2 – List of antibodies utilized in experiments. DB: Dot blot. IF: Immunofluorescence. WB: 
Western blot.  
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Results 
 
 
Mutant a-synuclein-dependent cognitive dysfunction in spatial learning and 
memory is both progressive and tau-dependent  
 
 Several a-synuclein (aS) transgenic mouse models display memory deficits 
(Chesselet et al., 2012; Lim et al., 2010, 2011; Magen et al., 2012), including the model 
expressing human mutant A53T aS (TgA53T) (Chesselet et al., 2012; Lim et al., 2010, 
2011; Paumier et al., 2013; Teravskis et al., 2018). However, the mechanistic basis for 
cognitive impairment in these mouse models is poorly defined. Previously, we established 
a novel connection between human mutant A53T aS (haSA53T) and postsynaptic 
impairments in AMPAR function that require tau phosphorylation and mislocalization to 
dendritic spines (Teravskis et al., 2018). Because these glutamatergic postsynaptic 
impairments are linked to cognitive dysfunction (Hoover et al., 2010), we hypothesized 
that cognitive deficits in TgA53T mice are tau-dependent. To directly test the requirement 
of tau in mediating aS-induced memory loss, we generated TgA53T mice lacking 
endogenous mouse tau expression by breeding TgA53T mice to the mouse tau knockout 
mice (mTau-/-) (Tucker et al., 2001). The four genotypes (TgA53T, TgA53T/mTau-/-, mTau-
/-, and non-transgenic (nTg) littermate controls) appear to develop and age normally for 
the duration of the study (Figure 2.1).  
Previously, we showed that TgA53T mice exhibit spatial memory deficits in the Barnes 
maze (BM) (Barnes, 1979; Sunyer et al., 2007) at 12 months of age (Teravskis et al., 
2018), however, it is unknown if general overexpression of haS also leads to memory 
deficits. To confirm that only TgA53T mice exhibit memory deficits in our experimental 
conditions, we examined whether TgWT (haSWT) and TgA30P (haSA30P) mice in our colony 
exhibit deficits in spatial learning and memory at older ages. TgA53T and TgA30P mice 
have similar human mutant aS transgene expression levels, while TgWT mice display 
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lower human aS transgene expression by comparison (Teravskis et al., 2018). We 
previously showed that TgWT and TgA30P neurons exhibit presynaptic deficits as 
indicated by reductions in the probability of neurotransmitter release, but intact 
postsynaptic function and long-term potentiation (LTP) (Teravskis et al., 2018). Thus, we 
employed these models to directly test whether presynaptic deficits alone are sufficient to 
cause impairments in learning and memory. Spatial learning and memory analysis of 12-
month-old TgWT, TgA30P, and nTg littermates using the BM paradigm shows that all 
groups of mice are able to learn and retain goal quadrant and escape box location (Figure 
2.2b-d). Taken together, our findings show that aS-dependent presynaptic impairments 
alone are not sufficient to cause memory deficits in mouse models of a-synucleinopathy 
under our experimental conditions, and that memory deficits in TgA53T mice involves both 
pre and postsynaptic abnormalities.  
To better define memory deficits in TgA53T mice, we assessed the progressive nature 
these deficits hippocampal-dependent spatial learning and memory via BM and whether 
endogenous tau was required for cognitive deficits in TgA53T mice. At 6 months of age, 
TgA53T mice exhibit a slight delay in acquisition compared to the nTg and mTau-/- controls 
(Figure 2.3b), mitigated by extra training as they successfully learn the location of the 
escape hole in the goal quadrant in a timing similar to controls by training day 4 (Figure 
2.3b). Consistent with previous data, 12-month-old TgA53T mice display severe 
impairments in the ability to learn the BM task, as they failed to display improved 
performance over consecutive training days (Figure 2.3c). Significantly, the loss of tau 
completely reverses the haSA53T-mediated learning deficit exhibited by TgA53T mice as 
TgA53T/mTau-/- showed normal learning during training in the acquisition phase (Figure 
2.3c). 
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In the ensuing probe trial, a putative measure for spatial learning and memory 
retention, all 6-month-old animals, including TgA53T, spent significantly more time in the 
goal quadrant compared to other quadrants in the maze (Figure 2.3b and d, and Figure 
2.4a and f), indicating that TgA53T mice have normal long-term spatial memory at 6 
months of age. By 12 months, TgA53T mice did not show evidence of spatial memory 
retention during the probe trial, consistent with impaired memory acquisition (Figures 
2.3c-d, and Figure 2.4b and f). The memory deficits in the 12-month-old TgA53T mice is 
independent of motor deficits as the total distance traveled during the probe test was 
comparable between groups at both 6 and 12 months of age (Figure 2.4c-d).  
Consistent with the normal learning and acquisition exhibited by TgA53T/mTau-/- mice, 
loss of tau expression completely rescues TgA53T-associated memory deficits as 12-
month-old TgA53T/mTau-/- effectively learn and recall escape hole location within the goal 
quadrant. Collectively, these results demonstrate that tau expression is required for the 
progressive spatial learning and memory deficits in the TgA53T model.  
 
TgA53T mice exhibit deficits in multiple memory modalities  
 While TgA53T mice demonstrate intact spatial learning and memory relative to nTg 
littermates at 6 months of age, hippocampal LTP deficits occur by 6 months in this model 
(Teravskis et al., 2018). Given that TgA53T mice may display mild BM learning deficits in 
early training days at 6 months of age, we hypothesized that TgA53T mice may exhibit 
more obvious tau-dependent deficits at earlier ages in other memory modalities involving 
hippocampal function. We first used contextual fear conditioning (CFC) to determine if 
TgA53T mice show deficits in this dual hippocampal and amygdala-dependent task (Bach 
et al., 1995; McKernan and Shinnick-Gallagher, 1997; Phillips and LeDoux, 1992). 3-
month-old TgA53T mice show normal learning and memory comparable to the nTg 
littermates (Figure 2.5b-d). At 6 months of age, TgA53T mice respond similarly to foot 
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shocks during the context conditioning trial as compared to nTg, TgA53T/mTau-/-, and 
mTau-/- cohort counterparts (Figure 2.5e), indicating that these mice do not exhibit gross 
sensorimotor abnormalities that could confound these findings. TgA53T mice exhibit 
significantly less freezing when exposed to the “similar” context as compared to the other 
three strains tested (Figure 2.5f), indicating that CFC is impaired in 6-month-old TgA53T 
mice. All groups displayed reduced freezing tendencies in the “novel” setting, controlling 
for any sensorimotor differences (Figure 2.5d and g). Significantly, TgA53T/mTau-/- 
animals showed equivalent CFC capacities compared to control mice (nTg and mTau-/-), 
demonstrating that tau is required for mutant aS-dependent deficits in CFC.  
Both the BM and CFC represent situations that subject mice to stressful environments 
to promote task performance. Thus, to reduce any confounds associated with the 
differential stress responses, we asked whether TgA53T mice have cognitive deficits in 
short-term memory using a spatial variant of the Y maze (YM), a less stressful assessment 
of spatial learning and memory (Conrad et al., 1996). Animals undergo an initial learning 
trial where the “novel” arm is blocked off followed by a “recognition” trial where all arms 
are open for exploration (Figure 2.6a). The recognition trial takes advantage of an 
animal’s propensity to explore novel objects and environments and tests their capacity to 
discriminate between novel and familiar environments (Antunes and Biala, 2012; 
Taglialatela et al., 2009). As such, measuring the amount of time spent in the novel (N) 
versus familiar (F) arms of the YM provides an assessment of short-term spatial learning 
and memory. 6-month-old nTg mice spent significantly more time in the N arm while 
littermateTgA53T mice spent equal amounts (chance) between N and F arms during the 
recognition trial (Figure 2.6b and d). The haSA53T-mediated reductions in spatial 
discrimination is suggestive of an impaired capacity for this hippocampal-dependent short-
term spatial memory at 6 months of age. More importantly, the YM spatial discrimination 
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deficit was reversed in TgA53T/mTau-/- mice, indicating that endogenous tau expression 
is required for haSA53T-associated impairments in both short- and long-term spatial 
learning and memory (Figure 2.6b and d). In TgA53T mice, Lewy-like amyloid 
intraneuronal accumulations of haS are found primarily the dorsal midbrain, cerebellar 
nuclei, brainstem, and spinal cord, accompanied by astrogliosis but no neurodegeneration 
(Lee et al., 2002). However, these neuropathological changes are absent in cortical and 
limbic system structures, including the hippocampus and amygdala, of TgA53T mice 
brains (Lee et al., 2002) suggesting that haSA53T-mediated neuronal dysfunction can occur 
in the absence of aggregate formation. This observation is consistent with another 
haSA53T-expressing transgenic mouse line that develops motor and gait deficits but no aS-
positive intracellular inclusions (Gispert et al., 2003).   
 
Presymptomatic motor hyperactivity of TgA53T mice is tau-independent 
 Our results so far indicate that removing tau expression restores learning and memory 
deficits in TgA53T mice, particularly those associated with intact hippocampal function. 
However, TgA53T mice exhibit other presymptomatic abnormalities in advance of overt a-
synucleinopathy-associated motor dysfunction presentation. In particular, TgA53T mice, 
but not TgWT and TgA30P, exhibit spontaneous locomotor hyperactivity associated with 
increased striatal D1 dopamine receptor sensitivity (Graham and Sidhu, 2010; Unger et 
al., 2006; Zhuang et al., 2001). Thus, we tested whether endogenous tau was required for 
haSA53T-dependent hyperactivity. As expected, TgA53T mice exhibit a progressive 
increase in locomotor hyperactivity as measured by distance traveled in the open field 
arena at 3, 6, and 12 months. This hyperactivity was tau-independent as TgA53T and 
TgA53T/mTau-/- mice exhibit similar levels of hyperactivity that progress in a nearly-
identical, age-dependent manner as well (Figure 2.7b-c). While tau is required for mutant 
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aS-mediated deficits in hippocampal function, we conclude that mutant aS-driven 
abnormalities associated with nigro-striatal circuitry appear tau-independent, suggesting 
a cell-type specificity of pathologic interactions between aS and tau. 
 
Tau is required for A53T aS-linked impairments in excitatory and evoked neuronal 
activity 
 
 In our model for how mutant aS produces cognitive deficits, we propose that mutant 
aS causes tau-dependent postsynaptic deficits characterized by the loss of AMPAR and 
subsequent deficits in hippocampal glutamatergic signaling, LTP, and memory 
impairments (Teravskis et al., 2018). However, it is unknown if these pathways are directly 
interrelated. We therefore examined if endogenous tau expression was also required for 
aS-mediated synaptic deficits using acute hippocampal slice recordings (Teravskis et al., 
2018). Further, to determine if these neurophysiological deficits in TgA53T neurons are 
progressive, we examined hippocampal slices from mice at 2-3 months of age, where 
animals have intact cognition, and 5-6 months of age, where mice first display impairments 
in CFC and YM. Consistent with our previous study, neurons from all mice show similar 
profiles in analysis of basal synaptic transmission at both age points, including analysis of 
input/output curves and paired-pulse facilitation (Figure 2.8a-c). Analysis of synaptic 
fatigue shows that neurons lacking tau, either mTau-/- or TgA53T/mTau-/-, exhibit variable 
attenuation of stimulus-dependent reductions in EPSC (excitatory postsynaptic current) 
amplitude, suggesting that tau may be involved in the regulation of high-frequency 
synaptic transmission under physiological conditions (Figure 2.8f). Neurons from 6-
month-old TgA53T mice exhibit reduced synaptic strength as measured by comparing 
AMPAR currents to NMDA receptor (NMDAR) currents (AMPA/NMDA ratio) (Figure 2.8g-
h). By contrast, neurons from 2-3-month-old TgA53T mice show a normal AMPA/NMDA 
ratio when compared to nTg littermate controls (Figure 2.8g-h), indicating that haSA53T-
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mediated reductions in synaptic strength are progressive. Significantly, loss of tau 
expression in TgA53T/mTau-/- reversed TgA53T-associated reductions in the 
AMPA/NMDA ratio (Figure 2.8g-i) providing the first ex vivo confirmation that tau 
mediates mutant aS-driven deficits in synaptic function, and that these deficits coincide 
with onset of cognitive dysfunction. 
 Overexpression of synuclein-family proteins including haSWT, haSA53T, and b-synuclein 
(bS), have been shown to reduce presynaptic vesicle release and neurotransmission 
(Nemani et al., 2010). However, haSA53T causes reductions in both spontaneous pre- and 
postsynaptic activities without detectable synapse loss (Teravskis et al., 2018). Thus, we 
examined if tau expression modulates haSA53T reductions in synaptic activity by analyzing 
spontaneous neurotransmitter release and synaptic activity via recording of mini excitatory 
postsynaptic currents (mEPSCs). mEPSC frequency, reflecting the probability of 
neurotransmitter release from presynaptic vesicles, is reduced in TgA53T neurons at both 
2-3 months and 5-6 months of age, confirming that inhibition of neurotransmission is a 
direct, primary synaptic effect of aS expression (Figure 2.9a and c-d). More important, 
mEPSC amplitude, reflecting postsynaptic AMPAR function, were comparable between 
TgA53T and nTg neurons at 2-3 month of age, but show significant reductions in slices 
from 5-6-month-old animals (Figure 2.9b-d). These results, similar to memory deficits, 
indicate that postsynaptic deficits in TgA53T neurons are progressive with aging. Both 
mEPSC amplitude and frequency measured in neurons from TgA53T/mTau-/- slices are 
not different from nTg and mTau-/- controls, demonstrating that haSA53T-mediated pre and 
postsynaptic deficits require tau expression. The fact that mTau-/- neurons were not 
different from nTg neurons in these measures demonstrates that the reversal of mutant 
aS-dependent effects in TgA53T/mTau-/- neurons is not due to simple additive effects. 
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It is possible that the findings in acute hippocampal slices could involve tau-dependent 
alterations in circuit development or compensation. To account for this possibility, we used 
dissociated hippocampal neuronal cultures to test whether loss of tau can reverse the 
synaptic changes observed in TgA53T neurons (Teravskis et al., 2018). 
Neurophysiological analysis of primary cultures from TgA53T and TgA53T/mTau-/- shows 
that loss of tau expression blocks the effects of mutant aS overexpression (Figure 2.10), 
implicating tau as a direct mediator of mutant aS-induced pre and postsynaptic changes. 
Having established tau as a mediator of haSA53T-driven postsynaptic deficits in 
spontaneous neurotransmission, we next asked if tau contributes to A53T aS-mediated 
deficits in long-term plasticity by evaluating hippocampal LTP induction (Malinow and 
Malenka, 2002). Consistent with intact spatial learning and memory (Figures 2.3-2.6), 
LTP in TgA53T mice at 2-3 months is normal when compared to age-matched nTg 
littermates (Figure 2.11a and c-d). At 6 months, cognitively impaired TgA53T mice display 
tau-dependent memory deficits (Figures 2.5-2.6) and LTP deficits (Figure 2.11b-c and 
e). Taken together, our findings thus far demonstrate that tau is required for TgA53T-
associated progressive impairments in synaptic activity and plasticity and spatial learning 
and memory. Moreover, our results show that presynaptic effects due to aS 
overexpression are not sufficient to cause memory deficits, suggesting that altered 
postsynaptic glutamatergic signaling is required for cognitive dysfunction in the TgA53T 
model.  
 
Tau does not alter expression or oligomerization of aS in forebrains of TgA53T mice 
 
 Post-translational modifications of aS are believed to be integral to PD 
pathophysiology. Levels of aggregate-promoting C-terminally truncated aS (aSDC) are 
increased by familial PD-linked A30P and A53T missense mutations  (Li et al., 2005). 
Further, phosphorylated aS at Serine 129 (pSer129) is an accepted marker of aS 
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pathology in situ (Fujiwara et al., 2002; Samuel et al., 2016). Thus, we asked if tau-
dependent synaptic and memory deficits and cognitive decline in TgA53T mice were due 
to alterations in hippocampal and cortical aS expression, increased pathogenic aS 
modifications, aS oligomer accumulation, or abnormal tau accumulation. Immunoblot 
analysis demonstrates that total hippocampal and cortical tau levels were not different 
between nTg and TgA53T lysates, indicating that alterations in tau expression are not 
responsible for tau-dependent deficits in TgA53T mice and neurons. Conversely, the loss 
of tau also did not alter total aS levels in nTg or TgA53T mice (Figure 12a-d, and Figure 
13a and c). In addition, both aSDC and pSer129aS levels were unaffected by tau 
expression (Figure 12a-b Finally, consistent with previous studies (Colla et al., 2012a; 
Lee et al., 2002; Li et al., 2005), very little levels of detergent-insoluble aS are present in 
hippocampal lysates and levels of detergent-insoluble aS are not altered by tau 
expression (Figure 14).   
 Analysis of total tau expression via Tau5 antibody indicates that TgA53T cortices and 
hippocampi express comparable tau levels to that of nTg brains (Figure 12a-b, and 
Figure 13a and c). To determine if the synaptic deficits observed in TgA53T neurons were 
associated with increased tau phosphorylation (Teravskis et al., 2018), expression of 
phosphorylated tau species as recognized by AT8, CP13, and PHF1 antibodies was 
determined via concurrent immunoblot analysis (Khan et al., 2018). These results 
demonstrate that TgA53T brains exhibit modest, but significantly increased levels of AT8, 
CP13, and PHF1-positive phosphorylated tau (Figure 15). As expected, no 
immunoreactivity to tau-related epitopes are observed in mTau-/- animals. These results 
are consistent with our hypothesis that haSA53T drives synaptic deficits by phosphorylation-
dependent mislocalization of tau into dendritic spines (Teravskis et al., 2018).  
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aS and tau also have the capacity to induce each other’s aggregation and 
polymerization into fibrillar amyloid structures (Giasson et al., 2003) and aS oligomers can 
induce tau misfolding and downstream generation of oligomers (Castillo-Carranza et al., 
2018; Gerson et al., 2018). Thus, we next investigated if the levels of soluble aS and/or 
tau oligomers could be correlated with synaptic and memory deficits in TgA53T mice. In 
all cortical and hippocampal lysates, no general amyloid structures (OC), soluble 
oligomeric species (A11), or tau oligomers (T22) (Lasagna-Reeves et al., 2012) were 
present at detectable levels (Figure 12c-d, and Figure 16). As expected, a panel of 
antibodies against conformational-specific and higher order assemblies of aS showed 
increased levels in TgA53T lysates. However, they did not reveal any changes as a 
function of tau expression: Syn33 (oligomers, dimers and higher molecular weight 
aggregates), F8H7 (oligomers from 70 kDa and above), and MJFR-14-6-4-2 (soluble 
oligomeric and fibrillar structures) (Lasagna-Reeves et al., 2012; Lindersson et al., 2004; 
Paleologou et al., 2009; Sengupta et al., 2015). While the mutant aS-selective effects on 
synaptic function and behavioral deficits suggest that pathological aS species are 
involved, our results indicate that the tau-dependent effects are not due to simple 
modulation of aS expression and aS oligomerization. Collectively, based on our results, 
we propose that the effect of tau may be occurring downstream or independent of the 
pathological conversion of aS.  
 
Memory deficits in TgA53T mice occurs in the absence of synaptic degeneration 
 
 In vertebrates, aS is a part of the larger synuclein gene family that include homologs 
b- and g-synuclein (George, 2002; Lavedan, 1998; Maroteaux and Scheller, 1991). b-
synuclein (bS) can antagonize aS aggregation and toxicity (Hashimoto et al., 2001) and 
ameliorating endogenous bS enhances pathological aS phosphorylation and aggregation 
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(Fares et al., 2016). Consistent with previous findings (Thomas et al., 2011), expression 
of aS is inversely correlated with bS accumulation in the brain (Figure 2.12e-f, and Figure 
2.13b and d). Interestingly, the reduction in cortical and hippocampal bS expression of 
TgA53T mice is not rescued by removal of endogenous tau (Figure 2.12e-f, and Figure 
2.13b and d).  
Other aS transgenic mouse models that exhibit memory deficits are associated with 
various levels of neurodegenerative changes, including cortical aS pathology and cortical 
and hippocampal synaptic loss (Hatami and Chesselet, 2015; Koprich et al., 2017). While 
cortical and hippocampal pathology are not robust features of the TgA53T model, we 
examined whether the tau-dependent memory deficits in the TgA53T model are due to 
loss of synapses by evaluating the protein abundance of presynaptic (synaptophysin) and 
postsynaptic (PSD95) proteins. Biochemically, there were no differences in the amounts 
of either synaptic proteins across the four genotypes assessed at 12 months of age 
(Figure 2.12e-f, and Figure 2.13b and d). We next extended our biochemical findings 
with immunostaining to probe for changes in hippocampal and synaptic structure. TgA53T 
hippocampi at 12 months show similar hippocampal structure as compared to age-
matched nTg littermates via staining for neuronal nuclei (NeuN; Figure 17a), 
demonstrating that overt neuronal loss is not required for haSA53T-mediated cognitive 
decline. Furthermore, confocal images of somatodendritic (MAP2), presynaptic 
(synaptophysin), and postsynaptic (PSD95) structures qualitatively indicate intact synaptic 
structures in cognitively impaired 12 month TgA53T mice compared to nTg littermates 
(Figure 17b). Collectively, our results show that neither neuronal loss nor synaptic 
degradation are responsible for the aS-mediated cognitive dysfunction in TgA53T mice.  
In light of an apparent intact synaptic integrity in TgA53T mice, increased human wild-
type or mutant aS expression has been implicated in dysregulation of presynaptic function 
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by selectively reducing levels of synapsins (Larson et al., 2017; Nemani et al., 2010). 
Immunoblot analyses of cortical and hippocampal lysates confirm reduced levels of 
synapsin isoforms in TgA53T mice (Figure 2.12e-f, and Figure 2.13b and d). However, 
suppressed synapsin levels were not restored by loss of tau expression in TgA53T/mTau-
/- brains, indicating that tau functions in a distinct pathway or downstream of synapsin 
expression (Figure 2.12e-f, and Figure 2.13b and d). These results support our 
behavioral findings that aS-mediated presynaptic deficits alone are not sufficient for 
memory deficits. 
 
Synaptic and memory deficits in TgA53T mice associated with tau-dependent 
alterations in postsynaptic glutamate receptors 
 
 The cellular and molecular mechanisms driving LTP are mediated by postsynaptic 
AMPAR and NMDAR (Bliss and Collingridge, 1993; Malinow and Malenka, 2002; Malinow 
et al., 2000). Tau missorting to dendritic spines is associated with memory loss and 
impairments in postsynaptic AMPAR signaling in frontotemporal dementia and 
parkinsonism linked to chromosome 17 (FTDP-17), Alzheimer’s disease (AD) (Hoover et 
al., 2010; Miller et al., 2014). We showed that haSA53T-mediated tau missorting to dendritic 
spines is associated with calcineurin-dependent AMPAR internalization (Teravskis et al., 
2018). As the loss of hippocampal AMPARs likely contribute to deficits in LTP and 
memory, we sought to determine if reductions in AMPAR expression occurs in TgA53T 
mice. Immunoblot analysis displayed progressive reductions specific to hippocampal, but 
not cortical, AMPAR subunits (GluA1 and GluA2/3). Specifically, while AMPAR levels are 
not different between 3-month-old nTg and TgA53T mice, they are significantly reduced 
in TgA53T hippocampi at 6 and 12 months of age (Figures 2.18). These haSA53T-mediated 
deficits are tau-dependent as TgA53T/mTau-/- hippocampi displayed levels of AMPAR 
expression similar to nTg and mTau-/- controls at 12 months of age. Thus, loss of 
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hippocampal AMPAR levels correlate with age- and tau-dependent onset of synaptic and 
cognitive deficits. To determine the selectivity of AMPAR changes, we also examined 
NMDAR levels, receptors essential for LTP but not functionally altered by tau 
mislocalization to spines (Hoover et al., 2010). GluN1 and GluN2A expression remained 
unchanged in cognitively intact 3-month-old or impaired 6-month-old TgA53T mice 
compared to nTg controls (Figure 2.19). GluN1 expression was increased in 12-month-
old TgA53T hippocampi and cortices, but, unlike AMPAR subunit expression changes, 
was neither changed by the status of tau expression (Figure 2.18). Collectively, these 
results parallel our neurophysiological findings and further our proposal that the TgA53T 
model is associated with the selective impairments in hippocampal postsynaptic AMPAR 
signaling in a tau-dependent manner while NMDARs are largely unaffected or slightly 
increased in multiple brain regions.   
AD-associated amyloid-b (Ab) oligomers have been shown to alter postsynaptic 
signaling through binding to cellular prion protein (PrPC) that produces downstream Fyn 
activation and phosphorylation of the GluN2B subunit of NMDARs (Laurén et al., 2009; 
Um et al., 2012). It has recently been proposed that aS oligomers causes cognitive deficits 
through a mechanism involving activation of the cellular prion protein (PrPC), Fyn, and 
GluN2B (Ferreira et al., 2017). We therefore examined whether PrPC-Fyn-GluN2B 
signaling is altered in the TgA53T model. In contrast to this recent study (Ferreira et al., 
2017), TgA53T mice did not show increased PrPC expression, an established mechanism 
for mediating downstream increases in Fyn and GluN2B phosphorylation and activation 
(Ferreira et al., 2017; Um et al., 2012, 2013) (Figure 2.20b-e). We also determined that 
Fyn phosphorylation and activation was not increased in the TgA53T model (Figure 
2.21a-b). The final output for pathological PrPC and Fyn signaling is increased NMDAR 
signaling through phosphorylation of GluN2B by Fyn. Consistent with the absence of 
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increased PrPC expression and Fyn activation, phosphorylation-inducing activation of 
GluN2B was not detected in TgA53T mice with either intact or impaired cognition (Figure 
2.21c-d). Taken together, our results do not support involvement of PrPC-Fyn-GluN2B 
signaling in the memory deficits observed in TgA53T mice. Our conclusion is also 
supported a recent study showing that PrPC neither binds nor mediates the toxic effects 
of aS oligomers (La Vitola et al., 2019). 
 
TgA53T mice exhibit progressive hippocampal inhibitory circuit remodeling 
 Disruption of neuronal networks due to chronic network hyperactivity has been 
hypothesized to be a potential mechanism contributing to cognitive decline in 
neurodegenerative diseases (Palop et al., 2006), particularly via increased spontaneous 
epileptiform activity and compensatory remodeling of networks (Chin et al., 2005; Palop 
et al., 2007; Sun et al., 2009). Thus, we asked if TgA53T mice exhibit evidence of 
hippocampal circuit remodeling typical of chronic network hyperactivity (Palop and Mucke, 
2010; Palop et al., 2007): loss of c-Fos positive dentate granule cells, ectopic neuropeptide 
Y (NPY) expression in the mossy fiber pathway and molecular layer of dentate gyrus, and 
reduction in calbindin in the granule cells of dentate gyrus and stratum radiatum of CA1 
(Morris et al., 2015; Palop et al., 2007; Roberson et al., 2011). At 3 months of age, 
cognitively intact TgA53T mice display c-Fos, NPY, and calbindin staining 
indistinguishable from nTg mice (Figure 2.22b-d, and Figure 2.23a and c-e). These 
results indicate that when mice display normal postsynaptic function and memory, 
hippocampal circuits have not been exposed to chronic network hyperactivity. At 6 
months, two distinct populations of TgA53T are observed: one displaying circuit remolding 
consistent with chronic network hyperactivity and another “intermediate” group without 
circuit remodeling (Figure 2.22b-d, and Figure 2.23b-h). By 12 months of age, all 
TgA53T mice show prominent network changes indicative of chronic epileptic activity 
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(Figure 2.22). Importantly, these age-dependent, aS-mediated alterations in hippocampal 
circuits are absent in the 12-month-old TgA53T/mTau-/- mice. These results indicate that 
hippocampal network remodeling in the TgA53T model starts between 3 and 6 months of 
age, likely as a compensatory response to network hyperactivity. The variability observed 
in 6-month-old TgA53T mice is consistent with animals undergoing a transition period. 
Further, the TgA53T-linked inhibitory hippocampal circuit remodeling is absent in 
TgA53T/mTau-/- animals, indicating that haSA53T-associated network hyperactivity, along 
with progressive synaptic and memory deficits, require endogenous tau expression. 
 
Tau is a partial mediator of exogenous, fibrillar aS-induced disease onset in TgA53T 
mice 
 
 In a human mutant amyloid-precursor protein (hAPP) mouse model of AD, tau is 
required for Ab-induced lethality (Roberson et al., 2007). Interestingly, dementia in PD is 
associated with increased mortality risk (Emre et al., 2007; Levy et al., 2002; 
Svenningsson et al., 2012; Willis et al., 2012). Bridging these two observations, we 
therefore next asked if tau was required for haSA53T-induced premature morbidity and 
mortality in an accelerated model of PD that employed exogenous fibrillar aS species 
(Volpicelli-Daley et al., 2014). Misfolded fibrillar forms of aS, are hypothesized to represent 
a pathogenic and transmissible species of the protein. Peripheral injection of fibrils into 
transgenic mouse models of synucleinopathy has been demonstrated to induce robust aS 
pathology in the CNS, progressive motor impairments, and premature lethality on the 
order of weeks post-injection, representing an appealing model for studying the 
mechanisms underlying aS-induced disease pathogenesis (Ayers et al., 2017; Sacino et 
al., 2014). To assess the role of tau in mediating these pathological changes, we 
generated human wild-type aS pre-formed fibrils (PFFs) in line with accepted protocols 
  86 
(Volpicelli-Daley et al., 2014). Following this, 3-month-old mice received bilateral 
intramuscular injections of PFFs into the biceps femoris muscle. At this age, TgA53T 
animals in our colony do not display gross neurological and locomotor impairments, 
consistent with their original characterization (Lee et al., 2002). Post-injections, animals 
were monitored for two pre-defined phenotypic end points that would occur in sequential 
order: 1) disease onset and 2) end stage. PFF-induced disease-onset is characterized as 
an animal displaying hindlimb clasping and gait abnormalities (“wobbling”) when moving 
around in their home cage or on a level surface (Figure 2.24d and f-g). Following disease 
onset, the second end point of interest, termed end stage, is characterized as animals 
being moribund, no longer able to locomote, and displays cachexia due to inability to eat 
and drink (Figure 2.24e-g). The Kaplan-Meier curve analysis demonstrates that tau 
amelioration in TgA53T mice mildly, although significantly, slows the rate of PFF-induced 
disease onset and lethality in TgA53T animals (Figure 2.24d-e). Another component to 
the PFF model is disease progression, defined as the time between end point 1 (disease 
onset) and end point 2 (end stage). When assessing disease progression, there was no 
significant between TgA53T animals with or without endogenous mouse tau expression 
(Figure 2.43f-g). As such, it is possible that tau may be responsible in partially-mediating 
PFF-induced disease onset, explaining the subtle delay in TgA53T/mTau-/-, that persists 
through end stage. However, it is critical to note that no PFF-injected nTg nor mTau-/- mice 
became symptomatic or reached end point 1 during the time frame mice were monitored, 
during which all PFF-injected TgA53T and TgA53T/mTau-/- reached both end points (Fig 
2.24d-e). By that metric, it is evident that tau is not a major contributor to PFF-induced 
disease onset and lethality in mice expressing haSA53T, and it is likely that pathogenesis 
in this model may be occurring through pathways and mechanisms independent of tau.  
Discussion  
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 Dementia associated with a-synucleinopathy, particularly PDD and DLB, is one of the 
leading sources of global disability from neurological disorders (Dorsey et al., 2018; 
Jellinger and Korczyn, 2018). Currently, there are no effective therapies for managing 
PDD and DLB. Thus, understanding the cellular and molecular mechanisms of dementia 
in PDD and DLB will facilitate the development of new treatments. Previously, we 
proposed a model where haSA53T induces tau mislocalization to dendritic spines, leading 
to postsynaptic deficits in AMPAR signaling (Teravskis et al., 2018). However, it was not 
known if these tau-related changes are directly causative for deficits in synaptic plasticity 
and learning and memory in the TgA53T mouse model. In our present study we provide 
the first in vivo evaluation of the mechanistic relationships between aS abnormalities, tau 
expression, synaptic function, and memory. Our data shows that removal of endogenous 
tau expression reverses a range of synaptic and memory impairments in TgA53T mice. 
Further our results indicate that the effect of tau may be downstream or independent of 
potentially pathogenic aS oligomeric or fibrillar species. Because TgA53T-associated 
deficits in synaptic function and learning and memory are not connected with hippocampal 
neurodegeneration, it is likely that tau regulates haSA53T-alterations in synaptic physiology 
by perturbing neuronal function. In particular, our results indicate that tau-dependent loss 
of AMPAR function is an early event that is tightly correlated with LTP deficits, evidence 
of hippocampal network remodeling suggestive of chronic hyperactivity, and cognitive 
dysfunction in the TgA53T model. 
A convergence of aS, tau, and Ab pathologies has been observed in PDD and DLB 
patients with increased cognitive impairment, suggesting a mechanism for neuronal 
dysfunction in a-synucleinopathies involving more than aS pathology (Colom-Cadena et 
al., 2013; Irwin et al., 2013). Significantly, dementia, cortical and hippocampal aS 
pathology, and tau pathology are often noted features of PD patients with A53T mutation 
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in aS (Bougea et al., 2017; Duda et al., 2002; Golbe et al., 1990; Markopoulou et al., 2008; 
Spira et al., 2001). In this study, we expand on the interaction between aS and tau by 
showing that physiological tau expression independent contributes to neurophysiological 
and memory deficits in TgA53T mice. While we were not able to document accumulation 
of pathological tau oligomers, others have shown that pathological accumulation of tau 
oligomers in another TgA53T mouse model (Gerson et al., 2018), suggesting that tau may 
act downstream of aS pathology. Our results also add to the role of endogenous tau 
expression as a mediator of neuropathological phenotypes in AD models (Ittner et al., 
2010; Roberson et al., 2007, 2011; Vossel et al., 2010). The requirement of tau for memory 
deficits and the immunohistochemical markers of chronic epileptiform activity in the 
TgA53T model is reminiscent of studies in the hAPP-J20 transgenic mouse model of AD, 
where loss of tau expression reversed memory deficits and epileptic activity (Palop et al., 
2007; Roberson et al., 2007, 2011). In hAPP-J20 mice, chronic epileptiform activity is 
mechanistically linked to cognitive deficits. Thus, it is likely that network hyperactivity, as 
indicated by age-dependent remodeling of inhibitory networks in TgA53T mice, also 
contributes to memory deficits in the TgA53T mouse model. Significantly, another model 
of aS-dependent memory deficits (Thy1-haS: line 61) (Hatami and Chesselet, 2015) also 
shows increased epileptic activity, which was partially dependent on endogenous mouse 
tau expression (Morris et al., 2015). However, it is unknown if tau is required for memory 
deficits in the Thy1-haS model or in other models of aS-dependent synaptic and memory 
deficits. The pathologic link between epileptic activity and memory deficits may be relevant 
for understanding DLB as both AD and DLB are associated with higher incidences of 
seizures and signs of seizure-like network hyperactivity (Beagle et al., 2017; Martinez-
Losa et al., 2018; Minkeviciene et al., 2009; Morris et al., 2015; Palop et al., 2007; 
Roberson et al., 2011; Sun et al., 2009; Verret et al., 2012).  
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The progressive cognitive decline in TgA53T mice first observed at 6 months of age 
appears to correlate primarily with the loss of AMPAR expression leading to deficits in 
postsynaptic activity and LTP. Interestingly, TgA53T mice at this age point do not 
consistently display the molecular signature for chronic network hyperactivity of reductions 
in dentate granule cell c-Fos expression, increased ectopic NPY expression, and calbindin 
depletion in dentate granule cells, suggesting that the synaptic and memory deficits in the 
TgA53T model seem to precede inhibitory network remodeling. However, because 
network remodeling is a likely response to chronic and aberrant network hyperactivity 
(Palop and Mucke, 2010, 2016; Palop et al., 2006), we propose that the onset of this 
epileptiform activity is coincident with other synaptic deficits. It will be of significant future 
interest to determine the causal relationship between synaptic deficits, epileptic activity, 
and memory deficits as it has been studied in the hAPP-J20 model (Sanchez et al., 2012).  
While several transgenic Ab and aS mouse models share a final common outcome of 
memory loss through impairments in synaptic and neural network function, the 
mechanistic details appear to differ. One hypothesis for Ab-mediated cognitive decline 
involves postsynaptic dysfunction via activation of the PrPC-Fyn pathway, leading to 
phosphorylation and activation of the NMDAR subunit GluN2B, which, in turn, culminates 
in excitotoxicity and spine loss (Gimbel et al., 2010; Laurén et al., 2009; Roberson et al., 
2011; Um et al., 2012). This pathway has also been recently implicated in memory loss 
associated with a-synucleinopathies (Ferreira et al., 2017). However, in our studies, we 
did not observe PrPC-Fyn-GluN2B activation in TgA53T mice, indicating that haSA53T 
produces progressive postsynaptic and cognitive deficits through a mechanism 
independent of this pathway. Interestingly, in the hAPP-J20 model of AD, which, like 
TgA53T model of a-synucleinopathy, requires tau as a mediator of synaptic dysfunction 
and memory loss (Roberson et al., 2007), PrPC and Fyn activation appears to be 
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mechanistically disconnected as tau-dependent cognitive decline in hAPP-J20 mice is 
unaffected by PrPC ablation (Cissé et al., 2011). Furthermore, this view is consistent with 
a recent report (La Vitola et al., 2019) showing that, in contrast to the findings of Ferreira 
et al. (2017), PrPC does not mediate the detrimental effects of aS oligomers. Our results 
suggest that synaptic and memory deficits in the TgA53T model appear to be independent 
of alterations in NMDAR but associated with decreased AMPAR subunit expression. 
Finally, consistent with the lack of Fyn-GluN2B activation, we do not observe a significant 
loss of postsynaptic structures in aged TgA53T mice.   
Pathological aS can spread throughout the central nervous system, including cortical 
and hippocampal neurons, in a hierarchal progression that appears to follow functionally 
connected regions (Braak and Del Tredici, 2008; Braak et al., 2003), raising the possibility 
that certain neurodegenerative processes in PD may be produced by abnormal network 
activity. Supporting this mechanistic view, studies link PDD and DLB with LNs in the 
hippocampal CA2/3 region (Adamowicz et al., 2017; Hall et al., 2014). Here, we provide 
evidence where pathogenic aS causes reduced synaptic activity at specific excitatory 
synapses in the hippocampus, leading to deficits in AMPAR signaling and LTP. However, 
we also show that pathogenic haSA53T concurrently elicits aberrant excitatory activity as 
indicated by prominent compensatory remodeling of the inhibitory hippocampal circuits. 
One hypothesis to reconcile these seemingly contradictory observations is that depression 
of excitatory synaptic activity may be caused by a compensatory synaptic scaling 
mechanism reminiscent of the pro-excitatory effects of Ab. For example, while acute 
oligomeric Ab or aS application has been shown to transiently increase AMAPAR and 
NMDAR on the neuronal surface (Ferreira et al., 2017; Sanchez-Mejia et al., 2008), 
prolonged Ab oligomer exposure decreases AMPAR and NMDAR and suppresses 
synaptic plasticity (Hsieh et al., 2006; Shankar et al., 2007).  
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In our study, deficits in postsynaptic function, LTP, and memory are selectively 
associated with the expression of haSA53T. Since increased expression of a- or b-
synucleins lead to presynaptic deficits (Nemani et al., 2010; Teravskis et al., 2018), we 
conclude that aS-associated presynaptic deficit is not sufficient to cause LTP and 
cognitive decline. However, memory deficits have been documented in other transgenic 
mouse models expressing haSWT or haSA30P under the Thy-1 promoter (Hatami and 
Chesselet, 2015). Thus, under appropriate circumstances, it is clear that multiple haS 
variants can cause cognitive dysfunction. Currently, it is unknown if the postsynaptic 
deficits observed in our TgA53T animals are associated with memory deficits in these 
other TgWT or TgA30P mouse models. However, increased epileptic activity has been 
documented in the TgWT Thy1-haS model (line 61) (Morris et al., 2015), suggesting 
possible common mechanisms underlying aS-dependent synaptic and network deficits. 
We propose that a number of factors, including variations in transgene expression, 
background of mouse strains, housing conditions, and testing conditions and parameters 
could all contribute to the accumulation of toxic aS species that cause of memory deficits 
in TgWT and TgA30P models. It will be of significance in the future to determine if tau is 
required for memory deficits in multiple transgenic mouse models of a-synucleinopathy.  
Although synaptic loss is the major correlate for memory loss in AD patients (Scheff et 
al., 2006; Selkoe, 2002; Terry et al., 1991; de Wilde et al., 2016), clinical and pathological 
studies suggest that cognitive deficits in PDD/DLB occurs in the absence of large scale 
loss of hippocampal neurons (Bougea et al., 2017; Hely et al., 2008; Irwin et al., 2012; 
Kantarci et al., 2016). Further, while the amount of tau pathology correlates with the 
severity of dementia (Coughlin et al., 2018), tau pathology per se is not as strongly linked 
to the incidence of dementia in PDD and DLB as aS or Ab pathology (Hall et al., 2014; 
Irwin et al., 2012; Jellinger and Korczyn, 2018; Kalaitzakis et al., 2009). Significantly, the 
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MAPT H1 haplotype increases risk for PDD and DLB (Goris et al., 2007; Orme et al., 
2018). Since the MAPT H1 haplotype is thought to increase tau expression (Myers et al., 
2007), it is possible that basal tau expression, independent of tau pathology, contributes 
to aS-dependent memory impairments in humans.  
Prior to our current study, it was previously unknown how pathologic and genetic 
observations associated with PDD and DLB are related to the development of deficits in 
synaptic plasticity that underlie cognitive dysfunction. We provide evidence that the 
TgA53T model exhibits progressive, tau-dependent, memory loss associated with 
postsynaptic AMPAR dysfunction in the absence of overt synaptic loss and hippocampal 
neurodegeneration. More importantly, our results suggest that endogenous tau is required 
for the specific synaptic and memory deficits observed in TgA53T mice. Additionally, we 
propose that haSA53T causes tau-dependent synaptic alterations that lead to increased 
network hyperactivity that contribute to and exacerbate memory deficits (Figure 2.25). Our 
results, combined with previous studies in AD models, suggest that network 
hyperexcitability represents a novel therapeutic target for treating this driver of cognitive 
dysfunction in a-synucleinopathies. Collectively, this study introduces a mechanism that 
identifies key proteins and mechanisms that could mediate the neuronal dysfunction 
underlying memory deficits in PDD and DLB. Ultimately, building a more complete picture 
of how pathologic aS produces memory deficits is essential for developing novel 
therapeutic strategies for PDD and DLB.  
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Figure 2.1 – Breeding scheme to generate experimental animals and cohorts. a. Initial breeding 
diagram from parents (F0) to generation of F2 progeny that provides mice with appropriate genotypes 
to use for downstream breeding for generation of experimental cohorts. b. F0 parents and breeding 
approach to generation of offspring that creates our four genotypes (nTg, TgA53T, TgA53T/mTau-/-, 
mTau-/-) of interest without generating additional animals (mTau+/- heterozygotes) that would not be 
experimentally useful.  
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Figure 2.2 – Aged TgWT and TgA30P mice do not display deficits in long-term spatial learning 
and memory via Barnes Maze. a. Depiction of animals used: wild-type animals (nTg) do not express 
human aS. TgWT animals are heterozygous for a transgene that expresses wild-type human aS. 
TgA30P animals are heterozygous a transgene that expressed human mutant A30P aS. b. Barnes 
maze (BM) training trials for 12-month-old nTg, TgA30P, and TgWT animals demonstrating duration 
of training trials per group during each of the four training days. TgWT training: two-way repeated 
measures ANOVA with Geisser-Greenhouse correction and Sidak’s posthoc analysis revealed a 
significant effect of training (F(2.545,40.72) = 36.09, p < 0.0001), no effect of haSWT genotype (F(1,16) = 
3.249, p = 0.0903), and no significant training day* haSWT interaction (F(3,48) = 0.1449, p = 0.9325). 
TgA30P training: two-way repeated measures ANOVA with Geisser-Greenhouse correction and 
Sidak’s posthoc analysis revealed a significant effect of training (F(1.838,29.40) = 143.9, p < 0.0001), no 
effect of haSA30P genotype (F(1,16) =2.806, p = 0.1113), and no significant training day* haSA30P 
interaction (F(3,48) = 1.645, p = 0.1915). c. Time (seconds) spent occupying the target (goal) quadrant 
of the Barnes maze during the probe trial. Unpaired t test with Welch’s correction. TgWT: t = 1.472, 
df = 14.91; TgA30P: t = 1.439, df = 15. TgWT: N = 9 animals/genotype. TgA30P: nnTg = 7; nTgA30P = 9. 
d. Left column: probe test BM occupancy heat maps obtained by averaging the location of all animals 
in each genotype and cohort. Right column: representative individual animal traces tracking 
movement during the BM probe test. BM orientation shown in Fig 1c, yellow shading indicates goal 
quadrant. The findings here demonstrate that postsynaptic deficits, as observed in TgA53T mice but 
not in TgWT or TgA30P, are required for cognitive decline by 12 months of age as TgWT and TgA30P 
do not display such deficits at this time point. ns: not significant. Error bars represent mean ± standard 
error of the mean (S.E.M). Contributions: CG. 
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Figure 2.3 – Human mutant A53T aS driven deficits in spatial learning and memory are 
progressive and tau-dependent. a. BM diagram for testing and probe trial, with yellow shading 
indicating goal quadrant and dark grey showing escape box location in that quadrant. b and c. 
Average duration of training trials per group for each of the 4 training days during the Barnes Maze 
(BM) when tested at either 6 (b) or 12 months of age (c) (6M or 12M, respectively). b. 6M training: 
three-way repeated measures ANOVA with Geisser-Greenhouse correction and Tukey’s posthoc 
analysis revealed a significant effect of training day (F(2.448,105.3) = 190.7, p < 0.0001), significant effect 
of haSA53T genotype (F(1,43) = 18.63, p < 0.0001), no significant effect of mTau-/- genotype (F(1,43) = 
1.135, p = 0.2926), and no significant training day*haSA53T*mTau-/- interaction (F(3,129) = 0.1160 p = 
0.9506). One-way ANOVA with Tukey’s posthoc analysis to compare within 6M training days (TD): 
TD 1: F(3,43) = 5.856, p = 0.0019; TD 2: F(3,43) = 9.277, p < 0.0001; TD 3: F(3,43) = 2.466, p = 0.0768; TD 
4: F(3,43) = 2.189, p = 0.2330. c. 12M training: three-way repeated measures ANOVA with Geisser-
Greenhouse correction and Tukey’s posthoc analysis revealed a significant effects of training day 
(F(2.192,63.56) = 62.15, p < 0.0001), haSA53T genotype (F(1,29) = 13.78, p = 0.0009), and mTau-/- genotype 
(F(1,29) = 49.05, p < 0.0001), and no significant training day*haSA53T*mTau-/- interaction (F(3,87) = 3.734, 
p = 0.0141). One-way ANOVA with Tukey’s posthoc analysis to compare within 12M training days 
(TD): TD 1: F(3,29) = 1.407, p = 0.2607; TD 2: F(3,29) = 5.664, p = 0.0035; TD 3: F(3,29) = 10.64, p < 0.0001; 
TD 4: F(3,29) = 15.82, p < 0.0001. d. Time spent in goal quadrant during probe trial for 6M or 12M mice. 
To compare within genotype between 6M and 12M: unpaired t test with Welch’s correction; TgA53T: 
t = 3.369 and df = 15 (** p = 0.0042). To compare between genotypes at 6M or 12M: one-way ANOVA 
with Tukey’s posthoc analysis. 12M group probe test: F(3,29) = 9.216 (# p = 0.0002). 6M: nnTg = 13; 
nTgA53T = 11; nTgA53T/mTau-/-= 10; nmTau-/- = 8. 12M: nnTg = 9; nTgA53T = 7; nTgA53T/mTau-/- = 11; nmTau-/- = 8. e. 
Probe test BM occupancy heat maps during probe test obtained by averaging the location of all 
animals in each genotype and cohort. Orientation of BM is shown in (a). In all figures: 1) the color 
code is: nTg (black), TgA53T (red), TgA53T/mTau-/- (blue), and mTau-/- (green); 2) the data are 
expressed as mean ± standard error of the mean (S.E.M.); and 3) * p < 0.05, ** p < 0.01, *** p < 0.001, 
and **** p < 0.0001, unless stated otherwise. Contributions: MAB. 
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Figure 2.4 – Barnes Maze quadrant analysis demonstrating progressive deficits in long-term 
spatial learning and memory in TgA53T mice in absence of locomotor neurological deficits. a 
and b. Analysis of time animals spent in each quadrant of the Barnes Maze (BM) during the probe 
test of the BM at 6 months (6M) (a) and 12 months (12M) (b). 12M BM goal quadrant: F(3,29) = 10.47, 
p < 0.0001, one-way ANOVA with Tukey’s posthoc analysis. c and d. Total distance traveled on the 
BM by animals during the probe test at 6M (c) and 12M (d). 12M: F(3,31) = 0.9377, p = 0.4347 by one-
way ANOVA with Tukey’s posthoc analysis. 6M: nnTg = 13; nTgA53T = 11; nTgA53T/mTau-/-= 10; nmTau-/- = 8. 
12M: nnTg = 9; nTgA53T = 7; nTgA53T/mTau-/- = 11; nmTau-/- = 8. e. BM diagram for testing and probe trial, with 
yellow shading indicating goal quadrant and dark grey showing escape box location in that quadrant. 
f. Representative individual animal traces tracking movement during the BM probe test. Yellow 
shading indicates goal quadrant. These results demonstrate that TgA53T mice have age-dependent 
deficits in spatial learning and memory that are dependent on endogenous mouse tau expression and 
precede onset of locomotor abnormalities. One-way ANOVA: *** p < 0.001. ns: not significant. Error 
bars represent mean ± S.E.M. Contributions: MAB. 
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Figure 2.5 – Mutant synuclein impairs hippocampal contributions to contextual fear 
conditioning in both age and tau-dependent manners. a. Diagram of contextual fear conditioning 
(CFC) testing paradigm. CFC results in mice at 3 months (3M) (b-d) and 6 months (6M) of age (e-g). 
3M conditioning trial (b): three-way repeated measures ANOVA with Geisser-Greenhouse correction 
and Tukey’s posthoc analysis revealed a significant effect of inter-trial interval (F(3.200,89.59) = 67.91, p 
< 0.0001), no significant effect of haSA53T genotype (F(1,28) = 2.123, p = 0.1562), no significant effect 
of mTau-/- genotype (F(1,28) = 0.2536, p = 0.6185), and no significant inter-trial interval*haSA53T*mTau-
/- interaction (F(4,112) = 1.075, p = 0.3723). 6M conditioning trial (e): three-way repeated measures 
ANOVA with Geisser-Greenhouse correction and Tukey’s posthoc analysis revealed a significant 
effect of inter-trial interval (F(3.175,120.6) = 52.72, p < 0.0001), a significant effect of haSA53T genotype 
(F(1,38) = 5.429, p = 0.0252), no significant effect of mTau-/- genotype (F(1,38) = 0.7273, p = 0.3991), and 
no significant inter-trial interval*haSA53T*mTau-/- interaction (F(4,152) = 2.257, p = 0.0655). One-way 
ANOVA with Tukey’s posthoc analysis was used to compare within 3M and 6M inter-trial intervals. 
6M inter-trial interval 5: F(3,38) = 2.779, p = 0.0782. Percent of time spent freezing during conditioning 
trials (b and c) show similar responses in all genotypes. When mice are exposed to the Similar 
environment, all genotypes show similar freezing responses at 3M (c) while 6M TgA53T mice freeze 
less than controls (f) (one-way ANOVA with Tukey’s posthoc analysis: F(3,37) = 7.538, p = 0.0005), 
indicating defective CFC. In contrast, 6M TgA53T/mTau-/- mice show normal memory (f). Responses 
to the Novel environment are not different between groups at both 3M (d) and 6M (e). 3M: nnTg = 8; 
nTgA53T = 7; nTgA53T/mTau-/- = 8; nmTau-/- = 9. 6M: nnTg = 13; nTgA53T = 11; nTgA53T/mTau-/- = 10; nmTau-/- = 8. One- 
and three-way ANOVA: ** p < 0.01. ns: not significant. Error bars represent mean ± S.E.M.    
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Figure 2.6 – TgA53T mice show impaired short-term spatial learning and memory in a tau-
dependent manner. a. Diagram depicting the Y maze (YM) orientation and experimental testing 
paradigm. YM testing was divided into two discrete phases: first, a Learning trial (Novel arm blocked 
off), followed by a Recognition test (all arms open, including Novel). Walls at the end of each arm 
were marked by different patterns: start with triangles, familiar with square checkerboard, and novel 
with stripes. b. Time spent in novel (N) and familiar (F) arms of the Y maze during the 300-second-
long recognition trial. Unpaired t test with Welch’s correction was used compare time animals spent 
in N versus F arms during recognition trial within genotype. nTg: t = 5.967, df = 22, p < 0.0001; 
TgA53T: t = 0.9192, df = 20.40, p = 0.3687; TgA53T/mTau-/-: t = 3.425, df = 18.34, p = 0.0030; mTau-
/-: t = 4.291, df = 11, p = 0.0011. c. Left panel: average speed (meters/second) of mice during the 
recognition trial: F(3,39) = 2.609, p = 0.0652, one-way ANOVA with Tukey’s posthoc analysis. Right 
panel: total distance traveled (meters) by animals during the recognition trial. F(3,39) = 2.632, p = 
0.0635, one-way ANOVA with Tukey’s posthoc analysis. 6M: nnTg = 13; nTgA53T = 11; nTgA53T/mTau-/-= 10; 
nmTau-/- = 8. d. Top row: heat maps demonstrating time all animals tested spent occupying areas of the 
YM during the recognition trial. Bottom row: individual trace of representative animal for each group 
tested during the recognition trial. Orientation of YM is preserved from diagram in a. Taken together, 
this experiment demonstrates that TgA53T mice present with tau-dependent deficits in spatial learning 
and memory via YM prior to developing deficits that can be detected via Barnes Maze. t test and one-
way ANOVA: ** p < 0.01 and **** p < 0.0001. ns: not significant. Error bars represent mean ± S.E.M. 
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Figure 2.7 – Locomotor hyperactivity in the TgA53T model is tau-independent. a. Distance 
traveled (meters), binned into 5-minute intervals, for the entire 60-minute activity trial. b. Summary 
graph of total distance traveled during the entire 60-minute trial. TgA53T and TgA53T/mTau-/- mice 
exhibit increases activity compared to controls (nTg and mTau-/-). 3 months (3M): F(3,21) = 13.81 (p < 
0.0001), one-way ANOVA with Tukey’s posthoc analysis. 6 months (6M): F(3,40) = 11.47 (p < 0.0001), 
one-way ANOVA with Tukey’s posthoc analysis. 12 months (12M): F(3,47) = 19.28 (p < 0.0001), one-
way ANOVA with Tukey’s posthoc analysis. 3M: nnTg = 9; nTgA53T = 6; nTgA53T/mTau-/- = 6; nmTau-/- = 5. 6M: 
nnTg = 11; nTgA53T = 12; nTgA53T/mTau-/- = 11; nmTau-/- = 9. 12M: nnTg = 13; nTgA53T = 9; nTgA53T/mTau-/- = 11; 
nmTau-/- = 8. One-way ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Error bars 
represent mean ± S.E.M.    
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Figure 2.8 – Tau is required for progressive loss of AMPAR-mediated neurotransmission in 
TgA53T neurons. Core excitatory postsynaptic current (EPSC) synaptic parameters assed in acute 
hippocampal slices from animals at 2-3 (3 Months, 3M) and 5-6 (6 Months, 6M) months of age, 
respectively: a and d. Input-output curve. b and e. Short-term potentiation measured via paired-pulse 
facilitation. c and f. Short-term depression analyzed through synaptic fatigue. 3M: Input-output: 
genotype F(1,262) = 4.790, p = 0.0295, stimulus intensity F(10,262) = 28.19, p < 0.0001, genotype*stimulus 
intensity interaction F(10,262) = 0.1596, p = 0.9985; Paired-pulse: genotype F(1,176) = 7.422,  p = 0.0071; 
inter-stimulus interval F(7,176) = 15.34,  p < 0.0001; genotype*inter-stimulus interval interaction F(7,176) 
= 0.1785,  p = 0.9894; Synaptic fatigue: genotype F(1,360) = 14.26, p = 0.0002, EPSC in train F(14,360) = 
4.611, p < 0.0001, genotype*EPSC in train interaction F(14,360) = 0.2468, p = 0.9978; all two-way 
ANOVA with Sidak’s posthoc analysis. 6M: Input-output: genotype F(3,407) = 0.7457, p = 0.5253, 
stimulus intensity F(10,407) = 13.90, p < 0.0001, genotype*stimulus intensity interaction F(30,407) = 
0.05744, p > 0.9999; Paired-pulse: genotype F(3,318) = 0.8501, p = 0.4674, inter-stimulus interval F(7,318) 
= 51.83, p < 0.0001, genotype*inter-stimulus interval interaction F(7,318) = 0.7178, p = 0.8147; Synaptic 
fatigue: genotype F(3,645) = 42.33, p < 0.0001, EPSC in train F(14,645) = 5.048, p < 0.0001, 
genotype*EPSC in train interaction F(42,645) = 0.7835, p = 0.8360; all two-way ANOVA with Tukey’s 
posthoc analysis. 3M (mice/slices/cells): nnTg = 3/7/13; nTgA53T = 3/7/13. 6M (mice/slices/cells): nnTg = 
5/10/11; nTgA53T = 5/9/11; nTgA53T/mTau-/- = 4/8/8; nmTau-/- = 4/11/11. Except for modest reductions in 
synaptic fatigue associated with the mTau-/- genotype (f), there are no obvious differences in evoked 
synaptic parameters. g. Ratio of amplitude of AMPA:NMDA currents in CA1 pyramidal neurons from 
nTg and TgA53T mice at 3M, and nTg, TgA53T, TgA53T/mTau-/-, and mTau-/- at 6M. AMPA/NMDA: 
F(3,31) = 5.044, p = 0.0058, by one-way ANOVA with Tukey’s posthoc analysis. 3M (mice/slices/cells): 
nnTg = 3/6/9 cells; nTgA53T = 3/6/9 cells. 6M (mice/slices/cells): nnTg = 7/9/10 cells; nTgA53T = 4/10/10 cells; 
nTgA53T/mTau-/- = 3/7/7 cells; nmTau-/- = 3/8/9 cells. Example AMPA and NMDA current traces from 3M (h) 
and 6M groups (i). While the AMPA/NMDA ratio is normal in 3-month-old TgA53T neurons, there is 
significant reduction in 6-month-old neurons. t test, and one- and two-way ANOVA: * p < 0.05 and *** 
p < 0.001. Error bars represent mean ± S.E.M. Contributions: AC and CN. 
  101 
 
Figure 2.9 – Spontaneous synaptic activity deficits in TgA53T neurons are reversed by loss of 
mTau expression. Spontaneous recordings of mini excitatory postsynaptic currents (mEPSCs) from 
CA1 pyramidal neurons in acute hippocampal slices were recorded from and analyzed for frequency 
(a) and amplitude (b) of mEPSCs from mice at 2-3 months (3M) and 5-6 months (6M) of age. 3M 
mEPSC frequency: t =2.32, df = 13.51, p = 0.0364, by unpaired t test with Welch’s correction. 6M 
mEPSC frequency: F(3, 31) = 6.213, p = 0.0020, by one-way ANOVA and Tukey’s posthoc analysis. 6M 
mEPSC amplitude: F(3, 31) = 4.187, p = 0.0134, by one-way ANOVA and Tukey’s posthoc analysis. c. 
Example mEPSC traces from 2-3-month-old TgA53T and nTg littermate controls. 3M 
(mice/slices/cells): nnTg = 3/7/11; nTgA53T = 3/6/10. 6M (mice/slices/cells): nnTg = 5/8/8 cells; nTgA53T = 
3/7/9 cells; nTgA53T/mTau-/- = 5/11/12 cells; nmTau-/- = 3/6/7 cells. d. Example mEPSC traces from 5-6-
month-old nTg, TgA53T, TgA53T/mTau-/-, and mTau-/- mice. The results show that reductions in 
mEPSC frequency in TgA53T neurons is not progressive from 3M to 6M, while reductions in mEPSC 
amplitude in TgA53T neurons is age-progressive over this time frame. t test and one-way ANOVA: * 
p < 0.05 and ** p < 0.01. Error bars represent mean ± S.E.M. Contributions: AC and CN. 
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Figure 2.10 – Tau is required for synaptic deficits in cultured TgA53T neurons. Average mini 
excitatory post-synaptic current (mEPSC) frequency (a) and amplitude (b) from in vitro recordings 
utilizing mouse primary hippocampal neuronal cultures. Each point represents average mEPSC 
frequency or amplitude from recording of a single neuron, with neurons coming from multiple litters 
(cultures). mEPSC frequency: F(3,50) = 3.872, p = 0.0144, by one-way ANOVA and Tukey’s posthoc 
analysis. mEPSC amplitude: F(3,46) = 4.551, p = 0.0071, by one-way ANOVA and Tukey’s posthoc 
analysis. c. Relative cumulative distribution frequency (CDF) of whole-cell mEPSC inter-burst interval 
(frequency, left panel) and amplitudes (right panel) from recordings of cultured neurons. mEPSC inter-
burst interval CDF: Kolmogorov-Smirnov test, D = 0.4681, p < 0.0001. mEPSC amplitude CDF: 
Kolmogorov-Smirnov test, D = 0.6042, p < 0.0001. N = 3 cultures/genotype, nnTg = 13 cells; nTgA53T = 
12 cells; nTgA53T/mTau-/- = 15 cells; nmTau-/- = 14 cells. d and e. Representative traces of whole-cell 
mEPSCs recorded from dissociated mouse primary hippocampal neuronal cultures. mEPSC 
recordings from dissociated hippocampal neuron cultures demonstrate that both pre and postsynaptic 
deficits TgA53T neurons are tau-dependent. One-way ANOVA: * p < 0.05, **** p < 0.0001. Error bars 
represent mean ± S.E.M. Contributions: PJT.  
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Figure 2.11 – Progressive deficits in long-term potentiation in TgA53T neurons are tau-
dependent and correlate with onset of cognitive impairments. a and b. Excitatory postsynaptic 
currents (EPSC) recorded via whole cell recordings from hippocampal CA1 pyramidal neurons during 
long-term potentiation induced by high frequency stimulation (HFS) of Schaffer collaterals of animals 
at 2-3 months (3M) (a) and 5-6 months (6M) of age (b). Arrowhead indicates application of HFS. c. 
EPSC amplitudes 45 minutes following HFS (Post), relative to baseline established prior to HFS (Pre), 
from both 3M and 6M animals. 6M LTP EPSC: F(3,22) = 2.584, p = 0.0262, by one-way ANOVA and 
Tukey’s posthoc analysis. 3M (mice/slices/cells): nnTg = 4/9/9 cells; nTgA53T = 4/7/7 cells. 6M 
(mice/slices/cells): nnTg = 5/6/6 cells; nTgA53T = 5/6/6 cells; nTgA53T/mTau-/- = 3/7/7 cells; nmTau-/- = 3/7/7 
cells. These results show that TgA53T neurons exhibit normal LTP at 3M but severe LTP deficits at 
6M. Further, TgA53T/mTau-/- neurons exhibit normal LTP at 6M. d and e. Example EPSC traces from 
LTP experiments. Presented here are Pre and Post HFS in 3M neurons (d) and 6M neurons (e). t test 
and one-way ANOVA: * p < 0.05. Error bars represent mean ± S.E.M. Contributions: AC and CN.  
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Figure 2.12 – Tau-dependent synaptic and cognitive deficits in TgA53T mice are independent 
of expression or aggregate-specific changes in aS or key presynaptic proteins. a. 
Representative western blot analysis of hippocampal lysates from 12-month-old mice. b. 
Densitometry of hippocampal protein expression. For tau and total aS (full length), values were 
normalized to the average values for nTg samples within each gel. For truncated aS (aS C), human 
aS (HuSyn1), aS phosphorylated at Ser129 (pS129 aS), values were normalized to the average 
densitometric values of TgA53T samples within each gel. For western blot densitometry: one-way 
ANOVA with Tukey’s posthoc analysis. Total aS: F(3,20) = 252.4, p < 0.0001. aS C: F(3,20) = 335.9, p 
< 0.0001. HuSyn1: F(3,20) = 616.2, p < 0.0001. pS129 aS: F(3,20) = 88.70, p < 0.0001. While aS-
associated protein levels are increased in TgA53T mice, the levels are not altered in TgA53T/mTau-/- 
mice. N = 6 animals/genotype. c. Representative dot blots from non-denatured 12-month-old 
hippocampal lysates for the epitopes associated with total aS (4D6), human aS (LB509), and various 
pathological aS oligomers (Syn33, MJFR14). Dot blots for additional aS oligomers and pathological 
tau are shown in Suppl. Figure 5 (Online Resources). d. Dot blot densitometry for levels of total aS 
(4D6) and human aS (LB509), normalized to actin levels. For higher order aS species, Syn33 and 
MJFR14, densitometry values were normalized to the average densitometric values of TgA53T 
samples within each gel. For all dot blot densitometry: one-way ANOVA with Tukey’s posthoc 
analysis. 4D6: F(3,23) = 232.9, p < 0.0001. LB509: F(3,23) = 68.53, p < 0.0001. Syn33: F(3,23) = 116.4, p 
< 0.0001. MJFR14: F(3,23) = 101.1, p < 0.0001. N = 8 animals/genotype. While aS and aS oligomer 
species levels are increased in TgA53T mice, they are unchanged by tau removal in TgA53T/mTau-/- 
mice. e. Representative western blot images of presynaptic and postsynaptic proteins of interest in 
12-month-old hippocampi. f. Densitometry of hippocampal protein expression. Values were 
normalized to the average values for nTg samples within each gel. For western blot densitometry: 
one-way ANOVA with Tukey’s posthoc analysis. b-synuclein: F(3,20) = 49.86, p < 0.0001. Synapsin 
Ia+b: F(3,20) = 8.501, p = 0.0008. Synapsin IIa+b. F(3,20) = 9.482, p = 0.0004. Synapsin IIIa: F(3,20) = 
46.62, p < 0.0001. N = 6 animals/genotype. Densitometry shows that while b-synuclein and synapsin 
isoforms are decreased in TgA53T mice, they are not altered by loss of tau expression. Further, the 
levels of synaptophysin and PSD95 are comparable in all animals, indicating a lack of synaptic loss. 
For all, values were normalized to the average densitometric values of nTg samples within each gel. 
One-way ANOVA: ** p < 0.01 and **** p < 0.0001. ns: not significant. Error bars represent mean ± 
S.E.M. Contributions: MAB and SEL.  
 
 
  105 
 
Figure 2.13 – Cortical levels of aS expression, aS post-translational modifications, and 
synaptic proteins are tau-independent. a and b. Representative western blot analysis of cortical 
lysates from 12-month-old mice probing for total tau or aS (a), or key pre and postsynaptic proteins 
of interest (b). c. Densitometry of cortical protein expression. For tau and total aS, values were 
normalized to the average values for nTg samples within each gel. For truncated aS (aS C), HuSyn1 
(human aS), aS phosphorylated at Ser129 (pSer-129-aS, pS129 aS), values were normalized to the 
average densitometric values of TgA53T samples within each gel. For all densitometry: one-way 
ANOVA with Tukey’s posthoc analysis. Total aS: F(3,20) = 198.9, p < 0.0001. aS C: F(3,20) = 298.2, p 
< 0.0001. HuSyn1: F(3,20) = 1163.0, p < 0.0001. pS129 aS: F(3,20) = 91.72, p < 0.0001. d. Synapse 
densitometry, with values normalized GAPDH and compared to average of nTg samples. For western 
blot densitometry: one-way ANOVA with Tukey’s posthoc analysis. b-synuclein: F(3,20) = 41.07, p < 
0.0001. Synapsin Ia+b: F(3,20) = 9.161, p = 0.0005. Synapsin IIa+b. F(3,20) = 9.794, p = 0.0003. Synapsin 
IIIa: F(3,20) = 13.70, p < 0.0001. N = 6 animals/genotype. Densitometry shows that while b-synuclein 
and synapsin isoforms are decreased in TgA53T mice, they are not altered by loss of tau expression. 
Further, the levels of synaptophysin and PSD95 are comparable in all animals, indicating a lack of 
synaptic loss. One-way ANOVA: * p < 0.05, ** p < 0.01 and **** p < 0.0001. Error bars represent mean 
± S.E.M.    
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Figure 2.14 – Detergent-insoluble aS aggregates accumulate in symptomatic TgA53T animals 
in a tau-independent fashion. a and b. Nonionic detergent- (TritonTM X-100, TX) fractionation of 
insoluble and soluble components from 12M mice. Representative western blot images for levels and 
species of total aS, human aS (Syn101), and aS phosphorylated at serine 129 (pS129 aS) from the 
detergent-insoluble (a) and soluble fractions (b). Ponceau S staining of nitrocellulose membranes 
post-transfer demonstrates equal protein loading and consistent transfer across all lysates. The 
accumulation of nonionic detergent-insoluble aS species occurs exclusively in pathologically-affected 
brain regions of symptomatic “end-stage” (E.S.) TgA53T animals, particularly the brain stem and 
spinal cord. As a positive control, the A53T E.S. soluble and insoluble lysate fractions were prepared 
from the brain stem of an end stage TgA53T animal. Given the modest and comparable levels of 
insoluble aS in asymptomatic 12M TgA53T and TgA53T/mTau-/- animals, as well as the comparable 
levels of soluble aS levels in these groups, it suggests that soluble pathogenic species of aS are likely 
mediators of the haSA53T-driven synaptic and memory deficits. (nTgA53T-E.S. = 1, nnTg = 3, nTgA53T = 3, 
nTgA53T/mTau-/- = 3, nmTau-/- = 2).  
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Figure 2.15 –Synaptic and cognitive dysfunction in TgA53T are associated with modest but 
significant increases in pathological phosphorylated species of tau. a and b. Representative 
western blot analysis of hippocampal lysates from 6-month-old (6M) (a) 12-month-old (12M) (b) mice 
probing for disease-associated phosphorylated species of tau (AT8, CP13, and PHF1). c. 
Densitometry quantifying phosphorylated tau protein expression in the hippocampus. For 6M and 12M 
densitometry, expression of these pathological species of tau was normalized to total tau (Tau5) levels 
within each hippocampi, and then analyzed by unpaired t test with Welch’s correction between nTg 
and TgA53T lysate values. AT86M: t = 2.656, df = 9.115, p = 0.260. CP136M: t = 2.286, df = 9.050, p = 
0.0479. PHF16M: t = 2.340, df = 9.659, p = 0.0422. 6M: nnTg = 6; nTgAA53T = 6. AT812M: t = 0.4183, df = 
6.199, p = 0.06899. CP1312M: t = 0.9803, df = 7.750, p = 0.3566. PHF112M: t = 23.353, df = 7.844, p = 
0.0103. 12M: nnTg = 5; nTgAA53T = 5; nTgA53T/mTau-/- = 1; nmTau-/- = 1. t test: * p < 0.05. ns: not significant. 
Error bars represent mean ± standard error of the mean (S.E.M). 
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Figure 2.16 – Synaptic and cognitive deficits in TgA53T mice are independent of expression 
or oligomeric-specific changes in aS or tau. a. Representative dot blots of species of aS and tau 
in non-denatured cortical and hippocampal lysates from 12-month-old mice (12M). The antibodies 
used here recognize epitopes associated with total aS (4D6), human aS (LB509), various pathological 
aS oligomers (F8H7, FILA1, Syn33, MJFR14), total tau (Tau5), pathological tau oligomers (T22), pan 
soluble oligomers (A11), and amyloid fibrils (OC). Antibody details can be found in Suppl. Table 1 
(Online Resources). b. Densitometry of cortical protein expression normalized to the average 
densitometric values of nTg samples within each age. Only epitopes showing significant signal or 
increases in TgA53T mice were analyzed. For dot blot densitometry: one-way ANOVA with Tukey’s 
posthoc analysis. 4D6: F(3,27) = 191.0, p < 0.0001. LB509: F(3,27) = 59.12, p < 0.0001. Syn33: F(3,27) = 
86.28, p < 0.0001. MJFR14: F(3,27) = 84.98, p < 0.0001. c. Densitometry quantifying higher order 
synuclein species expression (Syn33 and MJFR14), normalized to the average total aS (4D6) within 
genotype. For dot blot densitometry: one-way ANOVA with Tukey’s posthoc analysis: Syn33/4D6: 
F(3,27) = 246.4, p < 0.0001. MJFR14/4D6: F(3,27) = 101.1, p < 0.0001. N = 8 animals/genotype. Western 
blotting and densitometry demonstrates that synaptic and memory abnormalities in TgA53T mice are 
not due to changes in insolubility of aS or protein expression of aS but may occur downstream or 
independent of pathological aS species, in a tau-dependent manner. One-way ANOVA: **** p < 
0.0001. Error bars represent mean ± S.E.M. Contributions: MAS and SEL. 
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Figure 2.17 – Neither synapse nor neuronal loss are required for synaptic dysfunction and 
memory deficits in TgA53T mice. a and b. Confocal images of immunohistochemical staining on 
12-month-old hippocampi from nTg, TgA53T, TgA53T/mTau-/-, and mTau-/- mice. Hippocampi stained 
for the neuronal nuclei marker NeuN (a). Scale bar: 500 µm. CA1 region of the hippocampus stained 
for somatodendritic (MAP2), presynaptic (synaptophysin), and postsynaptic (PSD95) structures (b). 
Scale bar: 50 µm. Qualitatively, the lack of changes in gross hippocampal structure as well as synapse 
integrity when comparing nTg and TgA53T mice at 12 months of age indicates that synaptic 
dysfunction, rather than loss, is responsible for haSA53T-mediated cognitive decline. Contributions: 
EO.  
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Figure 2.18 – Progressive loss of AMPA receptor subunits in the TgA53T is tau-dependent. 
Representative western blot images of hippocampal lysates of AMPA (GluA) and NMDA (GluN) 
receptor subunits at 3 (a), 6 (b), and 12 (c) months of age (3M, 6M, and 12M, respectively). d-g. 
Densitometry of immunoblots for AMPA and NMDA receptor subunits at 3M, 6M, and 12M. For all, 
values were normalized to the average densitometric values of nTg samples within each gel. For 3M 
and 6M: unpaired t test with Welch’s correction. For 12M densitometry: one-way ANOVA with Tukey’s 
posthoc analysis. 12M GluN1: F(3,20) = 7.004, p = 0.0021. 6M GluA1: t = 3.773, df = 9.679, p = 0.0039. 
12M GluA1: F(3,20) = 11.55, p = 0.0001. 6M GluA2/3: t = 3.801, df = 6.180, p = 0.0085. 12M GluA2/3: 
F(3,20) = 16.21, p < 0.0001. N = 6 animals/age/genotype. Compared to nTg mice, the NMDA receptor 
subunits are not decreased in TgA53T mice at all ages tested (d and e). However, AMPA receptor 
subunits are significantly decreased starting at 6M in TgA53T mice compared to nTg (f and g). 
Significantly, the loss of AMPA receptor subunits are reversed in TgA53T/mTau-/- animals (f and g). t 
test and one-way ANOVA: * p < 0.05, ** p < 0.01, and *** p < 0.001. Error bars represent mean ± 
S.E.M.  
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Figure 2.19 – Tau-dependent biochemical changes in postsynaptic glutamatergic (AMPA and 
NMDA) receptors are region-specific. a. Representative western blot images for AMPAR (GluA) 
and NMDAR (GluN) subunits of cortical lysates from 12-month-old animals. b. Densitometry 
quantifying protein expression in isolated cortices. For all, values were normalized to the average 
densitometric values of nTg samples within each gel. For all densitometry: one-way ANOVA with 
Tukey’s posthoc analysis. GluN1: F(3,20) = 11.49, p < 0.0001. N = 6 animals/genotype. Compared to 
nTg mice cortices, cortical AMPA and NMDA receptor expression is not decreased in TgA53T mice 
at 12 months of age, when TgA53T mice have established synaptic deficits, evidence of network 
abnormalities, and memory loss. One-way ANOVA: * p < 0.05, ** p < 0.01, and *** p < 0.001. Error 
bars represent mean ± S.E.M.    
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Figure 2.20 – Tau-dependent synaptic dysfunction in TgA53T neurons is not associated with 
increases in PrPC expression and signaling. a. Graphical depiction of cellular prion protein (PrPC) 
primary structure and antibody binding regions. b and c. Representative western blot images of 
hippocampal (b) and cortical (c) lysates for PrPC expression at 3, 6 and 12 months of age (3M, 6M, 
and 12M, respectively). d and e. Densitometry of protein expression in hippocampal (HIP) (d) and 
cortical (CTX) (e) lysates, normalized to the average densitometric values of nTg samples within each 
gel. For 3M and 6M densitometry, unpaired t test with Welch’s correction. For 12M densitometry: one-
way ANOVA with Tukey’s posthoc analysis. 12M HIP 6D11: F(3,20) = 3.193, p = 0.0458. 12M HIP 8B4: 
F(3,20) = 3.685, p = 0.0292. N = 6 animals/age/genotype. These results demonstrate that activation of 
PrPC signaling is not required for the age-dependent synaptic and memory deficits in TgA5T mice. t 
test and one-way ANOVA: * p < 0.05. Error bars represent mean ± S.E.M.    
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Figure 2.21 – Tau-mediated, mutant aS-induced synaptic and cognitive deficits are 
independent of postsynaptic Fyn and GluN2B activation. a and b. Western blot images for 
activation status of both Fyn (via pTyr416 Src) (a) and NMDA receptor subunit GluN2B (via pTyr1472 
GluN2B) (c) 3 (left) and 6 (right) months of age (3M and 6M, respectively) through analysis of total 
and active phosphorylated states. b and d. Densitometry quantifying 3M and 6M cortical lysates, 
normalized to the average densitometric values of nTg samples within each gel. Activation status was 
determined through examining ratio of values of activating phosphorylation site: pTyr416 for Fyn (b) 
and pTyr1472 for GluN2B (d), normalized to respective total levels of protein. For 3M and 6M 
densitometry, unpaired t test with Welch’s correction. 3M pTyr-Src/Fyn: t = 1.761, df = 8, p = 0.1163. 
N = 5 animals/age/genotype. 3M pTyr-GluN2B/GluN2B: t = 2.539, df = 8.066, p = 0.0345. N = 6 
animals/age/genotype. These findings build on Suppl. Figure 9, further showing that TgA53T mice do 
not display increased activation of the PrPC-Fyn-GluN2B signaling cascade as compared to age-
matched nTg littermates. Together, these results suggest that haSA53T-driven and impairments 
requiring tau are mediated independent of this pathway. t test: * p < 0.05. ns: not significant. Error 
bars represent mean ± S.E.M. Contributions: MAS and SEL. 
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Figure 2.22 – Progressive alterations in inhibitory circuits in the dentate gyrus of TgA53T mice 
is tau dependent and correlate with the onset of synaptic and memory deficits. a. 
Representative images from dentate gyri and hippocampi of 12-month-old (12M) nTg, TgA53T, 
TgA53T/mTau-/-, and mTau-/- mice. Representative images and quantification for 3-month-old (3M) 
and 6-month-old (6M) are shown in Figure 2.23. c-Fos scale bar: 300 µm. NPY and calbindin scale 
bar: 250 µm. b-d. Quantification of immunoreactivity (IR) via cell counting (b: c-Fos) or densitometry 
(c: NPY in the Molecular Layer “Molecular”; NPY in the Mossy Fiber pathway, “Mossy”; and, d: 
calbindin) at 3M, 6M, and 12M. 6M: c-Fos: U = 7, p = 0.0844; NPY-Molecular: U = 10, p = 0.2403; 
NPY- Mossy: U = 11, p = 0.3905; Calbindin: U = 6, p = 0.0649. 12M: c-Fos: F(3,16)= 14.88, p < 0.0001; 
NPY-Molecular: F(3,16) = 15.97, p < 0.0001; NPY-Mossy: F(3,16) = 19.77, p < 0.0001; Calbindin: F(3,16) = 
19.03, p < 0.0001. 3M analysis: unpaired t test with Welch’s correction. 6M analysis: Mann-Whitney t 
test. 12M analysis: one-way ANOVA with Tukey’s posthoc analysis. N = 6 animals/age/genotype, n = 
8 sections/animal. In 3M TgA53T mice, the levels of synaptic activity markers are comparable to nTg 
mice. In 6M TgA53T mice, two distinct populations of mice exist: TgA53T and TgA53TINT (analyzed in 
Suppl. Figure 11, Online Resources). All 12M TgA53T mice exhibit aberrant network remodeling 
which was reversed in TgA53T/mTau-/- mice. t test and one-way ANOVA: * p < 0.05, ** p < 0.01, *** 
p < 0.001, and **** p < 0.0001. ns: not significant. IR: immunoreactivity. ML: molecular layer. MF: 
mossy fiber. Error bars represent mean ± S.E.M. Contributions: EO and JM. 
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Figure 2.23 – Activity-dependent remodeling of hippocampal circuits is not observed in 
younger TgA53T mice with intact cognition and appears to follow glutamatergic signaling 
deficits. a and b. Representative confocal images from dentate gyri and hippocampi of 3-month-old 
(3M, a) and 6-month-old (6M, b) nTg and TgA53T mice stained for c-Fos, NPY, and calbindin. 3M 
and 6M c-Fos, NPY, and calbindin quantification values are reported in Fig 9c-e. c-Fos scale bar: 300 
µm. NPY and calbindin scale bar: 250 µm.  c-e. Quantification of immunoreactivity (IR) via cell 
counting (c: c-Fos) or densitometry (d: NPY in the Molecular Layer “Molecular”; NPY in the Mossy 
Fiber pathway, “Mossy”; and, e: calbindin) at 6M. 6M TgA53T animals were classified into two groups 
as some TgA53T mice displayed activity-related changes in c-Fos, calbindin, and NPY while others, 
the TgA53TINT (for “Intermediate”) resembled their age-matched nTg littermate controls. c-Fos: F(2,9)= 
22.16, p = 0.0003; NPY-Molecular: F(2,9) = 10.60, p = 0.0043; NPY-Mossy: F(2,9) = 20.74, p = 0.0004; 
Calbindin: F(2,9) = 4.174, p = 0.0522. All by one-way ANOVA with Tukey’s posthoc analysis. nnTg = 6; 
nTgA53T = 3; nTgA53T-INT = 3. f-h. Three-dimensional (3D) X-Y-Z scatterplot of c-Fos, NPY (Mossy Fiber, 
“NPY-Mossy”), and calbindin immunostaining at 3 (f), 6 (g), and 12 (h) months (3M, 6M, and 12M, 
respectively). 3M TgA53T mice do not display evidence of network remodeling. The two distinct 
TgA53T populations present at 6M are clearly observed: one TgA53T group displayed activity-related 
changes in c-Fos, calbindin, and NPY while others, the TgA53TINT (for “Intermediate”) more closely 
resembled their age-matched nTg littermate controls. By 12M, all aged TgA53T mice demonstrate 
signs of chronic hippocampal network hyperactivity. One-way ANOVA: * p < 0.05, ** p < 0.01, and *** 
p < 0.001. ns: not significant. Error bars represent mean ± S.E.M. Contributions: EO and JM. 
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Figure 2.24 – haSA53T-mediated progressive neurological motor deficits and premature lethality 
are partly tau-dependent. a. Model for contributions of amyloid, fibrillar species of a-synuclein (aS) 
to Parkinson’s disease (PD) pathology and pathogenesis. Under physiological conditions, aS exists 
as a soluble monomeric protein. However, in pathological states, like PD or dementia with Lewy 
bodies (DLB), aS can misfold and aggregate into higher order species, which likely represent the 
pathological drivers of PD dementia or DLB. b. Left: Monitoring the production and formation of 
amyloid, fibrillar aS species in vitro from monomeric aS via thioflavin T fluorescence (pre-formed 
fibrils, PFFs). Right: sedimentation assay of aS fibrils. Prepared aS fibrils resolved via SDS-PAGE 
and stained with Coomassie Brilliant Blue, confirming aS in both the supernatant and pellet. c. 
Overview of experimental design for determining the role of tau in aS PFF-mediated disease onset 
and end stage (lethality) following bilateral injection of aS PFFs or saline into biceps femoris muscle 
of mice. d. Kaplan-Meier curve demonstrating PFF-induced onset of disease (symptomatic). Log-rank 
(Mantel-Cox) test: 𝑥#= 9.382, df = 1, p = 0.0022. e. Kaplan-Meier curve demonstrating PFF-induced 
end stage (lethality). Log-rank (Mantel-Cox) test: 𝑥# = 6.288, df = 1, p = 0.0122. f. Graph depicting 
the progression of disease, as defined by the days following symptomatic disease onset to reaching 
pre-defined end stage (E.S.) point. Age refers to days post PFF-injection. Age of onset and age of 
reaching E.S. of an individual mouse are connected via line. g. Quantifying disease progression (days 
between disease onset and E.S.). Mann-Whitney t test: U = 21.50, p = 0.1025. nTgA53T = 8, nTgA53T/mTau-
/- = 10. Log-rank and t test: * p < 0.05, ** p < 0.01. ns: not significant. Error bars represent mean ± 
S.E.M. Contributions: HMM.  
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Figure 2.25 – Proposed model for aS-mediated, tau-dependent synaptic and cognitive deficits 
in haSA53T mice.  Neurons from cognitively-intact nTg control mice display intact AMPA receptor 
(AMPAR) expression and function, and thus display intact synaptic transmission. The presence of 
pathological species of aS, such as haSA53T in TgA53T mice leads to progressive postsynaptic 
synaptic deficits that underlie memory deficits in this model, and potentially PDD or DLB patients, 
without overt structural alterations at the synaptic or neuronal level. Pathogenic aS (haSA53T) 
expression or accumulation (1) leads to tau phosphorylation and mislocalization to dendritic spines 
(2), producing physiological deficits in AMPAR -mediated signaling and synaptic plasticity, likely 
through reductions in AMPAR expression (3). These haSA53T-mediated AMPAR deficits culminate in 
reduced glutamatergic signaling, particularly at hippocampal pyramidal neuron synapses. The 
AMPAR deficits lead to more global, circuit-level abnormalities in the brains of TgA53T mice. For 
example, it is possible that haSA53T-mediated, tau-dependent synaptic depression may also affect 
inhibitory interneurons, leading to homeostatic imbalance between inhibitory and excitatory 
neurotransmission and aberrant excitatory activity. These epileptiform changes can then lead to 
homeostatic responses in hippocampal circuits that attempt to suppress this hyperactivity, 
representing a potential mechanism underlying the hippocampal remodeling observed in the brains 
of TgA53T mice. However, future studies are warranted to better elucidate the biochemical, 
physiological, and structural mechanisms connecting haSA53T-mediated synaptic dysfunction and 
aberrant network changes. Ultimately, we hypothesize that haSA53T-driven, tau-mediated 
abnormalities at the individual synapse lead to network-level perturbations that together contribute to 
and exacerbate memory deficits in TgA53T mice. PDD: Parkinson’s disease dementia. DLB: dementia 
with Lewy bodies. Pre: presynaptic neuron. Post: postsynaptic neuron. A: AMPAR. a: haSA53T. 
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Chapter 3: Pathogenic, fibrillar a-synuclein induces dose-dependent synaptic 
degeneration and dysfunction 
 
 
Introduction 
 
 The deposition of proteinaceous aggregates in select cell populations is a pathological 
hallmark shared by many age-related neurodegenerative diseases (Jucker and Walker, 
2013). The clinical progression of PD correlates with the appearance of aS inclusions as 
they spread largely in a stereotypical manner temporally and anatomically throughout the 
nervous system (Braak and Del Tredici, 2008; Braak et al., 2003), affecting key midbrain 
and brainstem such as the striatum and substantia nigra, but also other cortical and 
glutamatergic areas that may precipitate cognitive decline (Kordower et al., 2013; Sulzer 
and Surmeier, 2013). Importantly, LBs and LNs in the cortex and hippocampus predict 
memory deficits in Parkinson’s disease (Parkinson’s disease dementia, PDD) and DLB 
(Hall et al., 2014; Halliday et al., 2014; Irwin et al., 2012), furthering the relationship 
between aS abnormalities and a-synucleinopathy disease processes. 
 Cognitive impairment is a defining symptom of DLB and upwards of 80% of PD 
patients develop PDD (Irwin et al., 2013). However, the mechanisms driving aS 
accumulation into LBs and LNs and how other pathological species of aS contribute to the 
neuronal abnormalities underlying cognitive dysfunction in PDD and DLB remains 
unknown. In PDD and DLB, the majority of hippocampal Lewy pathology is observed in 
cell bodies of neurons in the entorhinal cortex and within projections originating from CA2 
pyramidal neurons (Adamowicz et al., 2017). However, cognitive dysfunction is best 
predicted by aS pathology burden in CA1 pyramidal neurons, the output target of CA2 
(Adamowicz et al., 2017). From these pathological observations, it can therefore be 
hypothesized that pathological aS species associating the LNs of CA2 may be released 
and act trans-synaptically on CA1 postsynaptic sites and cell bodies to mediate synaptic 
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and cognitive dysfunction. Deficits in synaptic function and hippocampal activity have been 
observed in neurons acutely exposed to fibrillar species of aS comprised of recombinant 
haSST (aS pre-formed fibrils, PFFs) prior to the onset of inclusion formation (Froula et al., 
2018; Luna et al., 2018; Volpicelli-Daley et al., 2011; Wu et al., 2019). Acute application 
of soluble oligomeric species of aS has been shown to also disrupt synaptic plasticity 
independent of inclusion formation (Diogenes et al., 2012; Ferreira et al., 2015, 2017), 
supporting this hypothesis and the concept that aS species in PDD and DLB do not need 
to form Lewy-like inclusions to be neurotoxic.  
 However, the precise mechanisms mediating these abnormalities remain unknown. 
As such, there is a need to better define the impact of pathological aS species on neuronal 
dysfunction prior to the development of overt neuropathology, and the specific pathways 
involved in order to improve therapies for memory deficits in the a-synucleinopathies. 
Thus, we asked whether aS PFFs adversely impact synaptic structure and function. In 
further detail, building upon our recent work that demonstrating that aS-mediated, tau-
dependent postsynaptic deficits are critical for memory loss (Teravskis et al., 2018), we 
propose that memory deficits in both familial and sporadic forms of PDD and DLB may be 
a product of presynaptic release of toxic aS species, such as those in LNs, to induce 
postsynaptic abnormalities in a tau-dependent manner. 
 Upon testing this hypothesis, we show that aS PFFs are capable of inducing tau 
missorting to postsynaptic structures at a range of aS PFF concentrations in primary 
hippocampal neurons, leading to deficits in synaptic plasticity. aS PFFs also cause 
concentration-dependent synaptic loss that is dependent on endogenous aS but not tau, 
suggesting that different aS PFF-mediated neuronal deficits can occur through distinct 
mechanisms. 
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Materials and methods 
 
 All animal uses were in accordance with the NIH guidelines for the use of animals in 
research and approved by the Institutional Animal Care and Use Committee at the 
University of Minnesota. Experimental group sizes (n) are reported in each figure.  
 
Dissociated neuronal culture electrophysiology  
 
 Dissociated neuronal cultures were established from harvested from either Sprague 
Dawley rats (Charles River; Wilmington, MA) or mouse hippocampi postnatal day 0 or 1 
(P0-P1) as previously described (Teravskis et al., 2018) with modifications. Briefly, mouse 
hippocampi were dissected out and stored individually by pup in Hibernate A media (Brain 
Bits; Springfield, IL) at 4°C. After dissection, hippocampi were dissociated, and plated on 
onto 35 mm µ-dishes containing a poly-D-lysine- (Sigma-Aldrich; St. Louis, MO) and 
laminin-coated (Sigma-Aldrich) polymer coverslip (Ibidi; Fitchburg, WI). 24 hours (hrs) 
after initial plating, media was removed and NbActiv4 growth media was added (Brain 
Bits). NbActiv4 media was refreshed every 3-4 days by removing 1 mL media in the dishes 
and adding 1 mL fresh media. For all procedures and media exchanges, solutions were 
equilibrated in a tissue culture incubator (37°C, 5% CO2) for at least 2 hrs prior to use. The 
age of in vitro dissociated cultured hippocampal neurons began with the day of initial 
plating, and each day that followed was counted as one day in vitro (DIV). All experiments 
were performed on neurons from at least 3 independent cultures with a minimum of 5 
animals per culture. Miniature excitatory postsynaptic currents (mEPSC) were recorded 
from cultured dissociated mouse hippocampal neurons at 21–25 DIV with a glass pipette 
(resistance of ~5 MΩ) as previously described (Teravskis et al., 2018). Recordings ranged 
from 3-15 minutes (min) and stable traces longer than 1 min in duration were analyzed. 
All mEPSCs >2 pA were manually counted with MiniAnalysis (Synaptosoft Inc; Fort Lee, 
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NJ). Each mEPSC event was visually inspected and only events with a distinctly fast-rising 
phase and a slow-decaying phase were accepted. Relative cumulative frequencies were 
derived from individual events and the averaged parameters from each neuron were 
treated as single samples in any further statistical analyses.  
 
In vitro neuronal imaging and analysis 
 
 At 6-8 DIV, primary hippocampal neurons plated on 35 mm dishes underwent calcium-
phosphate transfection (Jiang and Chen, 2006) with modifications. Neurons were 
incubated with the DNA-calcium-phosphate precipitate solution for 3 hrs in a standard 
tissue culture incubator (37°C, 5% CO2). After this incubation period, media containing the 
transfection precipitate was removed and replaced with fresh, equilibrated NbActiv4 
media. After transfection, NbActiv4 media was refreshed every 3-4 days by removing 1 
mL media in the dishes and adding 1 mL fresh media until beginning experiments at 21 
DIV, a time at which neurons consistently express high numbers of mature dendritic spines 
in vitro (Hoover et al., 2010).  
 For live cell imaging, 35 mm cell culture dishes were fitted a custom holding chamber 
on a fixed platform above an inverted Nikon Eclipse TE300 microscope (Nikon; Melville, 
NY) placed on an X-Y translation stage (Burleigh; Thorlabs Inc, Newton, NJ). Images were 
subsequently acquired at 60x magnification in a Z-stack comprised of 15 images at 0.5 
µm intervals. Images were both acquired and analyzed using MetaMorph 7.1.0 (Molecular 
Devices; San Jose, CA). Live image stacks were then processed via 2D deconvolution 
and averaged into a single, stacked image. Dendritic spines were characterized as 
protrusions with a head width more than 50% the width of the neck. Spines were manually 
counted and then normalized to dendritic length within and between neurons. Imaging and 
electrophysiological experiments were performed from at least 2 independent cultures. 
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Immunohistochemical analyses 
 
 For immunohistochemical studies, neurons were plated on poly-D-lysine- (Sigma-
Aldrich) and laminin-coated (Sigma-Aldrich) glass coverslips in 6-well plates. After aS PFF 
treatment, neurons were fixed with 4% paraformaldehyde (PFA). Prior to staining neurons 
were washed in TBS, permeabilized with 0.1% Triton X-100 in tris-buffered saline (TBS) 
and blocked in 50% Background Sniper solution in TBS (Biocare Medical; Pacheco, CA). 
Primary and secondary antibodies were diluted to target concentrations in 5% Background 
Sniper in TBS with 0.1% Tween 20 (TBSTw). Primary antibody incubation was conducted 
overnight at 4°C and secondary antibody incubation was for 1 hr at room temperature in 
the dark. Alexa Fluor Plus (Thermo Fisher Scientific) secondary antibodies were used as 
dictated by primary antibody host. If required, sections were then 4′,6-diamidino-2-
phenylindole (DAPI)-counterstained (Thermo Fisher Scientific; Waltham, MA). All 
coverslips were then mounted on slides with ProLong Gold antifade mounting reagent 
(Thermo Fisher Scientific) for future imaging. Confocal microscopy images were acquired 
with the Nikon C2 Confocal Microscope System (Nikon; Melville, NY). Imaging processing 
and analysis were performed using NIS-Elements software (Nikon). Staining, imaging, and 
analysis were performed in collaboration with the University of Minnesota’s University 
Imaging Centers on the Twin Cities campus. 
 
Preparation of human wild-type aS monomers and pre-formed fibrils (haSWT PFFs) 
 
 A schematic is outlined in Figure 3.1. In detail: recombinant full length human wild-
type aS monomers and pre-formed fibrils (haSWT PFFs) were generated following the 
protocol established by Volpicelli-Daley et al., 2014. aS monomers destined for 
experiments were aliquoted and stored at -80°C at 5 mg/mL. In preparation for use, 
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monomers were thawed on ice, diluted to a working concentration of 0.25 mg/mL (250 
μg/mL) in phosphate-buffered saline (PBS), and then spun down for 20 mins at 100,000 
g (30 PSI) via Beckman Airfugeâ CLS air-driven ultracentrifuge (Beckman Coulter; 
Indianapolis, IN) to pellet any aggregates that may have formed. The resulting supernatant 
from this spin was then used for downstream experiments as monomeric aS.  
 aS PFFs were generated by first incubating purified recombinant monomeric aS at 5 
mg/mL in PBS at 37°C with continuous shaking for 7 days via ThermoMixer (Eppendorf; 
Hamburg, Germany). During this shaking process, the presence of amyloid aS fibrils 
production was assessed and confirmed using Thioflavin T fluorometry. Following shaking 
and saturation of Thioflavin T fluorescence levels, aS PFFs were subsequently aliquoted 
and stored at -80°C. The generation of aS PFFs and their seeding capacity were 
confirmed through sedimentation assay, subjecting an aliquot of aS PFFs to 
ultracentrifugation, and assessing the amount of aS in pellet and supernatant via SDS-
PAGE (BioRad) and Coomassie Brilliant Blue (Thermo Fisher Scientific) staining. For 
peripheral injections into mice, 5 mg/mL aS PFF aliquots in PBS were taken from -80°C, 
thawed at room temperature, and diluted to a working concentration of 0.25 mg/mL (250 
μg/mL) in PBS. aS PFFs at this concentration were then sonicated utilizing a Fisher 
Scientific Branson micro probe tip sonicator (Fischer Scientific; Hampton, NH) with 60 
pulses at 20% power for a total of 120 sec, 1 sec “on”, 1 sec “off”. Following sonication, 
PFFs were ready for further dilution and application to cells.  
 
Plasmid constructs 
 
 Both eGFP-tau and DsRed plasmids were expressed in the pRK5 vector and driven 
by the cytomegalovirus (CMV) promoter. The eGFP-tau construct (#46904, Addgene; 
Watertown, MA) expresses wild-type human four-repeat tau lacking the N-terminal repeat 
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domain (4R0N) and contained exons 1, 4, 5, 7, 9-14, and intron 13. The DsRed plasmid 
(Clonetech; Mountain View, CA) was cloned into the pRK5 construct.  
 
Antibodies 
 A detailed list of all antibodies used for experiments and studies here can be found in 
Table 2.1. 
 
Experimental design and statistical analyses 
 
 All statistical analyses were performed in Prism 8.1.0 (GraphPad Software; San Diego, 
CA). Data visualization and presentation were performed via Prism (GraphPad). For 
parametric data: one- and two-way ANOVAs were utilized for one and two variable 
analysis on multiple groups, respectively; t tests were also performed when analyzing only 
two groups. For nonparametric data: Kruskal-Wallis one-way ANOVA for three or more 
groups; Mann-Whitney test for two groups. Posthoc analyses were performed on all data 
that were significantly different. Welch’s correction, Sidak’s posthoc, and Tukey’s posthoc 
analyses were used due to considerations for within-group variances and sample size. 
For all, statistical significance was set for a = 0.05. Data representations are described in 
figure legends. 
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Results 
 
aS pre-formed fibrils contribute to synaptic dysfunction and synapse loss in a dose-
dependent manner  
 
 We first hypothesized that 1) aS PFF-mediated synaptic abnormalities are drivers of 
memory deficits in PDD and DLB, and 2) may occur through tau missorting to dendritic 
spines, a phenomenon associated with postsynaptic dysfunction and cognitive decline in 
models of AD (Hoover et al., 2010; Miller et al., 2014). To these initial hypotheses, 
postnatal rat primary hippocampal neurons cultures were established, co-transfected with 
DsRed to visualize neuronal structures and eGFP-tagged WT human tau (eGFP-tau) 
plasmids, and aged to 21 days in vitro (DIV), at which mature spines are present. At 21 
DIV, neurons were treated with aS monomers or PFFs and imaged 24 hours (hrs) post-
treatment (Figure 3.2a). While neither saline nor monomeric aS species contributed to 
the mislocalization of tau, acute exposure of primary hippocampal neurons to aS FFs at 
both low (0.10 µg/mL) and high (4.00 µg/mL) concentrations was sufficient to induce tau 
missorting to dendritic spines (Figure 3.2a-b). However, aS PFF treatment at high doses 
(4.00 µg/mL) also produced a loss of spines at this 24 hrs time point, as indicated by a 
reduced spine density (spine/pixel) count along dendrites (Figure 3.2a and c). Notably, 
this aS PFF-induced spine collapse was absent in neurons exposed to lower aS PFF 
concentrations (0.10 µg/mL), indicating a divergence between tau missorting to dendritic 
spines and loss of dendritic spines  
 To further investigate the concentration-dependent synaptotoxic effects of aS PFFs, 
primary hippocampal neurons were fixed 24 hrs post-aS PFF treatment and subsequently 
stained for pre and postsynaptic markers, Synapsin 1/2 and PSD95, respectively. 
Although aS PFFs at 4.00 µg/mL begin to induce neuron death beginning around 14 days 
post-treatment in culture (Volpicelli-Daley et al., 2014), qualitative analysis via confocal 
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microscopy suggest a reduction in colocalization of Synapsin 1/2 and PSD95, which may 
be indicative of synapse loss (Figure 3.3). As such, synaptic degeneration may represent 
early, acute responses to aS PFFs that precede overt neuropathology and 
neurodegeneration. Along these lines, both oligomeric and fibrillar forms of aS have been 
demonstrated to induce neuronal loss both in vitro and in vivo, suggesting that, with time, 
neuronal viability is compromised in the presence of pathogenic multimeric aS species 
(Luk et al., 2012a; Peelaerts et al., 2015; Volpicelli-Daley et al., 2011; Winner et al., 2011). 
 Tau missorting to dendritic spines is associated with electrophysiological deficits in 
glutamatergic a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 
(AMPAR) signaling (Hoover et al., 2010; Teravskis et al., 2018). aS PFFs have also been 
reported to induce functional neuronal deficits in vitro from a network perspective as 
suggested by calcium imaging (Volpicelli-Daley et al., 2011). We therefore next asked if 
aS PFF-induced tau mislocalization was also associated with functional deficits in vitro. At 
21 DIV, rat primary hippocampal neurons were treated with low (0.10 µg/mL) or high (4.00 
µg/mL) concentrations and analyzed 24 hrs following via whole cell patch clamp 
electrophysiology. Specifically, mini excitatory postsynaptic currents (mEPSC) were 
recorded and analyzed for frequency and amplitude (Figure 3.4). Acute exposure to aS 
PFFs at both high and low concentrations were sufficient to reduce mEPSC frequency, a 
metric of excitatory presynaptic vesicle release (Figure 3.4a and c-d). mEPSC amplitude, 
a measure of postsynaptic AMPAR presence and function, was also significantly 
depressed in neuron treated with aS PFFs (Figure 3.4b-d), suggesting that aS PFF-
induced postsynaptic AMPAR dysfunction may indeed be a consequence of tau missorting 
to dendritic spines. Taken together, these electrophysiological findings suggest that aS 
PFFs are capable of altering synaptic function and structure, reflected in the depressed 
mEPSC frequencies and amplitudes in neurons acutely exposed to high or low 
  127 
concentrations of aS PFFs. The reduced mEPSC frequency observed in neurons acutely 
exposed to 0.10 µg/mL or 4.00 µg/ml aS PFFs may be multi-factorial. High dose aS PFF-
induced synapse loss can present as reduced mEPSC frequency due to less opportunities 
for presynaptic vesicle release. However, increased aS expression is also associated with 
reduced vesicle release (Nemani et al., 2010), and thus may represent a presynaptic 
consequence of aS PFF exposure and internalization. 
 
aS PFF-induced tau missorting and spine loss involve different mechanisms  
  
 To investigate the mechanisms underlying aS PFF-induced tau missorting and 
synaptic deficits in primary hippocampal neuronal cultures, we next asked if specific 
posttranslational modifications of tau were required. In particular, tau phosphorylation and 
GSK3b activity, an established kinase of tau, are critical components for the induction of 
tau mislocalization into spines (Hoover et al., 2010; Teravskis et al., 2018). Consistent 
with these previous studies, pharmacological inhibition of GSK3b via 500 nM CHIR 99021 
(Tocris; BioTechne, Minneapolis, MN) prior to aS PFF exposure is sufficient to block tau 
missorting into dendritic spines at both low (0.10 µg/mL) and high (4.00 µg/mL) 
concentrations (Figure 3.5a-b). Surprisingly, aS PFF-induced spine loss at high 
concentrations was also rescued as neurons pre-treated with CHIR 99021 for 12 hrs prior 
to 4.00 µg/mL aS PFF exposure for 24 hrs displayed similar spine density levels as 
compared to 0.10 µg/mL aS PFF and control conditions (Figure 3.5a and c). Although 
tau missorting and associated AMPAR deficits are not thought to be connected with spine 
collapse (Hoover et al., 2010; Miller et al., 2014; Teravskis et al., 2018), it is possible that 
aS PFFs have other pathological actions downstream of GSK3b that ultimately produce 
the synaptotoxic effects observed here in culture.  
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 aS PFF-induced tau missorting is a pathological process that likely requires 
internalization of fibrils into neurons. However, it is also possible that extracellular aS PFFs 
contribute to neuronal abnormalities and degeneration. Cellular prion protein (PrPC) at the 
surface of postsynaptic densities is implicated as a mediator of amyloid-b (Ab)-induced 
synaptic dysfunction in primary neurons exposed to Ab oligomers and memory deficits in 
mouse models of Alzheimer’s disease (AD) (Gimbel et al., 2010; Laurén et al., 2009; Um 
et al., 2012, 2013). More recent studies have found that aS oligomer-mediated synaptic 
impairment occurs in a PrPC-dependent manner (Ferreira et al., 2017). Therefore, we next 
asked if the pathologic changes following aS PFF exposure could be attributed through 
extracellular effects of fibrils, specifically via PrPC. Neurons pre-treated with 100 nM 6D11 
(BioLegend; San Diego, CA), an antibody against PrPC, did not block aS PFF-induced tau 
missorting (Figure 3.6a-b). However, this antibody-mediated blocking of PrPC signaling 
prevented spine loss in primary hippocampal neurons exposed to high concentrations 
(4.00 µg/mL) of aS PFFs (Figure 3.6a and c). Taken together, it is evident that aS PFFs 
exert a range of neurotoxic effects through distinct intracellular and extracellular 
mechanisms. However, to further clarify these mechanisms, important future experiments 
are essential, which include controlling for key manipulations here, such as CHIR in 
dimethyl sulfoxide (DMSO), and immunoglobulin G (IgG) for the 6D11 IgG monoclonal 
antibody.  
  
Endogenous aS has differential roles on aS PFF-induced abnormalities in primary 
neurons  
  
 Endogenous mouse aS is a critical determinant of aS PFF-mediated neuronal 
changes, including aggregate formation within neurons, spine dynamics, and disruption of 
neurotransmission (Froula et al., 2018; Volpicelli-Daley et al., 2011). We therefore next 
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asked if tau mislocalization to dendritic spines and the dose-dependent effects on these 
postsynaptic structures required endogenous aS. To accomplish this, primary 
hippocampal neurons from SNCA-/- mouse pups were cultured, co-transfected with DsRed 
and eGFP-tau, treated with aS PFFs, and live imaged consistent with the previous 
experiments. aS PFF-mediated tau missorting at low and high concentrations was 
unaffected by removal of endogenous aS expression (Figure 3.7a-b). However, spine 
loss associated with exposure to high concentrations of aS PFF (4.00 µg/mL) was absent 
in SNCA-/- neurons (Figure 3.7a and c), further highlighting the differential pathways 
mediating aS PFF-induced neuronal dysfunction. SNCA-/- litters were obtained from 
homozygous SNCA-/- parents, precluding the ability to compare the role of endogenous 
aS between littermates. As such, while studies using culture neurons from C57BL6/J 
(BL6) hippocampi were not performed in parallel, tau missorting and synapse loss with 
high dose aS PFFs has been observed in multiple experiments. Tau mislocalization may 
be a primary effect of aS PFFs in cultured neurons. However, given these findings in 
SNCA-/- neurons, aS PFF-induced spine collapse likely requires corruption and 
recruitment of endogenous aS to specifically mediate these toxic effects on postsynaptic 
structures.  
 
   
Discussion 
 
 Despite the central role of aS in PDD and DLB pathogenesis, the manners in which 
different pathological species of aS contribute to neuronal dysfunction and degeneration 
remain unknown. Determining the driving forces behind aS aggregation, which species of 
aS are pathogenic and transmissible, and their mechanisms, are critical for the advancing 
our understanding of hippocampal dysfunction and memory deficits in the a-
synucleinopathies. In this study we investigated the structural and functional changes 
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associated with acute exposure to aS PFFs in primary hippocampal neuronal cultures, 
motivated by our hypothesis that aS PFFs may represent a pathological species that 
contributes to the neuronal dysfunction underlying cognitive impairment in PDD and DLB.   
 To date, monitoring aS-rich Lewy pathology in the cortex and limbic system represents 
one of the most sensitive and specific pathological measures for dementia in PD (Ballard 
et al., 2006; Halliday et al., 2014). However, it remains unknown if this pathology is a 
primary driver of neuronal abnormalities leading to memory changes or if this pathology 
merely reflects underlying disease processes. Neuronal dysfunction in cholinergic 
hippocampal neurons and CA1 pyramidal neurons, as opposed to neuropathology or 
neurodegeneration, are associated with impaired memory performance and dementia in 
PD and DLB (Adamowicz et al., 2017; Hall et al., 2014). To better evaluate connection 
between pathological species of aS and cellular deficits, we utilized a seeded model of a-
synucleinopathy that recapitulates key aspects of disease pathogenesis and progression 
(Volpicelli-Daley et al., 2014). Using this approach, acute application of aS PFFs to 
primary hippocampal neuronal cultures was able to induce pathological tau mislocalization 
to dendritic spines by 24 hrs post-treatment. However, we also observed concentration-
dependent synaptic alterations in aS PFF-treated neurons. While low (0.10 µg/mL) and 
high (4.00 µg/mL) amounts of aS PFFs were both capable of inducing tau missorting, 
neurons exposed to high concentrations of aS PFFs also displayed a reduced spine 
density when imaged 24 hrs post treatment. Correspondingly, we found that this 24 hr aS 
PFF exposure time frame was sufficient to induce deficits in spontaneous synaptic 
neurotransmission as measured by reductions in mEPSC amplitude as well as mEPSC 
frequency. Consistent with previous studies (Hoover et al., 2010; Miller et al., 2014), aS 
PFF-induced tau missorting also requires GSK3b, a known tau kinase. Interestingly, aS 
PFF-induced spine loss was rescued via pharmacological GSK3b inhibition, pointing to a 
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larger involvement of this kinase in aS PFF-mediated neurodegeneration. While aS PFFs 
are capable of endocytosis (Volpicelli-Daley et al., 2011), their extracellular effects cannot 
be excluded. Inhibition of PrPC was not sufficient to block tau missorting but did rescue aS 
PFF-dependent spine collapse, suggesting that pathogenic aS species exert their 
neurotoxic properties via differing pathways. Endogenous aS, known to aggregate and 
mediate neuronal deficits in response to aS PFF exposure, was also required for aS PFF-
mediated synaptotoxicity but not tau missorting. Taken together, our findings demonstrate 
a dose-dependent effect of aS PFFs on primary hippocampal neurons in culture, along 
with the initial efforts to understand the mechanisms by which aS PFFs contribute to 
disease pathogenesis and the role for aS aggregates and Lewy pathology in these 
processes.  
 aS is an abundant presynaptic protein enriched, comprising upwards of 1% of all 
cytosolic proteins, yet resists aggregation under physiologic conditions (Stefanis, 2012). 
The advent of the aS fibril model for studying PD pathogenesis is unique in its capacity to 
induce pathology and inclusion formation in cells that express endogenous levels of aS 
(Luk et al., 2012a; Volpicelli-Daley et al., 2011, 2014). However, the induction of 
endogenous aS aggregate formation begins with application of supra-physiologic levels 
of recombinant aS in the form of PFFs. Up to this point, the concentration-dependent 
effects of oligomeric or fibrillar aS on cultured neurons had not been examined, putting 
the relevance of the findings in question with respect to disease and translational 
relevance (Ferreira et al., 2017; Froula et al., 2018; Luna et al., 2018; Volpicelli-Daley et 
al., 2011). Thus, in addition to examining structural and functional synaptic changes 
associated with acute aS PFF exposure in primary hippocampal neurons at doses, these 
studies previously utilized, 4.00 µg/mL (~300 nM), this thesis work also examined a lower 
concentration, 0.10 µg/mL (~8 nM), hypothesizing that if aS PFFs indeed represent a 
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transmissible species responsible for PDD and DLB pathogenesis, the amounts found in 
the extracellular milieu following excretion or leakage from diseases neurons are likely to 
be much lower. This was partially validated as a concentration 0.10 µg/mL of aS PFFs 
was effective at inducing pathologic tau missorting to dendritic spines and synaptic deficits 
as measured via reduced frequency and amplitude of mEPSCs. While the established 
4.00 µg/mL concentration produced similar effects, it also resulted in spine and synapse 
loss. Although synapse loss and hippocampal atrophy can be observed in PDD and DLB 
(Camicioli et al., 2003), the lack of prominent neurodegenerative features in the 
hippocampus is more commonly a distinguishing feature for the diagnosis of PDD or DLB 
as compared to other dementias such as AD (Halliday et al., 2014; McKeith et al., 2017), 
again suggesting to a mechanism underlying memory deficits that is more centered on 
synaptic dysfunction as opposed to overt synapse loss.  
 An interesting finding of our studies is the discrepancy between synapse loss and 
neurophysiological dysfunction at 0.10 and 4.00 µg/mL of aS PFFs. Both doses induce 
tau missorting to dendritic spines and correspondingly AMPAR deficits as measured via 
reductions in mEPSC amplitude. Depressed mEPSC frequency is observed at both 
concentrations tested, but it is possible that origins of these observations may differ. As 
4.00 µg/mL aS PFF concentrations are associated with spine and synapse loss, mEPSC 
frequency reduction in this setting may be confounded by of overt synapse loss. However, 
consistent with its role in modulation of presynaptic neurotransmission and vesicle 
dynamics, aS overexpression is associated with reduced presynaptic vesicle in the 
absence of synapse loss (Larsen et al., 2006; Nemani et al., 2010; Teravskis et al., 2018). 
As such, this represents the likely mechanism for mEPSC deficits in neurons exposed to 
0.10 µg/mL aS PFFs, consistent with previous studies establishing aS PFF internalization 
and trafficking to presynaptic terminals, the site of aS PFF-induced pathology initiation 
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(Karpowicz et al., 2017; Volpicelli-Daley et al., 2011). It will be important to further examine 
spine and synapse loss following acute aS PFF exposure to determine if these changes 
are transient or irreversible responses to toxic levels of pathogenic aS. aS overexpression 
is also known to reduce synapsin levels (Larson et al., 2017; Nemani et al., 2010), and 
thus the qualitative reduction we observe in synapsin and PSD95 colocalization may 
instead reflect this change as opposed to “true” reductions in presynaptic terminals. 
 In addition to the spine loss observed here, 4.00 µg/mL of aS PFFs induces altered 
spine dynamics, and synaptic deficits on the order of hours post-exposure (Froula et al., 
2018; Wu et al., 2019), followed by neuronal loss beginning around 14 days post-exposure 
(Volpicelli-Daley et al., 2011, 2014). To that end, the use of lower aS PFF doses may 
provide for more disease-relevant studies and conclusions, particularly with respect to the 
dissection between aS-mediated neuronal deficits and aS inclusion formation. Increased 
endogenous aS expression within neurons is associated with faster induction of aS 
pathology and cell death (Luna et al., 2018). As such, it is possible that some of the 
phenotypes observed in neurons treated with 4.00 µg/mL may be due to their capacity to 
induce proteostatic, lysosomal, and mitochondrial stress at these higher concentrations 
(Dryanovski et al., 2013; Karpowicz et al., 2017), a potential byproduct of overwhelming 
cells with exogenous aS rather than a more physiologic, disease-relevant process that 
could be assumed from leakage of pathologic aS from presynaptic terminals (Vasili et al., 
2019). 
 The ability for aS PFFs to compromise synaptic and neuronal function has been 
previously observed (Di Scala et al., 2016; Dryanovski et al., 2013; Froula et al., 2018; 
Luna et al., 2018; Volpicelli-Daley et al., 2011), but only examined at time points that would 
concomitant with the presence of aS inclusions, precluding the capacity to determine what 
pathological forms of aS are directly responsible for the changes observed. Moreover, the 
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mechanisms underlying these changes and concentration-dependent nature of these 
changes was not known as all studies employed a single concentration that is now known 
to greatly exceed the physiologic concentration of endogenous aS and what is needed to 
seed aggregate formation (Afitska et al., 2019; Wilhelm et al., 2014). Here, we 
demonstrate that low doses of aS PFFs known to favor aggregate formation are capable 
of inducing synaptic deficits without the rapid neurotoxic effects associated with higher 
doses. In addition to these dose-dependent phenotypes, albeit at extreme ends of the 
concentration spectrums, we begin to establish the mechanisms underlying aS PFF-
mediated neuronal dysfunction, proposing that extracellular and intracellular pools of aS 
PFFs together contribute to disease pathogenesis.  
 Recent work demonstrating that the concentration of aS at the synapse is around 20 
µM (Wilhelm et al., 2014), a 30-fold difference from the established 4.00 µg/mL aS PFF 
dosage, further supports the pursuit of dissecting out aS PFF-induced dose-dependent 
versus dose-independent neuronal abnormalities. The ability of this high dose to corrupt 
and recruit endogenous aS into fibrillar inclusions may indeed represent a relevant 
disease process for transmission within the nervous system, but it may also represent an 
artifact of elevated intraneuronal aS. Lower aS concentrations favor the monomeric state 
of aS, and recent work has demonstrated that a concentration of 3-5 µM of aS PFFs 
represents a favorable concentration fibril seeds to drive recruit monomeric aS into de 
novo fibrils (Afitska et al., 2019). The 0.10 µg/mL dosage corresponds to approximately 8 
nM and thus it is possible that this concentration will also seed monomeric aS conversion 
to fibrils, although on a longer time scale as compared to the 4.00 µg/mL dose. To that 
end, prolonging the lag time for inclusion formation will provide for further dissection of 
neuronal abnormalities due to soluble or pre-fibrillar aS aggregates and those due to 
fibrillar aS inclusions. Moreover, it provides for the observation that tau missorting synaptic 
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dysfunction observed in neurons treated with 0.10 µg/mL aS PFFs is less likely a product 
of aS aggregation but the intrinsic pathogenicity of fibrils within neurons through varying 
mechanisms that can be revealed through future studies.  
 While the mechanisms describing how these pathological aS species corrupt 
endogenous aS remains unknown, it is clear that distinct conformational strains of fibrillar 
aS are capable inducing distinct neuropathological phenotypes (Guo et al., 2013; 
Peelaerts et al., 2015). Additionally, the rapid formation of aS inclusions and 
neurodegeneration observed in a-synucleinopathy animal models following aS PFF 
injection (Luk et al., 2012b; Masuda-Suzukake et al., 2013) may not just be a consequence 
of overt aS overexpression but also species of aS expressed. Cross-species seeding is 
clearly achieved at high doses of aS PFFs both in vitro and in vivo (Luk et al., 2012b; 
Volpicelli-Daley et al., 2011). However, exogenously human aS fibrils display enhanced 
pathogenicity when introduced to neurons expressing human aS expression as compared 
to mouse aS (Luk et al., 2016). It is therefore reasonable to conclude that the aS PFF-
induced spine collapse is distinct from aS PFF-induced tau missorting. Here, we show 
that spine loss, but not tau missorting, requires both endogenous mouse aS expression 
as well as PrPC signaling. One possible explanation for this finding follows the host 
compatibility studies in aS. Bigenic mice overexpressing human aS and tau display 
increased fibrillization of each protein as compared to singly transgenic mice, pointing to 
a synergistic interaction between these proteins from an aggregation perspective (Giasson 
et al., 2003). This concept has been furthered via the aS PFF model in primary neurons 
overexpressing human tau as aS PFFs are able to induce cross-seeding of tau 
aggregation in these cells, but not those cultured from non-transgenic mice (Guo et al., 
2013). The overexpression of human tau in our studies parallels these findings. For 
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example, human aS PFFs can directly influence certain pathologic processes, such as 
tau missorting, likely due to the host species matching, whereas other aspects of aS PFF-
induced neurodegeneration, such as spine and synapse loss, require protein 
intermediates like GSK3b and PrPC, as well as endogenous aS, to mediate these toxic 
effects. This is consistent with the concept that pathogenic Ab and aS oligomeric species 
can act through distinct intracellular and extracellular mechanisms that ultimately 
converge to comprise synaptic plasticity and neuronal function (Ferreira et al., 2017; 
Laurén et al., 2009; Miller et al., 2014; Um et al., 2012). 
 Prior studies support a connection between the burden of aS neuropathology and 
eventual neurotoxicity in aS PFF models (Luna et al., 2018; Masuda-Suzukake et al., 
2014; Volpicelli-Daley et al., 2011). However, neither neuropathology nor 
neurodegeneration are necessary for the manifestation of aS-mediated synaptic deficits 
in vitro and ex vivo (Ferreira et al., 2017; Teravskis et al., 2018), highlighting a divergence 
between aggregation and specific neuronal abnormalities. This relationship is supported 
by the findings here that aS PFFs alter neurotransmission at time points known to precede 
aS PFF-induced development of Lewy-like pathology. Significantly, aS-mediated 
neuronal dysfunction, independent of aS inclusion formation or neuronal loss, is sufficient 
to precipitate memory deficits in TgWT and TgA53T a-synucleinopathy mouse models 
(Ferreira et al., 2017; Magen et al., 2012; Teravskis et al., 2018). This concept is central 
to the studies presented in Chapter 2 of this thesis as haSA53T-meidated synaptic and 
memory deficits occur without the need for loss of synapses or neurons within the 
hippocampus. Furthermore, while these deficits require tau, they do not require alterations 
in aS expression or levels of pathological oligomeric, fibrillar, or insoluble species. It is 
possible, however, that pathogenic aggregates in TgA53T hippocampal neurons are 
essential for disease pathophysiology but may be upstream of tau in the of aS-mediated, 
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tau-dependent, synaptic and memory deficit pathway. This suggests that, in the context 
of low dose aS PFFs (e.g. 0.10 µg/mL), synaptic abnormalities are likely to be a direct 
consequence of fibrillar aS species, independent of inclusion formation or other 
neurodegenerative changes associated with higher aS PFF doses, synapse loss in 
particular.  
 These observations hold clinical relevance in several capacities. First, although 
increased cortical and hippocampal Lewy pathology burden is a sensitive and specific 
measure for predicting cognitive impairment, it is not observed in all patients with a 
diagnosis of PDD or DLB (Colosimo et al., 2003; Halliday et al., 2014). In addition, 
hippocampal neurodegeneration is not a common finding in PDD and DLB, with the 
observation of preserved hippocampal volumes successfully distinguishing dementia in 
PDD and DLB from other causes like AD (Hely et al., 2008; Kantarci et al., 2016; McKeith 
et al., 2017). Lastly, hippocampal neuronal dysfunction in specific regions such as CA1 
correlates better with impaired memory performance than areas with a higher aS 
pathology burden such as CA2, the entorhinal cortex, and parahippocampal gyri 
(Adamowicz et al., 2017; Hall et al., 2014; Harding and Halliday, 2001). However, as 
several of these regions project onto CA1 pyramidal neurons, it can be hypothesized that 
aS-induced memory deficits are a consequence of hippocampal synapse and circuit 
dysfunction rather than structural or neuronal degeneration. For example, neurons positive 
for Lewy-pathology (LNs in particular) that synapse onto CA1 pyramidal neurons may 
transmit pathological aS species, such as fibrillar aS, in a trans-synaptic manner onto their 
CA1 targets to mediate synaptic dysfunction in CA1 neurons independent of Lewy-
pathology development.  
 Tau pathology is gaining relevance as a biomarker for cognitive dysfunction in PDD 
and DLB (Coughlin et al., 2018; Irwin and Hurtig, 2018; Irwin et al., 2013), but how tau 
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contributes to aS-driven cognitive dysfunction is not fully established. These finding 
support a model that tau plays an active role in mediating synaptic dysfunction and 
AMPAR deficits underlying memory deficits in PDD and DLB, demonstrating that aS PFF 
introduction leads to impairments in neurotransmission at both pre and postsynaptic 
compartments, partially mediated via tau missorting to dendritic spines, prior to the onset 
of Lewy-like pathology (summarized in Figure 3.8). Collectively, these findings provide 
insight into how pathogenic species of aS are likely to mediate cognitive decline in the a-
synucleinopathies, helping to improve disease models and the potential translational 
relevance for these studies and future therapeutic approaches aimed at addressing 
memory deficits in PDD and DLB. 
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Figure 3.1 – Schematic depicting the protocol for generating and using recombinant aS monomeric 
and pre-formed fibril (PFF) species. a. Generation of aS PFFs begins via production of aS monomers 
via bacterial cell expression system, classically E. coli. Bacterial production of aS is followed by cell 
lysis, ammonium sulfate precipitation of proteins, and isolation of monomeric aS via anion exchange 
and size exclusion chromatographic processes. b. Monomeric aS at this point can be stored for future 
experimental application or used to generate PFFs via continuous shaking at set conditions for up to 
120 hrs (5 days). c. Production of aS PFFs from monomers is monitored via Thioflavin T (ThioT) 
fluorescence assays. After ThioT fluorescence intensity values have plateaued, PFF production is 
considered complete. Performing sedimentation assay via centrifugation of PFFs to produce 
supernatant and pellet fractions that are then resolved via SDS-PAGE is also essential to confirm aS 
PFF production and levels in both fractions. d. After production, confirmation, and storage, it is critical 
to dilute and sonicate aS PFFs prior to use to break up larger aggregates and generate a majority of 
PFFs that are short, 50 nm or less in length, as these have proven to be the most effective in seeding 
pathology and likely other precipitating neurotoxic effects. Contributions: HMM. 
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Figure 3.2 – aS pre-formed fibrils induce tau-mislocalization to dendritic spines and dose-dependent 
spine loss. a. Cultured rat primary hippocampal neurons were co-transfected with plasmid expressing 
DsRed to visualize neuronal architecture or eGFP-tagged to 4R0N human tau (eGFP-tau) to visualize 
tau localization and subjected to treatment with aS monomers (aS mono), aS pre-formed fibrils (aS 
PFF), or phosphate-buffered saline (PBS) control. Neurons were treated with PBS, aS mono, or aS 
PFFs and underwent live-cell imaging 24 hours (hrs) post-treatment. Scale bar: 10 µm. b. 
Quantification of spines containing tau as measured via DsRed and eGFP-tau co-localization. F(4,70) 
= 40.30, p < 0.0001, by one-way ANOVA with Tukey’s posthoc analysis. Cells/culture: nPBS = 21/4, 
n0.10-PFF= 31/4, n4.00-PFF = 16/4, n0.10-MONO = 5/2, n4.00-MONO = 5/2. c. Quantification of spine density as 
measured via spines per pixel length of dendrite. F(4,65) = 10,87, p < 0.0001, by one-way ANOVA with 
Tukey’s posthoc analysis. Cells/culture: nPBS = 19/4, n0.10-PFF= 22/4, n4.00-PFF = 13/4, n0.10-MONO = 8/2, n4.00-
MONO = 8/2. One-way ANOVA: ** p < 0.01 and **** p < 0.0001. Error bars represent mean ± S.E.M.  
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Figure 3.3 – Long-term aS PFF exposure produces dose-dependent synapse loss. Confocal images 
of rat primary hippocampal neurons treated with aS PFFs or PBS control, fixed 72 hrs post-treatment, 
and immunohistochemically stained for pre (Synapsin 1/2) and postsynaptic (PSD95) markers. Scale 
bar: 50 µm. 
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Figure 3.4 – Acute exposure to high concentrations of aS PFFs induces pre and postsynaptic 
dysfunction. Average mini excitatory post-synaptic current (mEPSC) frequency (a) and amplitude (b) 
from in vitro recordings utilizing rat primary hippocampal neuronal cultures. Each point represents 
average mEPSC frequency or amplitude from recording of a single neuron, with neurons coming from 
multiple litters (cultures). a. mEPSC frequency: F(2,31) = 15.60, p < 0.0001, by one-way ANOVA with 
Tukey’s posthoc analysis. b. mEPSC amplitude: F(2,31) = 6.701, p = 0.0038, by one-way ANOVA with 
Tukey’s posthoc analysis. c. Relative cumulative distribution frequency (CDF) of whole-cell mEPSC 
inter-burst interval (frequency, left panel) and amplitudes (right panel) from recordings of cultured 
neurons. mEPSC inter-burst interval CDF: Kolmogorov-Smirnov (K-S) test, D = 0.9096, p < 0.0001. 
mEPSC amplitude CDF: K-S test, D = 0.2186, p < 0.0001. d. Representative traces. Cell/cultures: 
nPBS = 11/4, n0.10-PFF = 13/2, n4.00-PFF = 11/2. t and K-S tests: * p < 0.05, ** p< 0.01, *** p < 0.001, **** 
p < 0.0001. Error bars represent mean ± S.E.M. 
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Figure 3.5 – aS PFF-mediated tau missorting is GSK3b-dependent.  a. Cultured rat primary 
hippocampal neurons were co-transfected with plasmid expressing DsRed to visualize neuronal 
architecture or eGFP-tagged to 4R0N human tau (eGFP-tau) to visualize tau localization, pre-treated 
with the GSK3b antagonist 500 nM CHIR 99021 (CHIR) for 12 hrs, and then exposed to aS PFFs. 
Neurons were then subject to live-cell imaging 24 hrs post-treatment. Scale bar: 10 µm. b. 
Quantification of spines containing tau as measured via DsRed and eGFP-tau co-localization. Two-
way ANOVA with Sidak’s posthoc analysis revealed a significant effect of aS PFF exposure (F(2,58) = 
35.05, p < 0.0001), significant effect of CHIR treatment (F(1,58) = 147.50, p < 0.0001), and significant 
aS PFF*CHIR interaction (F(2,58) = 24.91, p < 0.0001) on tau mislocalization. Cells/culture: nPBS = 14/2, 
nCHIR = 6/2, n0.10-PFF= 17/3, n0.10-PFF-CHIR = 10/3, n4.00-PFF = 10/3, n4.00-PFF-CHIR = 7/3. c. Quantification of 
spine density as measured via spines per pixel length of dendrite. Two-way ANOVA with Sidak’s 
posthoc analysis revealed a significant effect of aS PFF exposure (F(2,61) = 9.366, p = 0.0003), no 
significant effect of CHIR treatment (F(1,61) = 0.7176, p = 0.4003), and no significant aS PFF*CHIR 
interaction (F(2,61) = 1.420, p = 0.2496 ) on spine density. Cells/culture: nPBS = 14/2, nCHIR = 7/2, n0.10-
PFF= 14/3, n0.10-PFF-CHIR = 18/3, n4.00-PFF = 8/3, n4.00-PFF-CHIR = 7/3. Two-way ANOVA: ** p < 0.01, **** p < 
0.0001, and # denotes Sidak posthoc analysis p < 0.001 between PBS and 4.00 µg/mL aS PFF 
condition spine densities (c). Error bars represent mean ± S.E.M. 
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Figure 3.6 – Differential requirements of PrPC on aS-PFF induced neuronal changes. a. Cultured 
mouse primary hippocampal neurons were co-transfected with plasmid expressing DsRed to visualize 
neuronal architecture or eGFP-tagged to 4R0N human tau (eGFP-tau) to visualize tau localization, 
pre-treated with 100 nM PrPC inhibitor 6D11 for 4 hrs, and then exposed to aS PFFs. Neurons then 
underwent live-cell imaging 24 hrs post-treatment. Scale bar: 10 µm. b. Quantification of spines 
containing tau as measured via DsRed and eGFP-tau co-localization. F(2,45) = 52.11, p < 0.0001, by 
one-way ANOVA with Tukey’s posthoc analysis. Cells/culture: n6D11 = 18/2, n0.10-6D11 = 15/2, n4.00-6D11 = 
15/2. c. Quantification of spine density as measured via spines per pixel length of dendrite. F(2,45) = 
0.3569, p = 0.7018, by one-way ANOVA with Tukey’s posthoc analysis. Cells/culture: n6D11 = 18/2, 
n0.10-6D11 = 15/2, n4.00-6D11 = 15/2. One-way ANOVA: **** p < 0.0001. Error bars represent mean ± S.E.M. 
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Figure 3.7 – Dose-dependent, aS PFF-induced spine loss requires endogenous aS. a. Cultured 
mouse primary hippocampal neurons from C57BL6/J (BL6) or SNCA-/- mice that lack endogenous 
mouse aS expression, were co-transfected with plasmid expressing DsRed to visualize neuronal 
architecture or eGFP-tagged to 4R0N human tau (eGFP-tau) to visualize tau localization and exposed 
to aS PFFs. Neurons then underwent live-cell imaging 24 hrs post-treatment. Scale bar: 10 µm. b. 
Quantification of spines containing tau as measured via DsRed and eGFP-tau co-localization. F(3,40) 
= 78.77, p < 0.0001, by one-way ANOVA with Tukey’s posthoc analysis. Cells/culture: nBL6 = 20/2, 
nSNCA-/- = 13/2, n0.10-PFF = 24/2, n4.00-PFF = 9/2. c. Quantification of spine density as measured via spines 
per pixel length of dendrite. F(3,62) = 1.288, p = 0.2865, by one-way ANOVA with Tukey’s posthoc 
analysis. Line underneath bar graphs refers to cultures of mouse SNCA-/- neurons. Cells/culture: nBL6 
= 11/2, nSNCA-/- = 8/2, n0.10-PFF = 16/2, n4.00-PFF = 8/2. One-way ANOVA: **** p < 0.0001. Error bars 
represent mean ± S.E.M. Contributions: HMM.  
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Figure 3.8 – Proposed model of disease progression and aS PFF-mediated synaptic and neuronal 
deficits. Under physiology “healthy” conditions, aS aggregates are absent, along with synaptic and 
memory deficits. However, in a-synucleinopathies associated with prominent impairment such as 
PDD and DLB, hippocampal Lewy pathology may be suggestive of underlying synaptic dysfunction. 
Pathological aS species associated with LNs in CA2 projections may be actively or passively released 
from presynaptic terminals through a variety of mechanisms which are currently not yet known but 
potentially include direct penetration through presynaptic plasma membrane, tunneling nanotubes, or 
release in exosome or secretory vesicles. Transmission of pathological aS from CA2 to CA1 
pyramidal neurons likely leads to acute “early” and chronic “late” neuronal responses, dictated by 
stage and timing of disease progression. Early responses, prior to overt inclusion formation and aS 
aggregation, may include pre and postsynaptic deficits that impair synaptic plasticity and cognitive 
function. These may be a product of direct actions of pathogenic aS from CA2 neurites but can also 
via pathogenic aS recruiting endogenous aS and other protein intermediates like tau. The late stage 
is suggestive of more global compromised neuronal function, with the formation of new inclusions 
comprised of endogenous aS appearing and further exacerbating neuronal deficits. PDD: Parkinson’s 
disease dementia. DLB: dementia with Lewy bodies. ms aS: endogenous mouse aS. aS PFF: haSWT 
pre-formed fibrils. AMPAR: AMPA receptor. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  147 
CONCLUSIONS 
 
Findings 
 
 The overarching objective of this thesis was to examine the mechanisms underlying 
neuronal dysfunction and cognitive decline in the a-synucleinopathies, PDD and DLB in 
particular, through several approaches. In the first arm, studies utilizing the TgA53T 
mouse model of a-synucleinopathy demonstrate that haSA53T mediates progressive 
synaptic and memory deficits in a tau-dependent manner. One mechanism contributing to 
memory deficits revealed through this work occurs through postsynaptic dysfunction via 
reduced AMPAR expression and depressed glutamatergic signaling. haSA53T-driven, tau-
dependent, remodeling of hippocampal networks observed here suggests aberrant 
network hyperactivity also represents a driving factor of cognitive dysfunction in TgA53T 
mice. Findings from the longitudinal approach used to investigate cognitive decline in 
TgA53T mice suggests that memory deficits in these animals may be a consequence of 
disruptions in the balance between excitatory and inhibitory tone particularly within the 
limbic system and hippocampus produced via AMPAR deficits. The second arm of this 
thesis characterizes synaptic and neuronal deficits utilizing an in vitro model of a-
synucleinopathies that serves to recapitulate key processed in sporadic cases of PDD and 
DLB. Through this approach, it became evident that several features of aS-mediated 
cognitive decline in TgA53T mice may also be relevant in this model. For example, 
pathogenic fibrillar aS-induced tau missorting to dendritic spines and AMPAR deficits, 
independent of overt neurodegeneration, may represent a common pathway underlying 
synaptic and cognitive dysfunction in both familial and sporadic cases of PDD and DLB. 
  Two larger, more global, conclusions can be derived from this study which also may 
be applicable to other neurological disorders. The first conclusion highlights the 
importance of postsynaptic dysfunction as a critical mechanism driving cognitive deficits. 
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The second conclusion proposes that different components of neuronal dysfunction and 
disease-associated phenotypes likely occur through differing mechanisms, as opposed to 
a single common pathway, such as memory deficits versus locomotor deficits in the a-
synucleinopathies. It is likely that a variety of factors, including neuronal subtype and 
neuroanatomical location, contribute to these findings, but further investigation is 
warranted to better define these differing components of disease pathophysiology.  
 
 
Discussion 
 
 It is clear that addressing neurological disorders and cognitive dysfunction represents 
a global health priority. What is less clear, unfortunately, is how to do so. Through this 
thesis work and in relation to other currently published studies, approaching 
neurodegenerative diseases through a network-level lens may yield interesting and 
exciting results. Concepts relating to neuron dysfunction, memory deficits, and disease 
pathogenesis in AD may be applicable to other diseases like the a-synucleinopathies. 
From a neuropathological perspective similar to AD, PD also targets specific and 
progresses also functionally connected networks (Braak and Del Tredici, 2016; Braak et 
al., 2003). In addition, altered neuronal network function and hyperactivity are implicated 
as drivers of cognitive decline in AD (Chin et al., 2005; Martinez-Losa et al., 2018; Palop 
et al., 2007; Sanchez et al., 2012), a mechanism gaining increasing traction in PD as 
presented in thesis and by others (Morris et al., 2015). This thesis identifies two 
pathological species of aS, haSA53T and aS PFFs, as mediators of postsynaptic 
dysfunction and synaptic depression at excitatory, glutamatergic synapses. Aberrant 
excitatory activity is also observed in aged TgA53T mice, a potential reflection of a more 
global network imbalance in excitatory and inhibitory tone due to dysfunction at GABAergic 
synapses in addition to glutamatergic. As such, the relationship between AMPAR deficits, 
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synaptic depression, network disturbances, and epileptiform changes may represent a 
common mechanism underlying memory dysfunction in PDD and DLB, although the exact 
mechanism linking these observations are not yet known. In support of this, cultured 
neurons exposed aS PFFs display altered network connectivity and reductions in 
excitatory tone specifically to AMPARs (Volpicelli-Daley et al., 2011), perhaps 
representing the first step towards network-level dysfunction in this model and possibly 
sporadic PDD and DLB cases. Indeed, epileptic activity, seizures, and myoclonus are 
common features in PD and DLB, supporting network hyperactivity and dysfunction as a 
clinically-relevant disease process (Beagle et al., 2017; Gruntz et al., 2018; Morris et al., 
2015; Son et al., 2016).  
 Surprisingly, insight into network level changes in neurodegenerative diseases may 
also be found in pediatric conditions. Early infantile epileptic encephalopathy (EIEE) is a 
neurological disorder that has the unfortunate distinction of being one of the earliest and 
most severe forms of epilepsy also associated with cognitive disability. Mutations in the 
MUNC18-1 gene encoding for the Munc18-1 (Munc) protein, are linked to EIEE (Saitsu et 
al., 2008; Stamberger et al., 2016). EIEE-associated Munc mutations lead to reduced 
exocytosis and deficits in neurotransmission, highlighting a role of Munc in synaptic 
function (Martin et al., 2014; Shen et al., 2015). The synaptic function of Munc has recently 
been expanded to include chaperone for aS (Chai et al., 2016). Interestingly, this 
chaperone function is impaired in Munc harboring EIEE-associated mutations, leading to 
intraneuronal aS aggregate formation (Chai et al., 2016), highlighting a role for 
pathological species of aS in driving neuronal dysfunction that ultimately produces seizure 
activity. Although Munc mutations have not yet been implicated in PD, it could be 
hypothesized that SNCA mutations, such as the A53T missense mutation, would also 
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impair the ability for Munc to function as a chaperone for aS, resulting in synaptic 
dysfunction and an imbalance in neurotransmission leading to network hyperexcitability.  
 From a more regional perspective, the studies using aS PFFs further support the 
hypothesis trans-synaptic spread of pathologic aS in the hippocampus onto CA1 
pyramidal neurons in DLB may represent one mechanism leading to memory impairment 
(Adamowicz et al., 2017). This progression is reminiscent of the spread of pathological tau 
in mice also along functionally connected hippocampal circuits, from the entorhinal cortex 
to CA1 (Liu et al., 2012). Interestingly, propagation of tau and tau pathology is enhanced 
by increasing neuronal activity both in vitro and in vivo (Wu et al., 2016). However, similar 
to the observations of synaptic and network-level changes in TgA53T mice reported here, 
tau-mediated circuit dysfunction is independent of tau pathology in the rTg4510 tauopathy 
mouse model (Busche et al., 2019). As such, this common thread between neuronal 
pathology, neuronal activity, and circuit connectivity implicates network hyperexcitability 
not only as a driver as memory deficits in PDD and DLB, but also in accelerating disease 
progression. Such aberrant excitatory activity within hippocampal circuitry may 
additionally serve to exacerbate cognitive decline in a disease-associated feedforward 
loop of sorts by increasing the trans-synaptic spreading of pathological aS species to other 
anatomically- and functionally-connected areas of the hippocampus and cortex required 
for learning and memory.  
 While PDD and DLB are neuropathologically classified as a-synucleinopathies, 
disease pathophysiology extends beyond aS. This thesis introduces tau as a direct 
mediator of pathological aS-driven synaptic and cognitive deficits. The apparent synergy 
between aS and tau stems from postmortem studies identifying neurofibrillary tau tangles 
in individuals with genetic forms of PD (Duda et al., 2002; Kotzbauer, 2004) and that the 
extent of tau pathology correlates inversely with cognitive status in PDD and DLB (Irwin 
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et al., 2013). Overexpression of haSWT in Tg mouse models of AD has been shown to 
accelerate cognitive decline (Clinton et al., 2010; Khan et al., 2018; Larson et al., 2012, 
2017). Conversely, removal of endogenous aS in hAPP-J20 mice rescues cognitive 
deficits while simultaneously increasing plaque burden (Khan et al., 2018). In addition, 
while aS and tau can induce each other’s fibrilization in vitro (Giasson et al., 2003), soluble 
tau oligomers have been shown to enhance toxicity of aS oligomers and mediate haSA53T-
mediated biochemical and behavioral changes in TgA53T mice (Castillo-Carranza et al., 
2018; Gerson et al., 2018). Although aS-rich Lewy pathology and tau tangles are 
pathological hallmarks that effectively serve as biomarkers for cognitive status, our 
findings in TgA53T mice and neurons exposed to aS PFFs, along with these studies, 
provide further support for neuronal and memory dysfunction occurring independently of 
overt inclusions, with soluble species of aS and tau, such as oligomers, at the helm.  
 These studies directly implicate tau as a critical mediator of pathologic aS-driven 
synaptic and behavioral deficits in TgA53T mice, reminiscent of the role pathological tau 
plays in several hAPP mouse models (Ittner et al., 2010; Roberson et al., 2007). Though 
the physiologic role of tau is not fully established, it can be hypothesized that tau adopts 
pathologic roles that represent a gain of function in PDD, DLB, and AD due to its ability to 
undergo phosphorylation and mislocalization to postsynaptic sites to modulate NMDAR 
and AMPAR activity. From a therapeutic perspective, however, attempting to reduce tau 
expression to treat dementia in the a-synucleinopathies and AD may not represent the 
ideal target. Tau deficiency in mice is associated with altered microtubule organization in 
certain axons (Harada et al., 1994) and a subtle alterations in behavior (Ikegami et al., 
2000). More recently, genetic ablation of tau has been shown to impair insulin signaling 
within the hippocampus (Marciniak et al., 2017). Insulin resistance is a cardinal feature of 
neurons in AD (de la Monte, 2014), suggesting that tau may contribute to synaptic and 
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hippocampal dysfunction in neurodegenerative diseases through dual gain and loss of 
function mechanisms. To that end, it could be hypothesized that tau function in health and 
disease is regulated by post-translational modifications such as phosphorylation or 
acetylation. In addition to increasing the risk for PDD and DLB (Goris et al., 2007; Orme 
et al., 2018), the MAPT H1 haplotype is also associated with glucose intolerance 
(Prokopenko et al., 2014; Saxena et al., 2010). Significantly, exendin-4, a glucagon-like 
peptide-1 (GLP-1) receptor agonist has neuroprotective effects in PD models both in vitro 
and in vivo (Li et al., 2009), with recent clinical trials demonstrating its clinical benefit in 
partially alleviating motor and cognitive deficits in PD (Athauda et al., 2017, 2019; Aviles-
Olmos et al., 2014). Taken together, it is possible that the tau-dependent deficits in 
AMPAR signaling and cognitive function in TgA53T mice, and potentially aS PFF-treated 
neurons, may represent downstream consequences of aS-initiated, tau-mediated, deficits 
in neuronal metabolism, a hypothesis for future studies to test.  
 A central hypothesis tested in this thesis is the connection between pathologic aS, 
postsynaptic dysfunction and cognitive deficits. haS overexpression (haSWT, haSA30P, or 
haSA53T) leads to presynaptic deficits, yet only haSA53T-expressing neurons also display 
reductions in mEPSC amplitude and LTP (Teravskis et al., 2018). Moreover, TgA53T 
mice, but not TgWT or TgA30P display deficits in hippocampal-dependent spatial learning 
and memory at 12 months. Moreover, these deficits in TgA53T mice are tau-dependent 
and a product glutamatergic dysfunction rather than synapse or neuronal loss. But what 
are the exact mechanisms behind this relationship? The postsynaptic protein neurogranin 
(Ng) is involved in synaptic plasticity (Zhong and Gerges, 2012; Zhong et al., 2009), is 
emerging as a promising diagnostic and prognostic biomarker in cognitive impairment and 
AD, and may represent a potential link between aS, tau, and postsynaptic deficits. 
Cerebrospinal fluid (CSF) from AD patients contains increased Ng levels (Kester et al., 
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2015; Tarawneh et al., 2016). Correspondingly, Ng is decreased in brains of AD patients 
(Kvartsberg et al., 2019). Increased levels of CSF Ng are also predictive for progression 
from MCI to AD (Kester et al., 2015), and can also correlate with memory performance 
independent of AD-related biomarker status (Casaletto et al., 2017), supporting the 
specific relationship between postsynaptic integrity and memory. In detail, Ng is a critical 
protein for synaptic strength, LTP, and spatial learning and memory (Pak et al., 2000; 
Zhong et al., 2009), likely via the modulation and regulation of calmodulin and CaMKII 
(Hoffman et al., 2014; Pak et al., 2000; Zhong and Gerges, 2012). Protein kinase C (PKC) 
mediates Ng phosphorylation and activation (Díez-Guerra, 2010), and haS 
overexpression has been demonstrated to reduce PKC levels and activity in vitro (Jin et 
al., 2011; Ostrerova et al., 1999), highlighting potential avenues for aS-mediated 
postsynaptic deficits. Although the position for tau within this pathway is not yet apparent, 
the significant correlation of Ng levels with total tau and pathological phosphorylated tau 
levels within the CSF of cognitively impaired and AD patients (Kester et al., 2015) supports 
a possible mechanistic interaction between these proteins and aS.  
  With a focus on investigating postsynaptic dysfunction in aS-dependent cognitive 
impairment, an unexpected finding was the requirement of tau for haSA53T-mediated 
suppression of presynaptic vesicle release. Tau is distributed through the axons and soma 
of mature neurons under physiologic conditions. Tau missorting under pathological states 
has classically been examined at the postsynaptic site (Hoover et al., 2010; Ittner et al., 
2010; Teravskis et al., 2018). However, tau is also observed in synaptic terminals of AD 
brains (Fein et al., 2008; Sokolow et al., 2015) and synaptosomes isolated from Tg mice 
overexpressing human mutant P301L tau (hTauP301L) (Harris et al., 2012; Sahara et al., 
2014), suggesting that presynaptic tau may precipitate presynaptic dysfunction. Recently, 
hTauP301L has been demonstrated localizing to presynaptic terminals and colocalizing with 
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CSPa (Zhou et al., 2017), a protein that coordinates with aS in SNARE complex assembly 
(Chandra et al., 2005), providing a potential mechanistic link between these two proteins. 
Zhou and colleagues (2017) further demonstrate that this presynaptic tau binds synaptic 
vesicles and reduces synaptic transmission by reducing vesicle recycling and vesicle pool 
mobilization, reminiscent of mechanisms underlying haSWT-mediated presynaptic 
depression (Nemani et al., 2010; Scott and Roy, 2012). Surprisingly, hTauP301L and haSWT 
are both capable of actin polymerization and F-actin stabilization (Ordonez et al., 2018; 
Zhou et al., 2017), which can lead to cross-linking and immobilization of synaptic vesicles. 
Taken together, pathologic species of tau and aS appear to produce presynaptic deficits 
through common protein mediators and mechanisms. However, more work is essential to 
test the hypothesis that these pathological changes reflect converging, rather than parallel, 
pathways, of aS and tau, especially in different model systems given that haSA53T-
mediated pre and postsynaptic and memory deficits are dependent on endogenous WT 
tau species and levels.  
 Ultimately, while hTauP301L overexpression in mice causes presynaptic tau pathology 
and presynaptic electrophysiological deficits, these are not sufficient for the manifestation 
of cognitive deficits (Harris et al., 2012; Polydoro et al., 2014), supporting the hypothesis 
and findings in this thesis that postsynaptic deficits as essential drivers of cognitive 
dysfunction in models of a-synucleinopathy, and may apply to dementia in other 
neurodegenerative diseases. Still, the investigation of tau in presynaptic biology is 
essential to determine the mechanisms underlying the transmission of pathological 
species of tau and aS between neurons and brain regions, particularly with implications 
for the development of cognitive deficits given the similar pathological progressions within 
hippocampal circuity in AD, PD, and DLB (Adamowicz et al., 2017; Braak and Del Tredici, 
2016; Vasili et al., 2019). 
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Future Directions 
 
 The major findings of this thesis directly implicate tau as a mediator of aS-induced 
hippocampal synaptic dysfunction as a driver of cognitive decline. Still, future studies are 
essential to expand upon this mechanism and identify clinically feasible therapeutic 
targets. In particular, it is of importance to better define the connection between 
postsynaptic depression in excitatory glutamatergic synapses within the hippocampus, 
chronic aberrant excitatory neuronal activity, and remodeling of hippocampal circuitry. In 
these studies, haSA53T-mediated synaptic depression is examined exclusively in the 
context of excitatory synapses within the hippocampus. Furthermore, in our model, we 
hypothesize that the excitation-inhibition balance within hippocampal networks is 
disrupted and tilted in favor of chronic hyperexcitability and seizure-like changes, likely 
driving the hippocampal remodeling in TgA53T mice. It is possible that this hyperactive 
state may be produced due to inhibitory, GABAergic neurons, demonstrating an increased 
level synaptic depression as compared to their glutamatergic counterparts. However, it is 
also possible that this network-level phenotype may be a product of decreased excitatory, 
glutamatergic, tone on inhibitory interneurons within the hippocampus and CA1 outputs 
such as the subiculum and entorhinal cortex. While the hAPP-J20 mouse model of AD 
also displays hippocampal markers of aberrant network excitability, this pathological 
imbalance between GABAergic and glutamatergic signaling is shifted towards increased 
inhibitory activity (Palop et al., 2007; Sun et al., 2009). However, if these changes are 
driving epileptiform activity or compensatory attempts to suppress this activity remain 
unknown. For example, more recent studies in hAPP-J20 mice have also demonstrated 
that impaired parvalbumin-positive inhibitory neuron function, associated with reduced 
inhibitory signaling, underlies network abnormalities and memory deficits in this model 
(Martinez-Losa et al., 2018; Verret et al., 2012). Additionally, pathologic reductions in 
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proteins critical for learning and memory in glutamatergic neurons within the dentate also 
correlate with memory deficits in these hAPP-J20 animals (Palop et al., 2003). Taken 
together, the neurotransmitter, cellular, and synaptic mechanisms driving network-level 
abnormalities and behavioral deficits in neurodegenerative diseases are not easily defined 
and distinguished, likely multi-factorial and overlapping in origin and timing in disease 
progression. As such, given that the findings presented in this thesis suggest that TgA53T 
mice are likely to display excitatory synaptic depression prior to the onset of hippocampal 
remodeling, it is critical to determine the contributions and timeframe of GABAergic 
dysfunction and inhibitory neural network abnormalities to haSA53T-mediated synaptic and 
memory dysfunction. 
 It is imperative to note that the hippocampal remodeling observed via 
immunohistochemical changes  (calbindin, c-Fos, and NPY) are suggestive of responses 
to chronic aberrant excitatory activity and not direct measures of epileptiform network 
changes (Vezzani et al., 1999; You et al., 2017). To that end, a longitudinal study 
performing electroencephalogram (EEG) and electromyogram (EMG) analysis in awake, 
freely behaving TgA53T and TgA53T/mTau-/- mice for evidence of epilepsy-related 
alterations (spike complexes, seizures, myoclonus, shifts in spectral power) is a logical 
next step to further defining mechanisms underlying cognitive dysfunction in PDD and 
DLB.  
 Cross-species interactions, such as overexpression of haSA53T in TgA53T mice 
already expressing mouse aS, may influence disease pathogenesis and findings in mice. 
While Tg mouse models of a-synucleinopathies fail to consistently display dopaminergic 
neurodegeneration (Dawson et al., 2010), overexpression of haS in Drosophila, which do 
not express an endogenous aS homolog, leads to significant neuronal loss (Feany and 
Bender, 2000). Carrying this back to rodents, TgA53T mice lacking endogenous aS 
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expression exhibit exacerbated pathology (Cabin et al., 2005) and overexpression of haS, 
via aS PFFs, in neurons lacking aS, bS, and gS leads to increased fibrillization of haS 
(Fares et al., 2016). Moreover, mouse aS inhibits haS fibrillization in vitro (Rochet et al., 
2000), and aS PFF-induced pathology is enhanced when species of target neuron aS 
expression matches that of the introduced aS PFF (Luk et al., 2016). Taken together, it is 
clear that investigating aS-mediated, tau-dependent cognitive decline in TgA53T studies 
could be advanced by doing so in mice that lack endogenous aS and mTau expression, 
but conversely express haSA53T and human tau (hTau). These animals would provide an 
ideal platform to investigate the synergy between aS and tau in mediating disease 
pathogenesis, as previous studies suggest (Castillo-Carranza et al., 2018; Giasson et al., 
2003; Sengupta et al., 2015). The species-matching of aS and tau could provide new 
insight into the contributions of potential pathogenic oligomeric species and other higher 
order aggregates to synaptic dysfunction and cognitive deficits that may be absent in the 
TgA53T employed in this thesis.  
 Within the second arm of this thesis, the study of aS PFF exposure on synaptic 
dysfunction in primary hippocampal neurons is ripe with potential avenues of future 
investigation. Given the hypothesis that aS PFF-induced tau missorting to dendritic spines 
precipitates AMPAR deficits and postsynaptic dysfunction, it is of importance to examine 
if tau is indeed required for pre and postsynaptic deficits as measured via mEPSCs. The 
initial studies in SNCA-/- neurons demonstrating endogenous aS is not required for tau 
missorting but is required for aS PFF-induced synaptotoxicity at high concentrations, 
would benefit from electrophysiological studies and mESPC analysis as this would provide 
measures of the roles aS PFFs and endogenous aS play in early synaptic dysfunction, 
prior to the onset of overt inclusion formation. Along these lines, establishing the time 
course for neuronal responses to 0.10 µg/mL aS PFF treatment, similar to what has been 
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established for 4.00 µg/mL (Volpicelli-Daley et al., 2014), would allow for a greater 
understanding of the role pathogenic aS species and aggregates play in driving synaptic 
and neuronal deficits. Although 0.10 µg/mL aS PFF is a concentration above the threshold 
needed for the conversion of monomers to fibrils (Afitska et al., 2019), it could be 
hypothesized that there would be a greater lag time between aS PFF application and 
appearance of inclusions for the 0.10 µg/mL concentration when compared to 4.00 µg/mL. 
This would provide for a greater window to examine aS PFF-mediated neuronal 
dysfunction prior to the onset of overt neuropathology.  
 Although aS PFFs are the species of aS being applied, the exact pathogenic species 
responsible for structural and functional deficits in culture is unknown. It is therefore 
feasible that intermediates from aS PFF catabolism within neurons or pre-fibrillar 
aggregates composed of endogenous aS may be the culprit. As such, comparing the 
species of aS present within neurons along the established timeline for aS PFF-induced 
neuronal alterations would provide for insight into the kinetics behind recruitment aS PFF 
processing and the aggregation, oligomerization, and fibrillization of endogenous aS. 
Another interesting concept potentially worth pursuing is how different strains of fibrillar 
aS affect hippocampal neuron function. Recent studies have demonstrated differential 
neuronal susceptibility to aS PFFs that positively correlates with endogenous aS 
expression (Luna et al., 2018) and that different aS strains have differing seeding, 
pathogenic, and neurotropic preferences (Bousset et al., 2013; Guo et al., 2013; Peelaerts 
et al., 2015). In combining these two lines of investigation, the formation, spread, and cell-
type specificity of different aS aggregates, such as the GCIs of MSA and the LBs of PD, 
is heavily dictated by intracellular environment, with little capacity for these different 
aggregates to cross over between different cell types (Peng et al., 2018). Building upon 
this, it is possible that the cortical and hippocampal aS fibrils found in PDD and DLB 
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patients may be different not only between those two a-synucleinopathies, but also 
different between the neurons in these brain regions and other regions that are affected 
earlier in the disease, such as the SNPc (Braak et al., 2003). Moreover, as fibrils transmit 
from one neuron and brain region to another, it is possible that repeated seeding of fibrils 
may generate slightly different strains that impart different pathogenic features, meaning 
that the fibrils observed in midbrain LBs are distinct from those in cortical and limbic 
structures. This hypothesis is consistent with the observation that midbrain and cortical 
LBs have different morphologies (Braak et al., 2003; Harding and Halliday, 2001). With 
these concepts and observations in mind, it would be interesting to examine how different 
aS strains impact hippocampal neuron function in culture. In addition to generating aS 
strains in vitro (e.g. fibrils and ribbons), it would be interesting to examine the potency and 
pathogenicity of aS aggregates produced via aS PFF induction in primary neurons 
cultured from different brain regions, such as the cortex and midbrain.  
 Ultimately, the use of several technical approaches and models to investigate the 
mechanisms continuing to cognitive decline in the a-synucleinopathies is critical to framing 
observations into a broader context and understanding of disease pathogenesis. Indeed, 
a major aim of this thesis was to expand upon our scientific body of knowledge in this area 
to better inform areas of therapeutic intervention for aS-mediated memory deficits. 
However, this work also provided a platform to develop a technical and experimental 
skillset, learn the scientific method, and become a critical, independent, and innovative 
scientist. Lastly, in accomplishing these aims, the findings reported here, along with their 
implications allow for others to continue on the investigation of the pathological processes 
leading to dementia in neurodegenerative diseases. Given the increasing burden of 
neurological disorders, compounded by an expanding and aging population, using basic 
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science advances to translate to and inform meaningful clinical intervention is vital for 
improving not just years lived, but also quality of life within those years. 
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